[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 168
1. Yu MC, Yuan JM, Lu SC: Alcohol, cofactors and the genetics of hepatocellular carcinoma. J Gastroenterol Hepatol; 2008 Mar;23 Suppl 1:S92-7
Hazardous Substances Data Bank. ETHANOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alcohol, cofactors and the genetics of hepatocellular carcinoma.
  • Heavy alcohol consumption, chronic infection with the hepatitis B virus (HBV) or the hepatitis C virus (HCV), tobacco smoking, and diabetes are risk factors for hepatocellular carcinoma (HCC).
  • In the Los Angeles Non-Asian HCC Study, heavy alcohol intake was shown to exhibit synergistic effects with viral hepatitis (HBV, HCV) and diabetes in the causation of HCC among individuals with joint exposures.
  • Although chronic infection with HBV is recognized as the most important causal factor for HCC in humans, only a minority of HBV carriers eventually develop HCC, suggesting the presence of important cofactors in HBV-related HCC.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Carcinogenesis. 1997 Nov;18(11):2071-6 [9395204.001]
  • [Cites] Cancer. 2005 Feb 15;103(4):740-8 [15643599.001]
  • [Cites] Alcohol. 2005 Apr;35(3):227-34 [16054984.001]
  • [Cites] J Nutr. 2007 Feb;137(2):407-13 [17237319.001]
  • [Cites] Hepatology. 2007 Sep;46(3):749-58 [17659576.001]
  • [Cites] Cancer. 2004 Sep 1;101(5):1009-17 [15329910.001]
  • [Cites] Gastroenterology. 2004 Nov;127(5 Suppl 1):S72-8 [15508106.001]
  • [Cites] Carcinogenesis. 1983 Dec;4(12):1619-29 [6317218.001]
  • [Cites] Cancer Res. 1984 Feb;44(2):703-9 [6692373.001]
  • [Cites] Jpn J Cancer Res. 1985 Oct;76(10):977-83 [3935628.001]
  • [Cites] Cancer Res. 1989 May 1;49(9):2506-9 [2539905.001]
  • [Cites] Cancer Res. 1992 Sep 15;52(18):5042-5 [1516060.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1993 Nov-Dec;2(6):537-44 [8268770.001]
  • [Cites] Cancer Res. 1995 May 1;55(9):1894-901 [7794383.001]
  • [Cites] Am J Clin Nutr. 1997 Jan;65(1):46-52 [8988912.001]
  • (PMID = 18336674.001).
  • [ISSN] 1440-1746
  • [Journal-full-title] Journal of gastroenterology and hepatology
  • [ISO-abbreviation] J. Gastroenterol. Hepatol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA 98497; United States / NCI NIH HHS / CA / CA098497-02; United States / NCI NIH HHS / CA / R01 CA098497-02; None / None / / R01 AT001576-05; United States / NCCIH NIH HHS / AT / R01 AT001576-05; United States / NCI NIH HHS / CA / R35 CA 53890; United States / NCI NIH HHS / CA / R01 CA 80205; United States / NCI NIH HHS / CA / R01 CA098497-05; United States / NCI NIH HHS / CA / CA098497-05; United States / NCI NIH HHS / CA / R01 CA098497; United States / NIDDK NIH HHS / DK / R01 DK051719-11; United States / NCCIH NIH HHS / AT / R01 AT001576; United States / NCI NIH HHS / CA / CA098497-03; United States / NCI NIH HHS / CA / CA098497-01A2; United States / NCI NIH HHS / CA / R01 CA098497-01A2; United States / NIDDK NIH HHS / DK / R01 DK051719; United States / NCI NIH HHS / CA / R01 CA043092; United States / NCI NIH HHS / CA / R01 CA098497-06; United States / NCI NIH HHS / CA / CA098497-06; United States / NCI NIH HHS / CA / R01 CA043092-20; United States / NIAAA NIH HHS / AA / R01 AA013847; United States / NIAAA NIH HHS / AA / R01 AA 13847; United States / NCI NIH HHS / CA / R01 CA 43092; United States / NIAAA NIH HHS / AA / R01 AA012677; United States / NCI NIH HHS / CA / R01 CA098497-04; United States / NIDDK NIH HHS / DK / DK051719-11; United States / NCI NIH HHS / CA / CA098497-04; United States / NCI NIH HHS / CA / R35 CA053890; United States / NIAAA NIH HHS / AA / R01 AA012677-05; United States / NIAAA NIH HHS / AA / R01 AA013847-05; United States / NCI NIH HHS / CA / R01 CA080205; United States / NIDDK NIH HHS / DK / R01 DK 51719; United States / NIAAA NIH HHS / AA / R01 AA 12677; United States / NCCIH NIH HHS / AT / R01 AT 1576; United States / NCI NIH HHS / CA / R01 CA098497-03; United States / NIAAA NIH HHS / AA / AA012677-05; United States / NIAAA NIH HHS / AA / AA013847-05
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] Australia
  • [Chemical-registry-number] 3K9958V90M / Ethanol
  • [Number-of-references] 17
  • [Other-IDs] NLM/ NIHMS49953; NLM/ PMC2391242
  •  go-up   go-down


2. Sakamoto T, Higaki Y, Hara M, Ichiba M, Horita M, Mizuta T, Eguchi Y, Yasutake T, Ozaki I, Yamamoto K, Onohara S, Kawazoe S, Shigematsu H, Koizumi S, Tanaka K: hOGG1 Ser326Cys polymorphism and risk of hepatocellular carcinoma among Japanese. J Epidemiol; 2006 Nov;16(6):233-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] hOGG1 Ser326Cys polymorphism and risk of hepatocellular carcinoma among Japanese.
  • BACKGROUND: The Ser326Cys polymorphism in human oxoguanine glycosylase 1 (hOGG1), which is involved in the repair of 8-hydroxy-2-deoxyguanine in oxidatively damaged DNA, has been associated with susceptibility to certain cancers, but has not been examined in causation of hepatocellular carcinoma (HCC).
  • METHODS: We conducted a case-control study to investigate whether this polymorphism was related to HCC risk with any interaction with alcohol consumption and cigarette smoking.
  • We could not detect any significant gene-alcohol interaction (p = 0.95 or 0.16) or gene-smoking interaction (p = 0.70 or 0.69).

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. L-SERINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17085873.001).
  • [ISSN] 0917-5040
  • [Journal-full-title] Journal of epidemiology
  • [ISO-abbreviation] J Epidemiol
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 452VLY9402 / Serine; EC 3.2.2.- / DNA Glycosylases; EC 3.2.2.- / oxoguanine glycosylase 1, human
  •  go-up   go-down


3. Kane RC, Farrell AT, Madabushi R, Booth B, Chattopadhyay S, Sridhara R, Justice R, Pazdur R: Sorafenib for the treatment of unresectable hepatocellular carcinoma. Oncologist; 2009 Jan;14(1):95-100
Hazardous Substances Data Bank. NICOTINAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sorafenib for the treatment of unresectable hepatocellular carcinoma.
  • Food and Drug Administration (FDA) review and approval of sorafenib (Nexavar; Bayer Pharmaceuticals Corp., Montville, NJ, and Onyx Pharmaceuticals Corp., Emeryville, CA), an oral kinase inhibitor, for the treatment of patients with unresectable hepatocellular carcinoma (HCC).
  • Underlying liver diseases included hepatitis B (18%), hepatitis C (28%), and alcohol-related (26%).
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Benzenesulfonates / therapeutic use. Carcinoma, Hepatocellular / drug therapy. Liver Neoplasms / drug therapy. Protein Kinase Inhibitors / therapeutic use. Pyridines / therapeutic use

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Oncologist. 2009 Jan;14(1):92-4 [19144679.001]
  • (PMID = 19144678.001).
  • [ISSN] 1549-490X
  • [Journal-full-title] The oncologist
  • [ISO-abbreviation] Oncologist
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzenesulfonates; 0 / Phenylurea Compounds; 0 / Protein Kinase Inhibitors; 0 / Pyridines; 25X51I8RD4 / Niacinamide; 9ZOQ3TZI87 / sorafenib
  • [Number-of-references] 2
  •  go-up   go-down


Advertisement
4. Fehér J, Lengyel G: [Hepatocellular carcinoma: occurrence, risk factors, biomarkers]. Orv Hetil; 2010 Jun 6;151(23):933-40
Hazardous Substances Data Bank. NICOTINAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Hepatocellular carcinoma: occurrence, risk factors, biomarkers].
  • [Transliterated title] Hepatocellularis carcinoma: elofordulás, kórokok, biomarkerek.
  • Hepatocellular carcinoma (HCC) is the third most common cause of cancer-related death worldwide.
  • Primary hepatocellular carcinoma can be found most frequently (80-90 %) in patients with liver cirrhosis.
  • The most frequent causes of liver cirrhosis are chronic hepatitis B and C virus infections and chronic alcohol consumption.
  • The occurrence of hepatocellular carcinoma is about 3-15 % in patients with alcoholic liver disease.
  • [MeSH-major] Biomarkers, Tumor / blood. Carcinoma, Hepatocellular. Liver Neoplasms

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. IRON, ELEMENTAL .
  • Hazardous Substances Data Bank. COPPER, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20494888.001).
  • [ISSN] 0030-6002
  • [Journal-full-title] Orvosi hetilap
  • [ISO-abbreviation] Orv Hetil
  • [Language] hun
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Hungary
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzenesulfonates; 0 / Biomarkers, Tumor; 0 / Phenylurea Compounds; 0 / Pyridines; 25X51I8RD4 / Niacinamide; 789U1901C5 / Copper; 9ZOQ3TZI87 / sorafenib; E1UOL152H7 / Iron
  • [Number-of-references] 41
  •  go-up   go-down


5. Lengyel G, Fehér J: [Combined interferon, ribavirin treatment and the occurrence of hepatocellular carcinoma]. Orv Hetil; 2010 Jul 18;151(29):1177-81
Hazardous Substances Data Bank. RIBAVIRIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Combined interferon, ribavirin treatment and the occurrence of hepatocellular carcinoma].
  • [Transliterated title] Kombinált interferon-ribavirin kezelés és a hepatocellularis carcinoma elofordulása.
  • Hepatocellular carcinoma (HCC) is the sixth most common cause of cancer-related death worldwide.
  • Primary hepatocellular carcinoma can be found most frequently (80-90%) in patients with liver cirrhosis.
  • The most frequent causes of liver cirrhosis are chronic hepatitis B and C virus infections and chronic alcohol consumption.
  • [MeSH-major] Antiviral Agents / therapeutic use. Carcinoma, Hepatocellular / prevention & control. Hepatitis B, Chronic / drug therapy. Hepatitis C, Chronic / drug therapy. Interferons / therapeutic use. Liver Neoplasms / prevention & control. Ribavirin / therapeutic use

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20591786.001).
  • [ISSN] 0030-6002
  • [Journal-full-title] Orvosi hetilap
  • [ISO-abbreviation] Orv Hetil
  • [Language] hun
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Hungary
  • [Chemical-registry-number] 0 / Antiviral Agents; 49717AWG6K / Ribavirin; 9008-11-1 / Interferons
  • [Number-of-references] 25
  •  go-up   go-down


6. Ladeiro Y, Couchy G, Balabaud C, Bioulac-Sage P, Pelletier L, Rebouissou S, Zucman-Rossi J: MicroRNA profiling in hepatocellular tumors is associated with clinical features and oncogene/tumor suppressor gene mutations. Hepatology; 2008 Jun;47(6):1955-63
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MicroRNA profiling in hepatocellular tumors is associated with clinical features and oncogene/tumor suppressor gene mutations.
  • Molecular classifications defining new tumor subtypes have been recently refined with genetic and transcriptomic analyses of benign and malignant hepatocellular tumors.
  • Expression levels of 250 miRNAs in 46 benign and malignant hepatocellular tumors were compared to those of 4 normal liver samples with quantitative reverse-transcriptase polymerase chain reaction. miRNAs associated with genetic and clinical characteristics were validated in a second series of 43 liver tumor samples and 16 nontumor samples. miRNA profiling unsupervised analysis classified samples in unique clusters characterized by histological features (tumor/nontumor, P < 0.001; benign/malignant tumors, P < 0.01; inflammatory adenoma and focal nodular hyperplasia, P < 0.01), clinical characteristics [hepatitis B virus (HBV) infection, P < 0.001; alcohol consumption, P < 0.05], and oncogene/tumor suppressor gene mutations [beta-catenin, P < 0.01; hepatocyte nuclear factor 1alpha (HNF1alpha), P < 0.01].
  • Moreover, miR-96 was overexpressed in HBV tumors, and miR-126* was down-regulated in alcohol-related hepatocellular carcinoma.
  • CONCLUSION: Hepatocellular tumors may have a distinct miRNA expression fingerprint according to malignancy, risk factors, and oncogene/tumor suppressor gene alterations.
  • [MeSH-major] Carcinoma, Hepatocellular / genetics. Gene Expression Profiling / methods. Genes, Tumor Suppressor. Liver Neoplasms / genetics. MicroRNAs / genetics. Mutation / genetics

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • HAL archives ouvertes. Full text from .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Hepatology. 2008 Jun;47(6):1807-9 [18506877.001]
  • (PMID = 18433021.001).
  • [ISSN] 1527-3350
  • [Journal-full-title] Hepatology (Baltimore, Md.)
  • [ISO-abbreviation] Hepatology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Hepatocyte Nuclear Factor 1-alpha; 0 / MicroRNAs; 0 / beta Catenin
  •  go-up   go-down


7. Hill-Baskin AE, Markiewski MM, Buchner DA, Shao H, DeSantis D, Hsiao G, Subramaniam S, Berger NA, Croniger C, Lambris JD, Nadeau JH: Diet-induced hepatocellular carcinoma in genetically predisposed mice. Hum Mol Genet; 2009 Aug 15;18(16):2975-88
Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diet-induced hepatocellular carcinoma in genetically predisposed mice.
  • Hepatocellular carcinoma (HCC) is one of the leading causes of cancer death worldwide, with approximately 70% of cases resulting from hepatitis B and C viral infections, aflatoxin exposure, chronic alcohol use or genetic liver diseases.
  • The remaining approximately 30% of cases are associated with obesity, type 2 diabetes and related metabolic diseases, although a direct link between these pathologies and HCCs has not been established.

  • MedlinePlus Health Information. consumer health - Dietary Fats.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2005 Dec 27;102(52):19075-80 [16365291.001]
  • [Cites] N Engl J Med. 2005 Oct 27;353(17):1793-801 [16251535.001]
  • [Cites] J Clin Invest. 2006 Jun;116(6):1582-95 [16710476.001]
  • [Cites] Cancer Lett. 2006 Aug 28;240(2):157-69 [16239065.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Aug 15;103(33):12481-6 [16885212.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2006 Oct;291(4):G575-83 [16710052.001]
  • [Cites] Hepatology. 2006 Oct;44(4):1003-11 [17006931.001]
  • [Cites] Int J Cancer. 2006 Dec 1;119(11):2557-66 [16988945.001]
  • [Cites] Diabetes. 2007 Jan;56(1):161-7 [17192478.001]
  • [Cites] J Biol Chem. 2007 Apr 13;282(15):11197-204 [17227769.001]
  • [Cites] Clin Liver Dis. 2007 Feb;11(1):191-207, x-xi [17544979.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Sep 11;104(37):14771-6 [17785413.001]
  • [Cites] RNA. 2008 Jan;14(1):35-42 [18025253.001]
  • [Cites] Stem Cells. 2008 Jan;26(1):17-29 [17916804.001]
  • [Cites] J Clin Invest. 2008 Feb;118(2):683-94 [18188449.001]
  • [Cites] Asian Pac J Cancer Prev. 2007;8 Suppl:35-80 [18260705.001]
  • [Cites] Oncology. 2007;72(5-6):397-402 [18196926.001]
  • [Cites] Cancer Res. 2008 Apr 1;68(7):2391-9 [18381447.001]
  • [Cites] Am Fam Physician. 2008 Jun 1;77(11):1573-8 [18581838.001]
  • [Cites] Adv Exp Med Biol. 2008;630:72-93 [18637486.001]
  • [Cites] Semin Liver Dis. 2008 Nov;28(4):370-9 [18956293.001]
  • [Cites] RNA. 2008 Nov;14(11):2290-6 [18812437.001]
  • [Cites] Mamm Genome. 2009 Feb;20(2):71-82 [19137372.001]
  • [Cites] Int J Cancer. 2006 Jun 15;118(12):3030-44 [16404738.001]
  • [Cites] Nat Genet. 2000 May;25(1):25-9 [10802651.001]
  • [Cites] J Biol Chem. 2001 Jan 5;276(1):629-38 [11024029.001]
  • [Cites] Cancer Res. 2001 Jul 1;61(13):5016-23 [11431335.001]
  • [Cites] Hepatology. 2001 Nov;34(5):935-42 [11679964.001]
  • [Cites] Nat Genet. 2002 Aug;31(4):339-46 [12149612.001]
  • [Cites] Semin Liver Dis. 2004 Feb;24(1):99-106 [15085490.001]
  • [Cites] Science. 2004 Apr 16;304(5669):445-8 [15031436.001]
  • [Cites] Curr Opin Genet Dev. 2004 Feb;14(1):37-42 [15108803.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jun 22;101(25):9309-14 [15184677.001]
  • [Cites] Gastroenterology. 2004 Nov;127(5 Suppl 1):S218-24 [15508087.001]
  • [Cites] Metabolism. 1995 May;44(5):645-51 [7752914.001]
  • [Cites] PLoS Biol. 2004 Nov;2(11):e363 [15502875.001]
  • [Cites] Bioinformatics. 2004 Nov 22;20(17):3108-27 [15217816.001]
  • [Cites] Nat Genet. 2004 Dec;36(12):1306-11 [15565109.001]
  • [Cites] Alcohol. 2004 Aug;34(1):67-79 [15670668.001]
  • [Cites] Intervirology. 2005;48(1):6-9 [15785083.001]
  • [Cites] Diabetes. 2005 May;54(5):1314-23 [15855315.001]
  • [Cites] Hepatobiliary Pancreat Dis Int. 2005 May;4(2):173-7 [15908310.001]
  • [Cites] Acta Pharmacol Sin. 2005 Jun;26(6):659-65 [15916730.001]
  • [Cites] Carcinogenesis. 2005 Jun;26(6):1013-20 [15677630.001]
  • [Cites] Nucleic Acids Res. 2005 Jul 1;33(Web Server issue):W627-32 [15980550.001]
  • [Cites] Hepatology. 2005 Oct;42(4):880-5 [16175608.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50 [16199517.001]
  • [Cites] Nucleic Acids Res. 2006 Jan 1;34(Database issue):D140-4 [16381832.001]
  • (PMID = 19454484.001).
  • [ISSN] 1460-2083
  • [Journal-full-title] Human molecular genetics
  • [ISO-abbreviation] Hum. Mol. Genet.
  • [Language] ENG
  • [Grant] None / None / / P40 RR012305-07; United States / NIDDK NIH HHS / DK / DK075040-04; United States / NCRR NIH HHS / RR / P40 RR012305-07; United States / NIAID NIH HHS / AI / AI068730; United States / NCRR NIH HHS / RR / P40 RR012305-09; United States / NCRR NIH HHS / RR / P40 RR012305; None / None / / P40 RR012305-09; United States / NCRR NIH HHS / RR / RR12305; United States / NIDDK NIH HHS / DK / R01 DK075040-04; None / None / / P40 RR012305-08; United States / NIDDK NIH HHS / DK / R01 DK075040; United States / NCRR NIH HHS / RR / P40 RR012305-08; United States / NCI NIH HHS / CA / U54CA116867; United States / NIDDK NIH HHS / DK / DK075040
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Dietary Fats
  • [Other-IDs] NLM/ PMC2714725
  •  go-up   go-down


8. Caillot F, Derambure C, Bioulac-Sage P, Francois A, Scotte M, Goria O, Hiron M, Daveau M, Salier JP: Transient and etiology-related transcription regulation in cirrhosis prior to hepatocellular carcinoma occurrence. World J Gastroenterol; 2009 Jan 21;15(3):300-9
antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transient and etiology-related transcription regulation in cirrhosis prior to hepatocellular carcinoma occurrence.
  • AIM: To search for transcription dysregulation that could (1) differentiate hepatocellular carcinoma (HCC)-free from HCC-related cirrhosis (2) differentiate HCC-free cirrhosis related to HCV from that related to alcohol intake.
  • RESULTS: In HCC-free livers, we identified 70 transcripts which differentiated between alcoholic-related cirrhosis, HCV-related cirrhosis and control livers.
  • Dysregulation of Signal Transduction and Activator of Transcription-3 (STAT-3) was found along with related changes in STAT-3 targets which occurred in an etiology-dependent fashion in HCC-free cirrhosis.
  • [MeSH-major] Carcinoma, Hepatocellular / genetics. Gene Expression Regulation, Neoplastic. Liver Cirrhosis / etiology. Liver Cirrhosis / genetics. Liver Neoplasms / genetics. Transcription, Genetic

  • MedlinePlus Health Information. consumer health - Cirrhosis.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2001 Mar 1;61(5):2129-37 [11280777.001]
  • [Cites] Mol Cancer Res. 2008 May;6(5):675-84 [18505913.001]
  • [Cites] Gastroenterology. 2001 Jun;120(7):1763-73 [11375957.001]
  • [Cites] Inflamm Res. 2001 Aug;50(8):383-90 [11556518.001]
  • [Cites] Cytokine. 2001 Aug 21;15(4):175-87 [11563878.001]
  • [Cites] Cancer Res. 2002 Jul 15;62(14):3939-44 [12124323.001]
  • [Cites] Nat Genet. 2002 Aug;31(4):339-46 [12149612.001]
  • [Cites] J Virol. 2003 Jun;77(11):6367-75 [12743294.001]
  • [Cites] Oncogene. 2003 May 15;22(19):3007-14 [12771952.001]
  • [Cites] Int J Cancer. 2003 Sep 1;106(3):334-41 [12845670.001]
  • [Cites] Hepatology. 2003 Sep;38(3):577-88 [12939584.001]
  • [Cites] Genome Biol. 2003;4(9):117 [12952525.001]
  • [Cites] Lancet. 2003 Oct 4;362(9390):1126-7 [14552335.001]
  • [Cites] J Hepatol. 2003 Dec;39(6):1004-12 [14642619.001]
  • [Cites] Hepatology. 2004 Feb;39(2):353-64 [14767988.001]
  • [Cites] Hepatology. 2004 Feb;39(2):518-27 [14768006.001]
  • [Cites] Int J Oncol. 2004 Mar;24(3):565-74 [14767541.001]
  • [Cites] J Hepatol. 2004 Aug;41(2):336-9 [15288485.001]
  • [Cites] J Virol. 2005 Feb;79(3):1569-80 [15650183.001]
  • [Cites] Cancer Res. 2005 Jun 15;65(12):5054-62 [15958548.001]
  • [Cites] J Hepatol. 2006 Apr;44(4):798-805 [16488507.001]
  • [Cites] Oncogene. 2006 Jun 26;25(27):3778-86 [16799619.001]
  • [Cites] Oncogene. 2006 Jun 26;25(27):3801-9 [16799621.001]
  • [Cites] Oncogene. 2006 Jun 26;25(27):3848-56 [16799626.001]
  • [Cites] Int J Oncol. 2006 Aug;29(2):315-27 [16820872.001]
  • [Cites] Cell Cycle. 2006 Aug;5(15):1587-91 [16861929.001]
  • [Cites] Hepatology. 2006 Oct;44(4):1003-11 [17006931.001]
  • [Cites] Gastroenterology. 2006 Dec;131(6):1758-67 [17087938.001]
  • [Cites] Hepatology. 2007 Jan;45(1):53-61 [17187415.001]
  • [Cites] Hepatology. 2007 Jan;45(1):42-52 [17187432.001]
  • [Cites] Semin Liver Dis. 2007 Feb;27(1):55-76 [17295177.001]
  • [Cites] Lab Invest. 2007 Feb;87(2):173-81 [17318196.001]
  • [Cites] Hepatology. 2007 Mar;45(3):725-34 [17326147.001]
  • [Cites] J Virol. 2007 Oct;81(19):10249-57 [17626077.001]
  • [Cites] World J Gastroenterol. 2008 Mar 21;14(11):1749-58 [18350606.001]
  • [Cites] Curr Med Chem. 2008;15(9):834-43 [18473793.001]
  • [Cites] Cancer Res. 2001 Apr 1;61(7):3176-81 [11306505.001]
  • (PMID = 19140229.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 9001-91-6 / Plasminogen
  • [Other-IDs] NLM/ PMC2653326
  •  go-up   go-down


9. Craxì A, Cammà C: Does chemotherapy prevent HCV-related hepatocellular carcinoma? Cons. Dig Liver Dis; 2010 Jul;42 Suppl 3:S287-92
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Does chemotherapy prevent HCV-related hepatocellular carcinoma? Cons.
  • The accuracy and the reliability of well-recognized clinical, virologic, histologic, and molecular risk factors for hepatocellular carcinoma (HCC) are still insufficient.
  • A strategy aiming at preventing chronic liver disease of any etiology (HCV and HBV infection, alcohol, obesity, others) may be required to prevent HCC in low and intermediate incidence areas, and hence, worldwide.
  • In the setting of secondary chemoprevention, literature data pooling suggests a slight preventive effect of interferon (IFN) on HCC development in patients with HCV-related cirrhosis.
  • So, there is no sound evidence to support a recommendation for widespread use of IFN to prevent HCC in HCV-related cirrhosis.
  • [MeSH-major] Antiviral Agents / therapeutic use. Carcinoma, Hepatocellular / prevention & control. Hepatitis C, Chronic / drug therapy. Interferon-alpha / therapeutic use. Liver Neoplasms / prevention & control. Polyethylene Glycols / therapeutic use

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd.. All rights reserved.
  • [CommentOn] Dig Liver Dis. 2010 Jul;42 Suppl 3:S281-6 [20547315.001]
  • (PMID = 20547316.001).
  • [ISSN] 1878-3562
  • [Journal-full-title] Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  • [ISO-abbreviation] Dig Liver Dis
  • [Language] eng
  • [Publication-type] Comment; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / Interferon-alpha; 0 / Recombinant Proteins; 0 / peginterferon alfa-2a; 30IQX730WE / Polyethylene Glycols; 76543-88-9 / interferon alfa-2a
  •  go-up   go-down


10. El-Serag HB: Epidemiology of hepatocellular carcinoma in USA. Hepatol Res; 2007 Sep;37 Suppl 2:S88-94
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epidemiology of hepatocellular carcinoma in USA.
  • Hepatocellular carcinoma (HCC) is increasing in frequency the USA.
  • There are striking differences in the incidence of HCC related to age, gender, race, and geographic region.
  • Hepatitis C virus (HCV) infection acquired 2-4 decades ago explains at least half of the observed increase in HCC; HCV-related HCC is likely tocontinue to increase for the next decade.
  • A variable but significant proportion of cases (15-50%) do not have evidence for the risk factors of either viral hepatitis or heavy alcohol consumption.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17877502.001).
  • [ISSN] 1386-6346
  • [Journal-full-title] Hepatology research : the official journal of the Japan Society of Hepatology
  • [ISO-abbreviation] Hepatol. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


11. Schacherer D, Schoelmerich J, Zuber-Jerger I: [The diagnostic approach to hepatocellular carcinoma]. Z Gastroenterol; 2007 Oct;45(10):1067-74
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The diagnostic approach to hepatocellular carcinoma].
  • Risk factors and symptoms of hepatocellular carcinoma (HCC): The main risk factors of HCC include infection with hepatitis B or C virus, as well as alcohol consumption.
  • Among the various staging systems used in the context of HCC, the Barcelona-Clinic-Liver-Cancer (BCLC) staging system is currently the only staging system that takes into account tumour stage, liver function, physical status and cancer-related symptoms.
  • [MeSH-major] Carcinoma, Hepatocellular / diagnosis. Liver Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17924305.001).
  • [ISSN] 0044-2771
  • [Journal-full-title] Zeitschrift für Gastroenterologie
  • [ISO-abbreviation] Z Gastroenterol
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 49
  •  go-up   go-down


12. Fan JG, Farrell GC, Asia-Pacific Working Party for Prevention of Hepatocellular Carcinoma: Prevention of hepatocellular carcinoma in nonviral-related liver diseases. J Gastroenterol Hepatol; 2009 May;24(5):712-9
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prevention of hepatocellular carcinoma in nonviral-related liver diseases.
  • Although chronic infection with hepatitis B virus and/or hepatitis C virus are the most important risk factors for hepatocellular carcinoma (HCC) worldwide, other causes of cirrhosis can also lead to HCC.
  • Given the high prevalence of alcoholism and the worldwide obesity epidemic, the relevant importance of nonviral liver disease-related HCC is expected to increase in the future.
  • Community-based programs to discourage and deal with excessive alcohol intake, to promote tobacco smoking awareness, to avoid exposure to aflatoxin and other food toxins, and measures to reduce the pandemic of obesity and diabetes are vital for effective interruption of the rising tide of HCC from nonviral liver disease.
  • [MeSH-major] Carcinoma, Hepatocellular / prevention & control. Liver Cirrhosis / prevention & control. Liver Neoplasms / prevention & control
  • [MeSH-minor] Alcohol Drinking / adverse effects. Alcohol Drinking / prevention & control. Androgens / adverse effects. Diabetes Mellitus, Type 2 / complications. Diabetes Mellitus, Type 2 / therapy. Diet / adverse effects. Estrogens / adverse effects. Fatty Liver / complications. Fatty Liver / therapy. Food Contamination. Health Knowledge, Attitudes, Practice. Health Promotion. Hemochromatosis / complications. Hemochromatosis / therapy. Humans. Obesity / complications. Obesity / therapy. Risk Assessment. Risk Factors. Smoking / adverse effects. Smoking / prevention & control. Water Pollutants / adverse effects

  • MedlinePlus Health Information. consumer health - Cirrhosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19646014.001).
  • [ISSN] 1440-1746
  • [Journal-full-title] Journal of gastroenterology and hepatology
  • [ISO-abbreviation] J. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Androgens; 0 / Estrogens; 0 / Water Pollutants
  • [Number-of-references] 86
  •  go-up   go-down


13. Fujishima T, Ishikawa T, Shiratori Y, Kanda M, Tateishi R, Akamatsu M, Koike Y, Sato S, Obi S, Hamamura K, Teratani T, Shiina S, Yoshida H, Kawabe T, Omata M: Age-related comparison of the profiles of patients with hepatocellular carcinoma. Hepatogastroenterology; 2006 Nov-Dec;53(72):913-8
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Age-related comparison of the profiles of patients with hepatocellular carcinoma.
  • BACKGROUND/AIMS: It is not known whether the putative etiologic factors and clinical and pathological features of hepatocellular carcinoma differ between young adults and older patients.
  • Younger patients also had a higher ratio of alcohol consumption compared to elderly patients.
  • CONCLUSIONS: There were age-related differences in the clinicopathological characteristics of HCC patients.
  • Of the HCV-related HCC patients, heavy drinking may accelerate the progression from chronic hepatitis to cirrhosis and HCC.
  • [MeSH-major] Carcinoma, Hepatocellular / etiology. Carcinoma, Hepatocellular / pathology. Liver Neoplasms / etiology. Liver Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17153452.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


14. Kremsdorf D, Soussan P, Paterlini-Brechot P, Brechot C: Hepatitis B virus-related hepatocellular carcinoma: paradigms for viral-related human carcinogenesis. Oncogene; 2006 Jun 26;25(27):3823-33
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatitis B virus-related hepatocellular carcinoma: paradigms for viral-related human carcinogenesis.
  • As discussed in detail in other chapters of this review, chronic hepatitis B (HBV) infection is a major risk factor for hepatocellular carcinoma (HCC).
  • This review will summarize the current knowledge on the mechanisms involved in HBV-related liver carcinogenesis.
  • It will show in particular how viruses can be viewed as tools to discover and dissect new cellular pathways involved in cancer development and emphasize the potential synergistic effects between HBV and hepatitis C virus, as well as between viral infections and other environmental factors, such as alcohol.
  • [MeSH-major] Carcinoma, Hepatocellular / virology. Hepatitis B virus / pathogenicity. Liver Neoplasms / virology

  • Genetic Alliance. consumer health - Hepatitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16799624.001).
  • [ISSN] 0950-9232
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 173
  •  go-up   go-down


15. Stroffolini T, Almasio PL, Persico M, Bollani S, Benvegnù L, Di Costanzo G, Pastore G, Aghemo A, Stornaiuolo G, Mangia A, Andreone P, Stanzione M, Mazzella G, Saracco G, Del Poggio P, Bruno S, Italian Association of the Study of the Liver Disease (AISF): Lack of correlation between serum anti-HBcore detectability and hepatocellular carcinoma in patients with HCV-related cirrhosis. Am J Gastroenterol; 2008 Aug;103(8):1966-72
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lack of correlation between serum anti-HBcore detectability and hepatocellular carcinoma in patients with HCV-related cirrhosis.
  • BACKGROUND: While the likelihood of developing hepatocellular carcinoma (HCC) in patients coinfected with both HBV and HCV is increased, the role of previous exposure to HBV as a risk factor associated with tumor occurrence in subjects with HCV-related cirrhosis has not been fully investigated.
  • AIM: To assess whether serum anti-HBc positivity, as a marker of previous HBV exposure, is associated with HCC development in HCV-related positive, hepatitis B surface antigen (HBsAg) negative patients with cirrhosis treated with alfa-interferon (IFN) monotherapy.
  • Anti-HBc positive patients were more often men (67.0%vs 58.7%, P= 0.03), had lower transaminase levels (3.3 +/- 2.0 vs 3.8 +/- 2.5 u.l.n., P= 0.004), and had higher rate of alcohol intake (38.3%vs 22.5%, P < 0.001) than anti-HBc negative patients.
  • By Cox multiple regression, there was no association of serum anti-HBc with HCC development (HR 1.03, 95% CI 0.69-1.52) or liver-related deaths incidence (HR 1.21; 95% CI 0.76-1.95).
  • CONCLUSIONS: In comparison with anti-HBc negative subjects, serum anti-HBc positive patients with HCV-related/HBsAg negative cirrhosis treated with IFN monotherapy did not show a greater risk of HCC.
  • [MeSH-major] Antibodies, Viral / blood. Carcinoma, Hepatocellular / blood. Hepatitis B Core Antigens / immunology. Hepatitis B virus / immunology. Hepatitis C / blood. Liver Neoplasms / blood

  • MedlinePlus Health Information. consumer health - Hepatitis C.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18637087.001).
  • [ISSN] 1572-0241
  • [Journal-full-title] The American journal of gastroenterology
  • [ISO-abbreviation] Am. J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Viral; 0 / Hepatitis B Core Antigens
  • [Investigator] Boccia S; Di Marco V; Giannini E; Morisco F; Picciotto A; Fagiuoli S; Mazzaro C
  •  go-up   go-down


16. Schütte K, Bornschein J, Malfertheiner P: Hepatocellular carcinoma--epidemiological trends and risk factors. Dig Dis; 2009;27(2):80-92
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatocellular carcinoma--epidemiological trends and risk factors.
  • Hepatocellular carcinoma (HCC) is the third most common cause of cancer-related deaths worldwide with about 600,000 patients dying from the disease annually.
  • In regions with a high incidence the majority of cases are related to HBV and HCV hepatitis.
  • In developed countries, in addition to virus-related HCC, high consumption of alcohol as well as non-alcoholic fatty liver disease often in the context of metabolic syndromes are the prevalent causes.
  • Improvement in clinical management of patients with liver cirrhosis and the control of related complications are the key for the rising incidence of HCC.
  • [MeSH-major] Carcinoma, Hepatocellular / epidemiology. Hepatitis / complications. Liver Neoplasms / epidemiology
  • [MeSH-minor] Aflatoxins / adverse effects. Alcohol Drinking / adverse effects. Coffee. Diabetes Complications. Diet / adverse effects. Fatty Liver / complications. Female. Hemochromatosis / complications. Humans. Incidence. Male. Risk Factors. alpha 1-Antitrypsin Deficiency / complications

  • MedlinePlus Health Information. consumer health - Hepatitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 S. Karger AG, Basel.
  • (PMID = 19546545.001).
  • [ISSN] 1421-9875
  • [Journal-full-title] Digestive diseases (Basel, Switzerland)
  • [ISO-abbreviation] Dig Dis
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Aflatoxins; 0 / Coffee
  • [Number-of-references] 140
  •  go-up   go-down


17. Polesel J, Talamini R, Montella M, Maso LD, Crovatto M, Parpinel M, Izzo F, Tommasi LG, Serraino D, La Vecchia C, Franceschi S: Nutrients intake and the risk of hepatocellular carcinoma in Italy. Eur J Cancer; 2007 Nov;43(16):2381-7
Hazardous Substances Data Bank. BETA-CAROTENE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nutrients intake and the risk of hepatocellular carcinoma in Italy.
  • Although hepatitis C and B viruses and alcohol consumption are the major risk factors for hepatocellular carcinoma (HCC), dietary habits may also be relevant.
  • In conclusion, a diet rich in linoleic acid containing foods (e.g. white meats and fish) and beta-carotene was inversely related to HCC risk.
  • [MeSH-major] Alcohol Drinking / adverse effects. Carcinoma, Hepatocellular / etiology. Diet / adverse effects. Liver Neoplasms / etiology

  • MedlinePlus Health Information. consumer health - Alcohol.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. LINOLEIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17719221.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 01YAE03M7J / beta Carotene; 9KJL21T0QJ / Linoleic Acid
  •  go-up   go-down


18. Fukushima W, Tanaka T, Ohfuji S, Habu D, Tamori A, Kawada N, Sakaguchi H, Takeda T, Nishiguchi S, Seki S, Shiomi S, Hirota Y: Does alcohol increase the risk of hepatocellular carcinoma among patients with hepatitis C virus infection? Hepatol Res; 2006 Mar;34(3):141-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Does alcohol increase the risk of hepatocellular carcinoma among patients with hepatitis C virus infection?
  • We conducted a hospital-based case-control study to investigate the effects of alcohol drinking on hepatocellular carcinoma (HCC) among patients with hepatitis C virus (HCV) infection, with special reference to the disease course and changes in drinking habits.
  • In conclusion, our results did not demonstrate a strong positive association between alcohol drinking and HCV-related HCC in this population.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16427353.001).
  • [ISSN] 1386-6346
  • [Journal-full-title] Hepatology research : the official journal of the Japan Society of Hepatology
  • [ISO-abbreviation] Hepatol. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


19. Nguyen VT, Law MG, Dore GJ: Hepatitis B-related hepatocellular carcinoma: epidemiological characteristics and disease burden. J Viral Hepat; 2009 Jul;16(7):453-63
Genetic Alliance. consumer health - Hepatitis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatitis B-related hepatocellular carcinoma: epidemiological characteristics and disease burden.
  • Worldwide, 350 million people are chronically infected with hepatitis B virus (HBV) who are at greater risk of hepatocellular carcinoma (HCC) compared with uninfected people.
  • Factors associated with increased risk of HCC include demographic characteristics (male sex and older age), lifestyles (heavy alcohol consumption and smoking), viral factors (genotype C, D F, high level of HBV DNA, core/precore mutation) and clinical factors (cirrhosis, elevated alpha-fetoprotein (AFP) and alanine aminotransferase (ALT)).
  • HBV-related HCC has extremely poor prognosis with median survival less than 16 months.
  • Survival rates of HBV-related HCC ranged from 36% to 67% after 1 year and from 15% to 26% after 5 year of diagnosis.
  • Global burden of HBV-related liver disease is still a major challenge for public health in the 21st century.
  • While decreases in incidence of HBV infection have been observed in birth cohorts following the introduction of universal infant HBV vaccination programme, HBV-related HCC incidence in is projected to increase for at least two decades because of the high prevalence of chronic HBV infection and prolonged latency to HCC development.
  • To reduce HBV-related HCC continued expansion of universal infant HBV vaccination is required along with antiviral therapy targeted to those individuals at highest risk of HCC.
  • [MeSH-major] Carcinoma, Hepatocellular / epidemiology. Hepatitis B virus / isolation & purification. Hepatitis B, Chronic / complications

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19302335.001).
  • [ISSN] 1365-2893
  • [Journal-full-title] Journal of viral hepatitis
  • [ISO-abbreviation] J. Viral Hepat.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Number-of-references] 110
  •  go-up   go-down


20. Bhala N, Bhopal R, Brock A, Griffiths C, Wild S: Alcohol-related and hepatocellular cancer deaths by country of birth in England and Wales: analysis of mortality and census data. J Public Health (Oxf); 2009 Jun;31(2):250-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alcohol-related and hepatocellular cancer deaths by country of birth in England and Wales: analysis of mortality and census data.
  • BACKGROUND: The incidence of and mortality from alcohol-related conditions, liver disease and hepatocellular cancer (HCC) are increasing in the UK.
  • MAIN OUTCOME MEASURES: Standardized mortality ratios (SMRs) for alcohol-related deaths and HCC.
  • RESULTS: Mortality from alcohol-related deaths (23 502 deaths) was particularly high for people born in Ireland (SMR for men [M]: 236, 95% confidence interval [CI]: 219-254; SMR for women [F]: 212, 95% CI: 191-235) and Scotland (SMR-M: 187, CI: 173-213; SMR-F 182, CI: 163-205) and men born in India (SMR-M: 161, CI: 144-181).
  • Low alcohol-related mortality was found in women born in other countries and men born in Bangladesh, Middle East, West Africa, Pakistan, China and Hong Kong, and the West Indies.
  • CONCLUSIONS: These findings show persistent differences in mortality by country of birth for both alcohol-related and HCC deaths and have important clinical and public health implications.
  • [MeSH-major] Alcoholism / complications. Carcinoma, Hepatocellular / chemically induced. Carcinoma, Hepatocellular / mortality. Censuses. Liver Neoplasms / chemically induced. Liver Neoplasms / mortality

  • MedlinePlus Health Information. consumer health - Alcoholism and Alcohol Abuse.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19297455.001).
  • [ISSN] 1741-3850
  • [Journal-full-title] Journal of public health (Oxford, England)
  • [ISO-abbreviation] J Public Health (Oxf)
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


21. Takahashi H, Mizuta T, Kawazoe S, Eguchi Y, Kawaguchi Y, Otuka T, Oeda S, Ario K, Iwane S, Akiyama T, Ozaki I, Fujimoto K: Efficacy and safety of radiofrequency ablation for elderly hepatocellular carcinoma patients. Hepatol Res; 2010 Oct;40(10):997-1005

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy and safety of radiofrequency ablation for elderly hepatocellular carcinoma patients.
  • AIM:   This study was conducted to evaluate the efficacy and safety of radiofrequency ablation (RFA) therapy in elderly patients with hepatocellular carcinoma (HCC).
  • RESULTS:   In the elderly group, the proportion of men, alcohol consumption, serum alanine aminotransferase and γ-glutamyl transpeptidase levels were significantly lower compared with those in the non-elderly group.
  • In multivariate analysis, Child-Pugh grade and tumor-related factors were significant factors associated with survival, but age was not.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 The Japan Society of Hepatology.
  • (PMID = 20887335.001).
  • [ISSN] 1872-034X
  • [Journal-full-title] Hepatology research : the official journal of the Japan Society of Hepatology
  • [ISO-abbreviation] Hepatol. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


22. Kirchner G, Kirovski G, Hebestreit A, Schölmerich J, Schlitt HJ, Stoeltzing O, Hellerbrand C: Epidemiology and survival of patients with hepatocellular carcinoma in Southern Germany. Int J Clin Exp Med; 2010;3(2):169-79
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epidemiology and survival of patients with hepatocellular carcinoma in Southern Germany.
  • Hepatocellular carcinoma (HCC) belongs to the most frequent tumors worldwide with an incidence still rising.
  • The results indicate that chronic alcohol abuse was the most common risk factor (57.2%), followed by infection with hepatitis B and C viruses (HBV: 10.9% and HCV: 20.5%).
  • We conclude that chronic alcohol abuse is frequently associated with HCC in low hepatitis virus endemic areas, such as Germany.
  • Our study suggests the CLIP score as a valuable prognostic marker for patients' survival, particularly of patients with alcohol related HCC.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Gastroenterol Hepatol. 1999 Nov;11(11):1215-20 [10563529.001]
  • [Cites] Hepatology. 1998 Sep;28(3):751-5 [9731568.001]
  • [Cites] Dig Dis. 2001;19(4):345-51 [11935095.001]
  • [Cites] Minerva Gastroenterol Dietol. 2005 Mar;51(1):1-5 [15756142.001]
  • [Cites] Jpn J Clin Oncol. 2008 Oct;38(10):683-8 [18753360.001]
  • [Cites] J Gastroenterol Hepatol. 2009 Mar;24(3):346-53 [19220670.001]
  • [Cites] J Hepatol. 1998 Dec;29(6):944-52 [9875641.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2000 Jan;12(1):61-6 [10656212.001]
  • [Cites] Hepatology. 2000 Apr;31(4):840-5 [10733537.001]
  • [Cites] Scand J Infect Dis. 2000;32(2):147-52 [10826899.001]
  • [Cites] Liver. 2000 Jul;20(4):312-8 [10959810.001]
  • [Cites] J Med Virol. 2001 Feb;63(2):96-102 [11170044.001]
  • [Cites] Gesundheitswesen. 2001 Dec;63(12):775-82 [11735072.001]
  • [Cites] World J Gastroenterol. 2001 Apr;7(2):208-15 [11819762.001]
  • [Cites] Cancer. 2002 Mar 15;94(6):1760-9 [11920539.001]
  • [Cites] J Surg Oncol. 2002 Dec;81(4):195-202 [12451624.001]
  • [Cites] Hepatology. 2003 Mar;37(3):520-7 [12601348.001]
  • [Cites] Cancer. 1954 May;7(3):462-503 [13160935.001]
  • [Cites] Gut. 2005 Mar;54(3):411-8 [15710992.001]
  • [Cites] J Hepatol. 2006 Jan;44(1):158-66 [16290309.001]
  • [Cites] Liver Int. 2006 Aug;26(6):680-7 [16842324.001]
  • [Cites] Ann Oncol. 2007 Mar;18(3):581-92 [17287242.001]
  • [Cites] J Gastroenterol Hepatol. 2008 Mar;23(3):459-66 [17854425.001]
  • [Cites] J Gastroenterol Hepatol. 2007 Nov;22(11):1936-41 [17914973.001]
  • [Cites] Gesundheitswesen. 2008 Jan;70(1):28-37 [18273761.001]
  • [Cites] J Clin Gastroenterol. 2008 May-Jun;42(5):527-32 [18277889.001]
  • [Cites] Cancer. 1985 Aug 15;56(4):918-28 [2990661.001]
  • [Cites] Hepatology. 1995 Oct;22(4 Pt 1):1027-33 [7557847.001]
  • [Cites] Cancer. 1996 Jun 1;77(11):2217-22 [8635087.001]
  • [Cites] Gut. 2001 Jan;48(1):103-9 [11115830.001]
  • (PMID = 20607043.001).
  • [ISSN] 1940-5901
  • [Journal-full-title] International journal of clinical and experimental medicine
  • [ISO-abbreviation] Int J Clin Exp Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2894652
  • [Keywords] NOTNLM ; CLIP score / HCC / epidemiology / hepatocellular carcinoma / survival
  •  go-up   go-down


23. Di Costanzo GG, De Luca M, Tritto G, Lampasi F, Addario L, Lanza AG, Tartaglione MT, Picciotto FP, Ascione A: Effect of alcohol, cigarette smoking, and diabetes on occurrence of hepatocellular carcinoma in patients with transfusion-acquired hepatitis C virus infection who develop cirrhosis. Eur J Gastroenterol Hepatol; 2008 Jul;20(7):674-9
MedlinePlus Health Information. consumer health - Smoking.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of alcohol, cigarette smoking, and diabetes on occurrence of hepatocellular carcinoma in patients with transfusion-acquired hepatitis C virus infection who develop cirrhosis.
  • AIM: Alcohol drinking, cigarette smoking, and diabetes have been claimed as risk factors for hepatocellular carcinoma in case-control studies.
  • The aim of this study was to define the impact of these risk factors on the development of hepatocellular carcinoma in hepatitis C virus-related liver cirrhosis.
  • METHODS: A historical cohort of 138 patients with posttransfusion hepatitis C virus-related cirrhosis was selected by reviewing all files of patients referred to our liver unit.
  • Sixty-three of them (46%) developed hepatocellular carcinoma.
  • RESULTS: At univariate analysis, risk factors for hepatocellular carcinoma were observed in patients aged above 59 years [P=0.004; relative risk (RR): 2.08, 95% confidence interval (CI): 1.19-3.68], male sex (P<0.001; RR: 2.48, 95% CI: 1.59-3.87), habit of alcohol drinking (P=0.001; RR: 1.89, 95% CI: 1.24-2.88), and duration of alcohol consumption of more than 30 years (P=0.02; RR: 2.08, 95% CI: 0.98-4.40).
  • CONCLUSION: Diabetes, smoking, and alcohol drinking were not independently related to the risk of developing hepatocellular carcinoma in hepatitis C virus-related cirrhosis.
  • [MeSH-major] Alcohol Drinking / adverse effects. Carcinoma, Hepatocellular / etiology. Diabetes Complications. Liver Neoplasms / etiology. Smoking / adverse effects


24. Pekow JR, Bhan AK, Zheng H, Chung RT: Hepatic steatosis is associated with increased frequency of hepatocellular carcinoma in patients with hepatitis C-related cirrhosis. Cancer; 2007 Jun 15;109(12):2490-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatic steatosis is associated with increased frequency of hepatocellular carcinoma in patients with hepatitis C-related cirrhosis.
  • Previous studies have suggested that hepatic steatosis is a risk factor for hepatocellular carcinoma in patients with hepatitis C virus (HCV) infection.
  • The authors sought to determine whether hepatic steatosis is associated with hepatocellular carcinoma (HCC) in a cohort of patients with hepatitis C-related cirrhosis.
  • Steatosis, age, sex, body mass index, HCV RNA, HCV genotype, Model for End-Stage Liver Disease (MELD) score, chronic alcohol use, and diabetes were examined in univariate and multivariate analyses for association with HCC.
  • CONCLUSIONS: In patients with HCV-related cirrhosis, the presence of hepatic steatosis is independently associated with the development of hepatocellular carcinoma.
  • [MeSH-major] Carcinoma, Hepatocellular / etiology. Fatty Liver / complications. Hepatitis C, Chronic / virology. Liver Cirrhosis / virology. Liver Neoplasms / etiology

  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Cirrhosis.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2007 American Cancer Society.
  • (PMID = 17487861.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Kim SR, Ikawa H, Ando K, Mita K, Fuki S, Sakamoto M, Kanbara Y, Matsuoka T, Kudo M, Hayashi Y: Multistep hepatocarcinogenesis from a dysplastic nodule to well-differentiated hepatocellular carcinoma in a patient with alcohol-related liver cirrhosis. World J Gastroenterol; 2007 Feb 28;13(8):1271-4
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multistep hepatocarcinogenesis from a dysplastic nodule to well-differentiated hepatocellular carcinoma in a patient with alcohol-related liver cirrhosis.
  • We describe a rare case of the transformation of a dysplastic nodule into well-differentiated hepato-cellular carcinoma (HCC) in a 56-year-old man with alcohol-related liver cirrhosis.
  • This is the first case of multistep hepatocarcinogenesis from a dysplastic nodule to well-differentiated HCC within one year in alcohol-related liver cirrhosis.
  • [MeSH-major] Carcinoma, Hepatocellular / pathology. Cell Transformation, Neoplastic. Liver Cirrhosis, Alcoholic / pathology. Liver Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1984 Dec 1;54(11):2487-94 [6093981.001]
  • [Cites] Lancet. 1990 Nov 10;336(8724):1150-3 [1978027.001]
  • [Cites] Hum Pathol. 1991 Feb;22(2):172-8 [1848205.001]
  • [Cites] Gastroenterology. 2004 Nov;127(5 Suppl 1):S87-96 [15508108.001]
  • [Cites] Clin Cancer Res. 2006 Sep 15;12(18):5363-8 [17000669.001]
  • [Cites] Hepatology. 2003 Jan;37(1):198-207 [12500205.001]
  • [Cites] Hepatology. 1995 Sep;22(3):983-93 [7657307.001]
  • (PMID = 17451213.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC4147007
  •  go-up   go-down


26. McGlynn KA, London WT: Epidemiology and natural history of hepatocellular carcinoma. Best Pract Res Clin Gastroenterol; 2005 Feb;19(1):3-23
SciCrunch. KEGG: Data: Disease Annotation .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epidemiology and natural history of hepatocellular carcinoma.
  • Hepatocellular carcinoma (HCC) is a major contributor to cancer incidence and mortality.
  • In contrast, hepatitis C virus and alcohol consumption are more important risk factors in low-risk countries.
  • Reasons for both trends are not completely understood, but are likely related to public health efforts in Asia and the increase in hepatitis C virus infection in low-risk countries.
  • [MeSH-major] Carcinoma, Hepatocellular / epidemiology. Global Health. Liver Neoplasms / epidemiology
  • [MeSH-minor] Aflatoxins / adverse effects. Alcohol Drinking. Chemoprevention. Food Contamination. Genetic Predisposition to Disease. Hepatitis B / complications. Hepatitis C / complications. Humans. Incidence. Liver Cirrhosis / complications. Risk Factors

  • MedlinePlus Health Information. consumer health - International Health.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15757802.001).
  • [ISSN] 1521-6918
  • [Journal-full-title] Best practice & research. Clinical gastroenterology
  • [ISO-abbreviation] Best Pract Res Clin Gastroenterol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Aflatoxins
  • [Number-of-references] 130
  •  go-up   go-down


27. Saunders D, Seidel D, Allison M, Lyratzopoulos G: Systematic review: the association between obesity and hepatocellular carcinoma - epidemiological evidence. Aliment Pharmacol Ther; 2010 May;31(10):1051-63
MedlinePlus Health Information. consumer health - Obesity.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Systematic review: the association between obesity and hepatocellular carcinoma - epidemiological evidence.
  • We examined such evidence for hepatocellular carcinoma.
  • AIM: To review the effect of increased levels of body mass index on hepatocellular carcinoma risk.
  • METHODS: We reviewed systematically the literature examining the association between increased body mass index and hepatocellular carcinoma risk.
  • Of the cohort studies, 75% of person-years related to North Americans, 15% to East Asians, and 10% to Europeans.
  • Three cohort studies adjusted for alcohol consumption, only one cohort study adjusted for hepatitis infection status.
  • Seven cohort studies found a positive association between obesity (body mass index > or =30 kg/m(2)) and hepatocellular carcinoma risk (relative risks ranging from 1.4 to 4.1); two reported no association; and one reported a significant inverse association for a population subgroup (relative risk = 0.7, 95% confidence interval: 0.5-0.9).
  • CONCLUSION: Although most studies did not adjust for confounders and most data relate to a single world region, the overall evidence is suggestive of an increased hepatocellular carcinoma risk in obese and overweight individuals.
  • [MeSH-major] Carcinoma, Hepatocellular / complications. Liver Neoplasms / complications. Obesity / complications

  • Genetic Alliance. consumer health - Obesity.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Aliment Pharmacol Ther. 2010 Jul;32(2):304-5 [20636625.001]
  • (PMID = 20175765.001).
  • [ISSN] 1365-2036
  • [Journal-full-title] Alimentary pharmacology & therapeutics
  • [ISO-abbreviation] Aliment. Pharmacol. Ther.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 56
  •  go-up   go-down


28. Brechot C, Kremsdorf D, Soussan P, Pineau P, Dejean A, Paterlini-Brechot P, Tiollais P: Hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC): molecular mechanisms and novel paradigms. Pathol Biol (Paris); 2010 Aug;58(4):278-87
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC): molecular mechanisms and novel paradigms.
  • Chronic hepatitis B (HBV) infection is a major risk factor for hepatocellular carcinoma (HCC).
  • This review will summarise the current knowledge on the mechanisms involved in HBV-related liver carcinogenesis.
  • It will show in particular how viruses can be viewed as tools to discover and dissect new cellular pathways involved in cancer development and emphasize the potential synergistic effects between HBV and hepatitis C virus (HCV), as well as between viral infections and other environmental factors, such as alcohol.
  • [MeSH-major] Carcinoma, Hepatocellular / genetics. Carcinoma, Hepatocellular / virology. Hepatitis B, Chronic / complications. Liver Neoplasms / genetics. Liver Neoplasms / virology

  • Genetic Alliance. consumer health - Hepatitis.
  • Genetic Alliance. consumer health - Hepatocellular carcinoma, adult.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010. Published by Elsevier SAS.
  • (PMID = 20667665.001).
  • [ISSN] 1768-3114
  • [Journal-full-title] Pathologie-biologie
  • [ISO-abbreviation] Pathol. Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / DNA, Viral; 0 / Hepatitis B Surface Antigens; 0 / Trans-Activators; 0 / hepatitis B virus X protein
  •  go-up   go-down


29. Miki D, Aikata H, Uka K, Saneto H, Kawaoka T, Azakami T, Takaki S, Jeong SC, Imamura M, Kawakami Y, Takahashi S, Itamoto T, Asahara T, Arihiro K, Chayama K: Clinicopathological features of elderly patients with hepatitis C virus-related hepatocellular carcinoma. J Gastroenterol; 2008;43(7):550-7
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathological features of elderly patients with hepatitis C virus-related hepatocellular carcinoma.
  • BACKGROUND: It is well known that the incidence of hepatocellular carcinoma (HCC) in patients with hepatitis C virus (HCV) correlates with progression of liver fibrosis.
  • The aim of this study was to elucidate the clinicopathological features of elderly patients with HCV-related HCC.
  • Next, we selected pure HCV-related HCC patients by excluding the patients with other probable factors for hepatocarcinogenesis (anti-HBc, interferon therapy, and alcohol) and compared the two groups again.
  • RESULTS: Higher platelet count, lower male/female ratio, lower rate of habitual alcohol consumption, and better Child-Pugh class were recognized in the elderly group thant the younger group, statistically.
  • After selection of pure HCV-related HCC patients, in a stepwise multi variate analysis, male sex and platelet count <10 x 10(4)/mm3 were significant variables associated with age <70.
  • In addition to fibrosis, aging could be a factor affecting HCV-related hepatocarcinogenesis.
  • [MeSH-major] Carcinoma, Hepatocellular / virology. Hepatitis C, Chronic / complications. Liver Neoplasms / virology

  • Genetic Alliance. consumer health - Hepatitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1993 Jun 24;328(25):1797-801 [7684822.001]
  • [Cites] Gastroenterol Jpn. 1993 Aug;28(4):547-53 [7690725.001]
  • [Cites] Hepatology. 2002 Oct;36(4 Pt 1):986-92 [12297848.001]
  • [Cites] Hepatology. 1993 Jul;18(1):47-53 [7686879.001]
  • [Cites] J Med Virol. 1990 Mar;30(3):230-2 [2160517.001]
  • [Cites] Cancer. 2002 Jul 15;95(2):331-9 [12124834.001]
  • [Cites] Gastroenterology. 1996 Jul;111(1):199-205 [8698200.001]
  • [Cites] Hepatology. 1990 Sep;12(3 Pt 1):589-91 [2169456.001]
  • [Cites] Scand J Gastroenterol. 2003 Aug;38(8):894-900 [12940445.001]
  • [Cites] Gut. 2000 Jul;47(1):131-6 [10861275.001]
  • [Cites] Cancer. 1999 May 15;85(10):2132-7 [10326690.001]
  • [Cites] Lancet. 1989 Oct 28;2(8670):1004-6 [2572739.001]
  • [Cites] Exp Cell Res. 2000 May 1;256(2):578-82 [10772830.001]
  • [Cites] Hepatology. 1998 May;27(5):1394-402 [9581697.001]
  • [Cites] J Viral Hepat. 1997 May;4(3):199-208 [9181529.001]
  • [Cites] Science. 1989 Apr 21;244(4902):362-4 [2496467.001]
  • [Cites] Hepatology. 2003 Aug;38(2):518-26 [12883497.001]
  • [Cites] Gut. 1997 Jan;40(1):128-32 [9155590.001]
  • [Cites] Cancer. 1991 Jan 15;67(2):429-33 [1845946.001]
  • [Cites] Cancer. 2000 Jul 1;89(1):53-9 [10897000.001]
  • [Cites] Science. 1989 Apr 21;244(4902):359-62 [2523562.001]
  • [Cites] J Gastroenterol. 1996 Aug;31(4):552-8 [8844477.001]
  • [Cites] J Hepatol. 2001 May;34(5):730-9 [11434620.001]
  • [Cites] J Hepatol. 1991 May;12(3):367-71 [1658121.001]
  • [Cites] Ann Intern Med. 2005 Jan 18;142(2):105-14 [15657158.001]
  • [Cites] Am J Gastroenterol. 2002 Oct;97(10):2623-8 [12385450.001]
  • [Cites] Lancet. 1989 Oct 28;2(8670):1006-8 [2572740.001]
  • [Cites] Lancet. 1997 Mar 22;349(9055):825-32 [9121257.001]
  • [Cites] Hepatology. 1993 Dec;18(6):1326-33 [8244256.001]
  • [Cites] Mutat Res. 1996 Sep 23;356(2):209-16 [8841487.001]
  • [Cites] Ann Intern Med. 1990 Feb 1;112(3):232-3 [2153357.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Sep;87(17):6547-9 [2168552.001]
  • [Cites] J Natl Cancer Inst. 1990 Jun 20;82(12):1038-41 [2161463.001]
  • [Cites] Hepatology. 1994 Jun;19(6):1513-20 [8188183.001]
  • [Cites] Ann Intern Med. 1999 Aug 3;131(3):174-81 [10428733.001]
  • [Cites] Am J Gastroenterol. 2001 Nov;96(11):3142-6 [11721762.001]
  • [Cites] Lancet. 1990 Apr 14;335(8694):873-4 [1691422.001]
  • [Cites] Hepatology. 1999 Aug;30(2):408-12 [10421648.001]
  • (PMID = 18648742.001).
  • [ISSN] 0944-1174
  • [Journal-full-title] Journal of gastroenterology
  • [ISO-abbreviation] J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


30. Ascha MS, Hanouneh IA, Lopez R, Tamimi TA, Feldstein AF, Zein NN: The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology; 2010 Jun;51(6):1972-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis.
  • Nonalcoholic steatohepatitis (NASH) is a well-recognized cause of cirrhosis and has been increasingly associated with the development of hepatocellular carcinoma (HCC).
  • The aims of this study were to (1) estimate the incidence of HCC in patients with NASH-related cirrhosis, (2) compare incidence in NASH-related cirrhosis with hepatitis C virus (HCV)-related cirrhosis, and (3) identify risk factors of HCC in patients with NASH-related cirrhosis compared with HCV-related cirrhosis.
  • Multivariate regression analysis revealed that older age (P = 0.006) and alcohol consumption (P = 0.002) were independent variables associated with development of HCC in patients with NASH-cirrhosis.
  • Compared with nondrinkers, patients who reported any regular alcohol consumption were at greater risk for HCC development (hazard ratio: 3.6; P25, P75: 1.5, 8.3).
  • Alcohol consumption, a modifiable risk factor, appears to be the most significant factor associated with risk of HCC development in our study population.
  • [MeSH-major] Carcinoma, Hepatocellular / epidemiology. Fatty Liver / complications. Hepatitis C / complications. Liver Cirrhosis / complications. Liver Neoplasms / epidemiology
  • [MeSH-minor] Alcohol Drinking / adverse effects. Female. Humans. Incidence. Male. Middle Aged. Retrospective Studies. Risk Factors. United States / epidemiology

  • MedlinePlus Health Information. consumer health - Cirrhosis.
  • MedlinePlus Health Information. consumer health - Hepatitis C.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Hepatology. 2010 Sep;52(3):1172 [20683933.001]
  • (PMID = 20209604.001).
  • [ISSN] 1527-3350
  • [Journal-full-title] Hepatology (Baltimore, Md.)
  • [ISO-abbreviation] Hepatology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


31. Capocaccia R, Sant M, Berrino F, Simonetti A, Santi V, Trevisani F, EUROCARE Working Group: Hepatocellular carcinoma: trends of incidence and survival in Europe and the United States at the end of the 20th century. Am J Gastroenterol; 2007 Aug;102(8):1661-70; quiz 1660, 1671
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatocellular carcinoma: trends of incidence and survival in Europe and the United States at the end of the 20th century.
  • OBJECTIVES: There is large geographic variation in incidence levels and time trends of hepatocellular carcinoma.
  • METHODS: Since comparisons based on cancer registry data are problematic because of variations in liver cancer definition and coding, we considered a subset of cases likely to be mainly hepatocellular carcinoma, suitable for international comparison.
  • CONCLUSIONS: Increasing incidence in southern Europe is probably related to hepatitis B and C infection and increasing alcohol intake, while improving survival may be due to greater surveillance for cirrhosis.
  • [MeSH-major] Carcinoma, Hepatocellular / epidemiology. Liver Neoplasms / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17555459.001).
  • [ISSN] 0002-9270
  • [Journal-full-title] The American journal of gastroenterology
  • [ISO-abbreviation] Am. J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


32. ElSaadany S, Giulivi A: Epidemiology of hepatocellular carcinoma in Canada, 1995: analysis of death certificates. Chronic Dis Can; 2006;27(3):125-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epidemiology of hepatocellular carcinoma in Canada, 1995: analysis of death certificates.
  • A descriptive analysis of hepatocellular carcinoma (HCC) deaths in Canada for 1995 was undertaken.
  • Of these, the largest proportion (45 percent) was of unknown type while 23 patients (22 percent) had alcohol-related cirrhosis.
  • [MeSH-major] Carcinoma, Hepatocellular / epidemiology. Death Certificates. Liver Neoplasms / epidemiology

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17306064.001).
  • [ISSN] 0228-8699
  • [Journal-full-title] Chronic diseases in Canada
  • [ISO-abbreviation] Chronic Dis Can
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  •  go-up   go-down


33. Rossi L, Zoratto F, Papa A, Iodice F, Minozzi M, Frati L, Tomao S: Current approach in the treatment of hepatocellular carcinoma. World J Gastrointest Oncol; 2010 Sep 15;2(9):348-59

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Current approach in the treatment of hepatocellular carcinoma.
  • Hepatocellular carcinoma (HCC) is the most common malignant hepatobiliary disease; it is responsible for about 1 million deaths per year.
  • Risk factors include hepatitis B and C, hepatic cirrhosis, including alcohol related hepatitis, metabolic and nutritional hepatic damage.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21160806.001).
  • [ISSN] 1948-5204
  • [Journal-full-title] World journal of gastrointestinal oncology
  • [ISO-abbreviation] World J Gastrointest Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC2999141
  • [Keywords] NOTNLM ; Hepatocarcinogenesis / Hepatocarcinoma / Local treatments / Sorafenib / Systemic treatments / Targeted therapy
  •  go-up   go-down


34. Gomaa AI, Khan SA, Toledano MB, Waked I, Taylor-Robinson SD: Hepatocellular carcinoma: epidemiology, risk factors and pathogenesis. World J Gastroenterol; 2008 Jul 21;14(27):4300-8
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatocellular carcinoma: epidemiology, risk factors and pathogenesis.
  • Hepatocellular carcinoma (HCC) is the commonest primary malignant cancer of the liver in the world.
  • Given that the burden of chronic liver disease is expected to rise owing to increasing rates of alcoholism, hepatitis B and C prevalence and obesity-related fatty liver disease, it is expected that the incidence of HCC will also increase in the foreseeable future.
  • This article summarizes the international epidemiology, the risk factors and the pathogenesis of HCC, including the roles of viral hepatitis, toxins, such as alcohol and aflatoxin, and insulin resistance.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet. 2003 Dec 20;362(9401):2083-8 [14697812.001]
  • [Cites] Kurume Med J. 2004;51(2):141-9 [15373231.001]
  • [Cites] Carcinogenesis. 2004 Oct;25(10):2023-32 [15180947.001]
  • [Cites] Gastroenterology. 2004 Nov;127(5 Suppl 1):S5-S16 [15508102.001]
  • [Cites] Nature. 1991 Apr 4;350(6317):429-31 [1672732.001]
  • [Cites] Dig Dis Sci. 1991 Aug;36(8):1134-6 [1650690.001]
  • [Cites] Virology. 1992 May;188(1):331-41 [1314459.001]
  • [Cites] Lancet. 1992 Aug 15;340(8816):427 [1353577.001]
  • [Cites] Cancer Res. 1992 Nov 15;52(22):6358-64 [1330291.001]
  • [Cites] N Engl J Med. 1992 Dec 31;327(27):1906-11 [1454085.001]
  • [Cites] Cancer Res. 1993 Feb 15;53(4):790-4 [8381328.001]
  • [Cites] J Egypt Public Health Assoc. 1992;67(3-4):223-36 [1296960.001]
  • [Cites] J Infect Dis. 1993 Sep;168(3):789-90 [8394867.001]
  • [Cites] Jpn J Cancer Res. 1993 Jul;84(7):708-14 [8396564.001]
  • [Cites] Am J Trop Med Hyg. 1993 Oct;49(4):440-7 [7692754.001]
  • [Cites] Virology. 1994 Feb;198(2):489-503 [8291231.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Mar 15;91(6):2230-4 [8134379.001]
  • [Cites] J Hepatol. 1994 Aug;21(2):159-66 [7527435.001]
  • [Cites] Br J Haematol. 1994 Jul;87(3):555-61 [7993796.001]
  • [Cites] Hepatology. 1995 Jan;21(1):77-82 [7806171.001]
  • [Cites] J Hepatol. 1994 Oct;21(4):656-66 [7814813.001]
  • [Cites] J Virol. 1995 Mar;69(3):1851-9 [7853526.001]
  • [Cites] Lancet. 1995 Feb 18;345(8947):413-5 [7772123.001]
  • [Cites] N Engl J Med. 1995 Jun 1;332(22):1463-6 [7739682.001]
  • [Cites] Acta Trop. 1995 May;59(2):155-61 [7545863.001]
  • [Cites] Vaccine. 1995;13 Suppl 1:S47-9 [7571830.001]
  • [Cites] Hepatology. 1996 Apr;23(4):695-9 [8666319.001]
  • [Cites] J Hepatol. 1996 Mar;24(3):277-85 [8778193.001]
  • [Cites] Gastroenterology. 1996 Sep;111(3):691-700 [8780574.001]
  • [Cites] J Hepatol. 1996 Jan;24(1):27-32 [8834021.001]
  • [Cites] J Natl Cancer Inst. 1996 Oct 16;88(20):1472-7 [8841022.001]
  • [Cites] Prog Clin Biol Res. 1996;395:211-22 [8895991.001]
  • [Cites] Hepatology. 1997 Feb;25(2):449-58 [9021963.001]
  • [Cites] Nat Med. 1998 Sep;4(9):1065-7 [9734402.001]
  • [Cites] Carcinogenesis. 1998 Aug;19(8):1369-75 [9744531.001]
  • [Cites] N Engl J Med. 1999 Mar 11;340(10):745-50 [10072408.001]
  • [Cites] Hepatology. 1999 Mar;29(3):664-9 [10051466.001]
  • [Cites] Bull World Health Organ. 1998;76 Suppl 2:152-3 [10063701.001]
  • [Cites] Int J Cancer. 1999 Mar 15;80(6):827-41 [10074914.001]
  • [Cites] Cancer. 1999 May 15;85(10):2132-7 [10326690.001]
  • [Cites] Int J Hyg Environ Health. 2005;208(5):329-39 [16217918.001]
  • [Cites] Liver Int. 2005 Dec;25(6):1097-107 [16343058.001]
  • [Cites] Methods Enzymol. 2005;401:307-41 [16399395.001]
  • [Cites] Biochem Biophys Res Commun. 2006 Feb 17;340(3):916-28 [16403455.001]
  • [Cites] Gastroenterology. 2006 Mar;130(3):678-86 [16530509.001]
  • [Cites] Gastroenterology. 2006 Apr;130(4):1153-68 [16618410.001]
  • [Cites] Clin Chem Lab Med. 2006;44(5):653-6 [16681440.001]
  • [Cites] Hepatology. 2006 May;43(5):915-22 [16628669.001]
  • [Cites] Oncogene. 2006 Jun 26;25(27):3771-7 [16799618.001]
  • [Cites] J Infect Dis. 2006 Sep 1;194(5):594-9 [16897657.001]
  • [Cites] Am J Gastroenterol. 2006 Aug;101(8):1797-803 [16817842.001]
  • [Cites] N Engl J Med. 1976 Apr 1;294(14):746-9 [943694.001]
  • [Cites] Lancet. 1981 Nov 21;2(8256):1129-33 [6118576.001]
  • [Cites] Gastroenterology. 1986 Feb;90(2):263-7 [2416625.001]
  • [Cites] Int J Cancer. 1988 Dec 15;42(6):872-6 [2847988.001]
  • [Cites] Cancer Res. 1989 Feb 15;49(4):1049-51 [2912550.001]
  • [Cites] Hum Pathol. 1989 Jun;20(6):594-8 [2656500.001]
  • [Cites] Lancet. 1989 Oct 28;2(8670):1004-6 [2572739.001]
  • [Cites] Lancet. 1989 Oct 28;2(8670):1006-8 [2572740.001]
  • [Cites] Hepatology. 1990 Jan;11(1):74-80 [2295475.001]
  • [Cites] Hepatology. 1990 Oct;12(4 Pt 1):671-5 [2170265.001]
  • [Cites] Cancer. 1991 Jan 15;67(2):429-33 [1845946.001]
  • [Cites] Hepatology. 1999 Aug;30(2):517-25 [10421662.001]
  • [Cites] BMJ. 1999 Sep 4;319(7210):640 [10473489.001]
  • [Cites] Gastroenterology. 2004 Dec;127(6):1733-8 [15578511.001]
  • [Cites] Dis Mon. 2004 Oct;50(10):556-73 [15616490.001]
  • [Cites] Gastroenterology. 2005 Jan;128(1):24-32 [15633120.001]
  • [Cites] Food Chem Toxicol. 2005 Mar;43(3):433-41 [15680679.001]
  • [Cites] J Natl Cancer Inst. 2005 Feb 16;97(4):265-72 [15713961.001]
  • [Cites] Gut. 2005 Apr;54(4):533-9 [15753540.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] J Hepatol. 2005 Apr;42(4):444-6 [15763323.001]
  • [Cites] Int J Cancer. 2005 Jun 10;115(2):290-5 [15688396.001]
  • [Cites] Semin Liver Dis. 2005;25(2):143-54 [15918143.001]
  • [Cites] Liver Int. 2005 Aug;25(4):696-703 [15998418.001]
  • [Cites] Lancet Infect Dis. 2005 Sep;5(9):558-67 [16122679.001]
  • [Cites] World J Gastroenterol. 2005 Sep 7;11(33):5193-8 [16127751.001]
  • [Cites] Int J Cancer. 2006 Dec 15;119(12):2916-21 [16998792.001]
  • [Cites] J Med Virol. 2007 Jan;79(1):92-6 [17133558.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Dec;15(12):2521-5 [17164379.001]
  • [Cites] Cancer Sci. 2007 Feb;98(2):214-8 [17233838.001]
  • [Cites] Int J Cancer. 2007 Apr 1;120(7):1555-9 [17205531.001]
  • [Cites] J Viral Hepat. 2007 Mar;14(3):153-60 [17305880.001]
  • [Cites] Am J Med. 2007 Mar;120(3):194-202 [17349437.001]
  • [Cites] J Chin Med Assoc. 2007 Apr;70(4):141-5 [17475593.001]
  • [Cites] Hepatology. 2007 Aug;46(2):430-5 [17580359.001]
  • [Cites] Clin Liver Dis. 2007 Nov;11(4):797-816, viii [17981229.001]
  • [Cites] J Infect Dis. 2000 May;181(5):1528-36 [10823750.001]
  • [Cites] Teratog Carcinog Mutagen. 2000;20(4):229-40 [10910473.001]
  • [Cites] Eur J Epidemiol. 2000 May;16(5):419-23 [10997828.001]
  • [Cites] Immunol Lett. 2000 Oct 3;74(2):117-20 [10996386.001]
  • [Cites] Cell Immunol. 2000 Aug 1;203(2):111-23 [11006009.001]
  • [Cites] Infection. 2000 Nov-Dec;28(6):341-5 [11139151.001]
  • [Cites] Am J Gastroenterol. 2001 Jan;96(1):179-83 [11197250.001]
  • [Cites] Gastroenterology. 2001 Jul;121(1):91-100 [11438497.001]
  • [Cites] J Clin Gastroenterol. 2001 Aug;33(2):123-6 [11468438.001]
  • [Cites] J Clin Epidemiol. 2001 Aug;54(8):823-9 [11470392.001]
  • [Cites] J Hepatol. 2001 Sep;35(3):421-30 [11592607.001]
  • [Cites] J Gastroenterol. 2001 Oct;36(10):651-60 [11686474.001]
  • [Cites] Ann Intern Med. 2001 Nov 6;135(9):796-800 [11694104.001]
  • [Cites] Lancet. 1997 Mar 22;349(9055):825-32 [9121257.001]
  • [Cites] N Engl J Med. 1997 Jun 26;336(26):1855-9 [9197213.001]
  • [Cites] Eur J Cancer. 1997 Apr;33(4):629-34 [9274446.001]
  • [Cites] Hepatology. 1997 Sep;26(3 Suppl 1):2S-10S [9305656.001]
  • [Cites] J Natl Cancer Inst. 1997 Sep 17;89(18):1360-5 [9308706.001]
  • [Cites] J Virol. 1997 Oct;71(10):7387-92 [9311817.001]
  • [Cites] Zhonghua Yi Xue Za Zhi (Taipei). 1997 Jul;60(1):40-7 [9316327.001]
  • [Cites] Liver. 1997 Oct;17(5):215-23 [9387912.001]
  • [Cites] Int J Cancer. 1998 Jan 30;75(3):347-54 [9455792.001]
  • [Cites] Hepatology. 1998 Jun;27(6):1730-5 [9620350.001]
  • [Cites] J Gastroenterol Hepatol. 1998 Apr;13(4):419-26 [9641308.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Jul 21;95(15):8847-51 [9671767.001]
  • [Cites] Hepatology. 1998 Sep;28(3):805-9 [9731576.001]
  • [Cites] Hepatology. 1999 Dec;30(6):1356-62 [10573511.001]
  • [Cites] Hepatology. 2000 Feb;31(2):513-20 [10655279.001]
  • [Cites] Int J Cancer. 2000 Feb 15;85(4):498-502 [10699921.001]
  • [Cites] J Hepatol. 2000;32(1 Suppl):225-37 [10728807.001]
  • [Cites] Lancet. 2000 Mar 11;355(9207):887-91 [10752705.001]
  • [Cites] J Gastroenterol Hepatol. 2000 Apr;15(4):357-68 [10824878.001]
  • [Cites] Ann N Y Acad Sci. 2002 Jun;963:13-20 [12095924.001]
  • [Cites] Gastroenterology. 2002 Jul;123(1):134-40 [12105842.001]
  • [Cites] J Vasc Interv Radiol. 2002 Sep;13(9 Pt 2):S169-71 [12354833.001]
  • [Cites] Am J Gastroenterol. 2002 Nov;97(11):2886-95 [12425564.001]
  • [Cites] J Hepatol. 2002 Dec;37(6):806-13 [12445422.001]
  • [Cites] Jpn J Cancer Res. 2002 Dec;93(12):1287-92 [12495467.001]
  • [Cites] Gastroenterology. 2003 Feb;124(2):327-34 [12557138.001]
  • (PMID = 18666317.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] ENG
  • [Grant] United Kingdom / Medical Research Council / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aflatoxins
  • [Number-of-references] 134
  • [Other-IDs] NLM/ PMC2731180
  •  go-up   go-down


35. Yeh CB, Tsai HT, Chen YC, Kuo WH, Chen TY, Hsieh YH, Chou MC, Yang SF: Genetic polymorphism of CCR2-64I increased the susceptibility of hepatocellular carcinoma. J Surg Oncol; 2010 Sep 1;102(3):264-70
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetic polymorphism of CCR2-64I increased the susceptibility of hepatocellular carcinoma.
  • BACKGROUND AND OBJECTIVES: The purpose of this study was to investigate genetic impact of monocyte chemoattractant protein-1 (MCP-1) and its receptor chemokine receptor-2 (CCR2) gene polymorphisms on the susceptibility and clinicopathological characteristics of hepatocellular carcinoma (HCC).
  • There was no synergistic effect between gene polymorphism and environmental risk factors, including tobacco and alcohol consumptions, as well as clinicopathological parameters of HCC for MCP-1 -2518G/A and CCR2 V64I genes, respectively.
  • CONCLUSIONS: CCR2-64I gene polymorphism is an important factor for the susceptibility of HCC but it might not influence the clinical pathological progression of HCC, and the contribution of CCR2-64I gene polymorphism on the susceptibility of HCC could be not through the affection of liver injury-related clinical pathological characteristics.
  • [MeSH-major] Carcinoma, Hepatocellular / genetics. Genetic Predisposition to Disease. Liver Neoplasms / genetics. Polymorphism, Genetic. Receptors, CCR2 / genetics

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Wiley-Liss, Inc.
  • (PMID = 20740585.001).
  • [ISSN] 1096-9098
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CCL2 protein, human; 0 / CCR2 protein, human; 0 / Chemokine CCL2; 0 / Receptors, CCR2
  •  go-up   go-down


36. Barazani Y, Hiatt JR, Tong MJ, Busuttil RW: Chronic viral hepatitis and hepatocellular carcinoma. World J Surg; 2007 Jun;31(6):1243-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chronic viral hepatitis and hepatocellular carcinoma.
  • BACKGROUND: Hepatocellular carcinoma (HCC) is the third leading cause of death from malignancy worldwide, and its increasing incidence parallels rising global rates of hepatitis B (HBV) and hepatitis C (HCV).
  • Hepatitis B patients exhibited stronger family histories of liver disease (54%) and HCC (33%), whereas HCV risk factors included blood transfusion (56%), intravenous drug abuse (31%), and alcohol consumption (44%; p < 0.0001 for all comparisons).
  • CONCLUSIONS: Patients with HBV- and HCV-related HCC have different epidemiologic, clinical, and survival characteristics.
  • [MeSH-major] Carcinoma, Hepatocellular / diagnosis. Hepatitis B, Chronic / complications. Hepatitis C, Chronic / complications. Liver Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hepatology. 1995 Oct;22(4 Pt 1):1027-33 [7557847.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2000 Aug;12(8):941-8 [10958223.001]
  • [Cites] World J Gastroenterol. 2006 Aug 7;12 (29):4656-9 [16937435.001]
  • [Cites] Ann Surg Oncol. 2000 Dec;7(10):764-70 [11129425.001]
  • [Cites] Antiviral Res. 2001 Nov;52(2):199-207 [11672830.001]
  • [Cites] Hepatogastroenterology. 2003 Nov-Dec;50(54):1872-7 [14696422.001]
  • [Cites] Surgery. 1998 May;123(5):554-9 [9591008.001]
  • [Cites] Br J Surg. 1998 Oct;85(10):1319-31 [9782009.001]
  • [Cites] J Gastroenterol. 2005 Mar;40(3):225-35 [15830281.001]
  • [Cites] World J Surg. 2002 Jun;26(6):742-7 [12053231.001]
  • [Cites] Am J Gastroenterol. 2002 Jan;97(1):156-61 [11808941.001]
  • [Cites] Cochrane Database Syst Rev. 2003;(2):CD002799 [12804438.001]
  • [Cites] Lancet. 2003 Dec 6;362(9399):1907-17 [14667750.001]
  • [Cites] Gastroenterology. 2004 Nov;127(5 Suppl 1):S108-12 [15508073.001]
  • [Cites] Hepatology. 1998 Jan;27(1):273-8 [9425947.001]
  • [Cites] World J Surg. 2004 Aug;28(8):787-91 [15457359.001]
  • [Cites] J Hepatol. 2006 Jan;44(1):158-66 [16290309.001]
  • [Cites] Transpl Int. 2005 Dec;18(12):1328-35 [16297051.001]
  • [Cites] Dig Dis. 2001;19(4):263-8 [11935085.001]
  • [Cites] Eur J Cancer. 2006 Oct;42(15):2524-9 [16920352.001]
  • [Cites] Gastroenterology. 2004 Nov;127(5 Suppl 1):S17-26 [15508082.001]
  • [Cites] N Engl J Med. 1996 Mar 14;334(11):693-9 [8594428.001]
  • [Cites] Z Gastroenterol. 1997 Dec;35(12):1059-67 [9487638.001]
  • [Cites] World J Gastroenterol. 2001 Apr;7(2):208-15 [11819762.001]
  • [Cites] J Gastroenterol Hepatol. 1996 Oct;11(10):949-54 [8912133.001]
  • [Cites] Liver Int. 2005 Apr;25(2):236-41 [15780044.001]
  • [Cites] Hepatogastroenterology. 2003 Nov-Dec;50(54):2022-7 [14696457.001]
  • [Cites] Hepatology. 2005 Nov;42(5):1208-36 [16250051.001]
  • [Cites] Jpn J Clin Oncol. 1997 Apr;27(2):67-70 [9152792.001]
  • [Cites] J Gastrointest Surg. 2003 Mar-Apr;7(3):401-11 [12654567.001]
  • [Cites] J Viral Hepat. 2003 Nov;10(6):450-4 [14633179.001]
  • [Cites] Liver. 2000 Jul;20(4):312-8 [10959810.001]
  • (PMID = 17440771.001).
  • [ISSN] 0364-2313
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


37. Teramoto R, Minagawa H, Honda M, Miyazaki K, Tabuse Y, Kamijo K, Ueda T, Kaneko S: Protein expression profile characteristic to hepatocellular carcinoma revealed by 2D-DIGE with supervised learning. Biochim Biophys Acta; 2008 May;1784(5):764-72
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Protein expression profile characteristic to hepatocellular carcinoma revealed by 2D-DIGE with supervised learning.
  • Hepatocellular carcinoma (HCC) is one of the most common and aggressive human malignancies.
  • Although several major risks related to HCC, e.g., hepatitis B and/or hepatitis C virus infection, aflatoxin B1 exposure, alcohol drinking and genetic defects have been revealed, the molecular mechanisms leading to the initiation and progression of HCC have not been clarified.
  • We confirmed that SGB is able to identify the known HCC-related proteins, e.g., heat shock proteins, carbonic anhydrase 2.
  • Moreover, we identified the differentially expressed proteins associated with histological grade of HCC and AFP level and found that aldo-keto reductase 1B10 (AKR1B10) is related to well differentiated HCC, keratin 8 (KRT8) is related to both histological grade and AFP level and protein disulfide isomerase-associated 3 (PDIA3) is associated with both HCC and AFP level.
  • [MeSH-major] Carcinoma, Hepatocellular / chemistry. Liver Neoplasms / chemistry. Proteomics

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18359300.001).
  • [ISSN] 0006-3002
  • [Journal-full-title] Biochimica et biophysica acta
  • [ISO-abbreviation] Biochim. Biophys. Acta
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / alpha-Fetoproteins
  •  go-up   go-down


38. Asia-Pacific Working Party on Prevention of Hepatocellular Carcinoma: Prevention of hepatocellular carcinoma in the Asia-Pacific region: consensus statements. J Gastroenterol Hepatol; 2010 Apr;25(4):657-63
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prevention of hepatocellular carcinoma in the Asia-Pacific region: consensus statements.
  • Among approximately 650,000 people who die from hepatocellular carcinoma (HCC) each year, at least two-thirds live in Asia.
  • Separate reviews have summarized epidemiology of HCC, preventive approaches related to hepatitis B virus (HBV), hepatitis C virus (HCV) and non-viral liver diseases, and the role of surveillance to detect HCC at a curative stage.
  • There is currently insufficient evidence to give firm recommendations on alcohol, obesity/metabolic risk factors and other liver diseases.
  • [MeSH-major] Carcinoma, Hepatocellular / prevention & control. Hepatitis B, Chronic / prevention & control. Hepatitis C, Chronic / prevention & control. Liver Neoplasms / prevention & control. Mass Screening. Primary Prevention

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20492323.001).
  • [ISSN] 1440-1746
  • [Journal-full-title] Journal of gastroenterology and hepatology
  • [ISO-abbreviation] J. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Journal Article; Practice Guideline; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / Hepatitis B Vaccines
  • [Investigator] Farrell GC; Chan HL; Yuen MF; Amarapurkar DN; Chutaputti A; Fan JG; Hou JL; Han KH; Kao JH; Lim SG; Mohamed R; Sollano J; Ueno Y
  •  go-up   go-down


39. Gao C, Yao SK: Diabetes mellitus: a "true" independent risk factor for hepatocellular carcinoma? Hepatobiliary Pancreat Dis Int; 2009 Oct;8(5):465-73
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diabetes mellitus: a "true" independent risk factor for hepatocellular carcinoma?
  • BACKGROUND: Diabetes mellitus (DM) is thought to be associated with an increased risk of hepatocellular carcinoma (HCC) in some published studies.
  • DATA SOURCES: MEDLINE and PubMed searches were conducted for published studies (between January 1966 and June 2009) to identify relevant articles using the keywords "diabetes", "insulin resistance" and "hepatocellular carcinoma", including "primary liver cancer".
  • (1) the significant synergy between DM, hepatitis virus infection, and heavy alcohol consumption in HCC;.
  • Related issues should be clarified by more research.
  • [MeSH-major] Carcinoma, Hepatocellular / epidemiology. Diabetes Complications / complications. Liver Neoplasms / epidemiology
  • [MeSH-minor] Alcohol Drinking / adverse effects. Hepatitis C, Chronic / complications. Humans. Risk Factors

  • Genetic Alliance. consumer health - Diabetes.
  • MedlinePlus Health Information. consumer health - Diabetes Complications.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19822488.001).
  • [ISSN] 1499-3872
  • [Journal-full-title] Hepatobiliary & pancreatic diseases international : HBPD INT
  • [ISO-abbreviation] HBPD INT
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] China
  • [Number-of-references] 41
  •  go-up   go-down


40. Kwon OS, Jung YK, Kim YS, Kim SG, Kim YS, Lee JI, Lee JW, Kim YS, Chun BC, Kim JH: Effect of alcohol on the development of hepatocellular carcinoma in patients with hepatitis B virus-related cirrhosis: a cross-sectional case-control study. Korean J Hepatol; 2010 Sep;16(3):308-14
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of alcohol on the development of hepatocellular carcinoma in patients with hepatitis B virus-related cirrhosis: a cross-sectional case-control study.
  • BACKGROUND/AIMS: Whether alcohol intake increases the risk of hepatocellular carcinoma (HCC) in patients with chronic hepatitis B virus (HBV) infection remains controversial.
  • The aim of this study was to determine the effect of alcohol intake on the development of HCC.
  • All cases and controls were HBsAg positive, and had a history of lifetime alcohol intake.
  • The basal laboratory data, distribution of Child-Pugh class, HBeAg positivity (31.5% vs. 37.7%), HBV DNA level (5.74±2.35 vs. 5.98±2.29 log10 copies/mL), and proportion with a lifetime alcohol intake of more than 292 kg (30.8% vs. 34.9%) did not differ between cases and controls.
  • The cumulative alcohol intake and the proportion of heavy drinkers did not differ between the two groups in male patients.
  • CONCLUSIONS: Alcohol intake might not increase the risk of HCC in patients with HBV infection.
  • [MeSH-major] Alcohol Drinking / adverse effects. Carcinoma, Hepatocellular / etiology. Hepatitis B, Chronic / complications. Liver Cirrhosis / complications. Liver Neoplasms / etiology

  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Alcohol.
  • MedlinePlus Health Information. consumer health - Cirrhosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1998 Mar 1;82(5):827-35 [9486570.001]
  • [Cites] Am J Epidemiol. 1997 Jun 1;145(11):1039-47 [9169913.001]
  • [Cites] Clin Liver Dis. 2005 Feb;9(1):151-69 [15763234.001]
  • [Cites] JAMA. 2006 Jan 4;295(1):65-73 [16391218.001]
  • [Cites] Gastroenterology. 2006 Mar;130(3):678-86 [16530509.001]
  • [Cites] Gastroenterology. 2007 Jun;132(7):2557-76 [17570226.001]
  • [Cites] Liver Int. 2007 Dec;27(10):1356-63 [17900245.001]
  • [Cites] Gut. 2008 Jan;57(1):91-7 [17502344.001]
  • [Cites] Carcinogenesis. 2008 Jan;29(1):106-12 [17999990.001]
  • [Cites] Hepatology. 2009 May;49(5 Suppl):S56-60 [19399807.001]
  • [Cites] Korean J Hepatol. 2009 Sep;15(3):391-423 [19783891.001]
  • [Cites] Hepatology. 2010 Jan;51(1):307-28 [20034030.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2000 Jun;12(6):687-93 [10912490.001]
  • [Cites] J Gastroenterol Hepatol. 2000 May;15 Suppl:E20-4 [10921377.001]
  • [Cites] Alcohol Clin Exp Res. 2001 May;25(5 Suppl ISBRA):40S-45S [11391047.001]
  • [Cites] Am J Gastroenterol. 2001 Aug;96(8):2462-7 [11513191.001]
  • [Cites] Hepatology. 2001 Oct;34(4 Pt 1):714-8 [11584367.001]
  • [Cites] Br J Cancer. 2001 Nov 30;85(11):1700-5 [11742491.001]
  • [Cites] Am J Epidemiol. 2002 Feb 15;155(4):323-31 [11836196.001]
  • [Cites] Lancet Oncol. 2001 Sep;2(9):533-43 [11905707.001]
  • [Cites] N Engl J Med. 2002 Jul 18;347(3):168-74 [12124405.001]
  • [Cites] Hepatology. 2002 Nov;36(5):1206-13 [12395331.001]
  • [Cites] Cancer Causes Control. 2003 Dec;14(10):995-1000 [14750539.001]
  • [Cites] Gastroenterology. 2004 Nov;127(5 Suppl 1):S35-50 [15508101.001]
  • [Cites] Br J Addict. 1982 Dec;77(4):357-82 [6762224.001]
  • [Cites] J Med Virol. 1984;13(4):385-91 [6330293.001]
  • [Cites] Gut. 1991 Mar;32(3):294-8 [2013423.001]
  • [Cites] Hepatology. 1993 Jul;18(1):47-53 [7686879.001]
  • [Cites] Alcohol Clin Exp Res. 1996 Feb;20(1 Suppl):91A-94A [8659700.001]
  • [Cites] Alcohol Clin Exp Res. 1996 Jun;20(4):758-62 [8800396.001]
  • [Cites] Hepatology. 1998 Apr;27(4):914-9 [9537428.001]
  • (PMID = 20924214.001).
  • [ISSN] 1738-222X
  • [Journal-full-title] The Korean journal of hepatology
  • [ISO-abbreviation] Korean J Hepatol
  • [Language] eng
  • [Publication-type] Controlled Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / DNA, Viral; 0 / Hepatitis B Surface Antigens
  • [Other-IDs] NLM/ PMC3304590
  •  go-up   go-down


41. Chen JD, Yang HI, Iloeje UH, You SL, Lu SN, Wang LY, Su J, Sun CA, Liaw YF, Chen CJ, Risk Evaluation of Viral Load Elevation and Associated Liver Disease/Cancer in HBV (REVEAL-HBV) Study Group: Carriers of inactive hepatitis B virus are still at risk for hepatocellular carcinoma and liver-related death. Gastroenterology; 2010 May;138(5):1747-54
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carriers of inactive hepatitis B virus are still at risk for hepatocellular carcinoma and liver-related death.
  • METHODS: Participants in the Risk Evaluation of Viral Load Elevation and Associated Liver Disease/Cancer-Hepatitis B Virus (REVEAL-HBV) study who were seronegative for hepatitis B e antigen; had serum levels of HBV DNA <10,000 copies/mL; and did not have cirrhosis, hepatocellular carcinoma, or increased serum levels of alanine aminotransferase were classified as carriers of inactive HBV (n = 1932).
  • Liver-related death and new cases of hepatocellular carcinoma were ascertained through computerized data linkage with National Cancer Registry and Death Certification profiles.
  • Annual incidence rates of hepatocellular carcinoma and liver-related death were 0.06% and 0.04%, respectively, for inactive HBV carriers; rates were 0.02%, and 0.02% for controls, respectively.
  • The multivariate-adjusted hazard ratios for carriers of inactive HBV, compared to controls, were 4.6 (95% confidence interval: 2.5-8.3) for hepatocellular carcinoma and 2.1 (95% confidence interval: 1.1-4.1) for liver-related death.
  • Older age and alcohol drinking habits were independent predictors of risk for carriers of inactive HBV to develop hepatocellular carcinoma.
  • CONCLUSIONS: Carriers of inactive HBV have a substantial risk of hepatocellular carcinoma and liver-related death compared with individuals not infected with HBV.
  • [MeSH-major] Carcinoma, Hepatocellular / virology. Carrier State. Hepatitis B / diagnosis. Hepatitis B virus / pathogenicity. Liver Neoplasms / virology. Virus Inactivation
  • [MeSH-minor] Adult. Age Factors. Alcohol Drinking. Case-Control Studies. DNA, Viral / blood. Female. Hepatitis B Surface Antigens / blood. Hepatitis B e Antigens / blood. Hepatitis C Antibodies / blood. Humans. Incidence. Male. Middle Aged. Proportional Hazards Models. Registries. Risk Assessment. Risk Factors. Taiwan / epidemiology. Time Factors. Viral Load

  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Hepatitis B.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 AGA Institute. Published by Elsevier Inc. All rights reserved.
  • (PMID = 20114048.001).
  • [ISSN] 1528-0012
  • [Journal-full-title] Gastroenterology
  • [ISO-abbreviation] Gastroenterology
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Viral; 0 / Hepatitis B Surface Antigens; 0 / Hepatitis B e Antigens; 0 / Hepatitis C Antibodies
  • [Investigator] Hsieh C; Lee HS; Yang PM; Chen CH; Huang SP; Jan CF; Chen TH; Wu MH; Chen SY; Chu KE; Ho SC; Lu TG; Wu WP; Ou TY; Lin CG; Shih KC; Chung WS; Li C; Chen CC; How WC
  •  go-up   go-down


42. Hernandez-Vargas H, Lambert MP, Le Calvez-Kelm F, Gouysse G, McKay-Chopin S, Tavtigian SV, Scoazec JY, Herceg Z: Hepatocellular carcinoma displays distinct DNA methylation signatures with potential as clinical predictors. PLoS One; 2010;5(3):e9749
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatocellular carcinoma displays distinct DNA methylation signatures with potential as clinical predictors.
  • BACKGROUND: Hepatocellular carcinoma (HCC) is characterized by late detection and fast progression, and it is believed that epigenetic disruption may be the cause of its molecular and clinicopathological heterogeneity.
  • A wide panel of cancer-related gene promoters was analyzed using Illumina bead array technology, and CpG sites were then selected according to their ability to classify clinicopathological parameters.
  • However, aberrant methylation of an independent subset of promoters was associated with tumor progression and etiological risk factors (HBV or HCV infection and alcohol consumption).
  • [MeSH-major] Carcinoma, Hepatocellular / metabolism. DNA Methylation. Gene Expression Regulation, Neoplastic. Liver Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 2004 Apr 1;10(7):2441-6 [15073122.001]
  • [Cites] Cell Res. 2003 Oct;13(5):319-33 [14672555.001]
  • [Cites] Pharmacogenetics. 1996 Dec;6(6):501-12 [9014199.001]
  • [Cites] Nat Rev Cancer. 2004 Dec;4(12):988-93 [15573120.001]
  • [Cites] Genome Res. 2006 Mar;16(3):383-93 [16449502.001]
  • [Cites] Cancer Cell. 2006 Mar;9(3):199-207 [16530704.001]
  • [Cites] J Gastroenterol Hepatol. 2006 Jan;21(1 Pt 1):15-21 [16706806.001]
  • [Cites] Cancer Lett. 2006 Jul 28;239(1):10-20 [16154256.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2006;13(4):265-73 [16858536.001]
  • [Cites] Br J Cancer. 2007 Jan 29;96(2):183-8 [17179991.001]
  • [Cites] Clin Cancer Res. 2007 Apr 15;13(8):2378-84 [17438096.001]
  • [Cites] Cancer Res. 2007 Jun 15;67(12):5771-8 [17575144.001]
  • [Cites] J Clin Invest. 2007 Sep;117(9):2713-22 [17717605.001]
  • [Cites] Stat Med. 2007 Oct 30;26(24):4428-40 [17357994.001]
  • [Cites] Biochem Biophys Res Commun. 2008 Feb 15;366(3):643-8 [18054330.001]
  • [Cites] Cancer Sci. 2008 Feb;99(2):340-4 [18271934.001]
  • [Cites] World J Gastroenterol. 2008 Mar 21;14(11):1741-8 [18350605.001]
  • [Cites] Gastroenterology. 2008 May;134(6):1655-69 [18471545.001]
  • [Cites] World J Gastroenterol. 2008 Jul 21;14(27):4300-8 [18666317.001]
  • [Cites] Carcinogenesis. 2008 Oct;29(10):1901-10 [18632756.001]
  • [Cites] N Engl J Med. 2008 Nov 6;359(19):1995-2004 [18923165.001]
  • [Cites] Int J Cancer. 2009 Jan 1;124(1):81-7 [18823011.001]
  • [Cites] Cancer Res. 2009 Jan 1;69(1):243-52 [19118009.001]
  • [Cites] Clin Cancer Res. 2009 Feb 1;15(3):812-20 [19188151.001]
  • [Cites] Gut. 2000 Nov;47(5):703-9 [11034589.001]
  • [Cites] Hepatology. 2000 Nov;32(5):970-9 [11050047.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Dec 18;98(26):15149-54 [11742071.001]
  • [Cites] Lancet Oncol. 2001 Sep;2(9):533-43 [11905707.001]
  • [Cites] J Natl Cancer Inst. 2002 May 15;94(10):755-61 [12011226.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 May 14;99(10):6567-72 [12011421.001]
  • [Cites] Nat Rev Genet. 2002 Jun;3(6):415-28 [12042769.001]
  • [Cites] Hepatology. 2002 Aug;36(2):433-8 [12143053.001]
  • [Cites] Nat Genet. 2002 Aug;31(4):339-46 [12149612.001]
  • [Cites] J Comput Biol. 2002;9(3):505-11 [12162889.001]
  • [Cites] Mol Carcinog. 2002 Oct;35(2):85-92 [12325038.001]
  • [Cites] J Natl Cancer Inst. 2003 Jan 1;95(1):14-8 [12509396.001]
  • [Cites] BMC Cancer. 2002 Nov 15;2:29 [12433278.001]
  • [Cites] Am J Pathol. 2003 Sep;163(3):1101-7 [12937151.001]
  • [Cites] Clin Cancer Res. 2003 Aug 15;9(9):3376-82 [12960125.001]
  • [Cites] Am J Pathol. 2003 Oct;163(4):1371-8 [14507645.001]
  • [Cites] Br J Cancer. 2003 Nov 3;89(9):1599-604 [14583755.001]
  • [Cites] Bioinformatics. 2003 Dec 12;19(18):2448-55 [14668230.001]
  • [Cites] Neurochem Res. 2004 Jun;29(6):1213-22 [15176478.001]
  • (PMID = 20305825.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2840036
  •  go-up   go-down


43. Hu L, Liu J, Chen X, Zhang Y, Liu L, Zhu J, Chen J, Shen H, Qiang F, Hu Z: CTLA-4 gene polymorphism +49 A/G contributes to genetic susceptibility to two infection-related cancers-hepatocellular carcinoma and cervical cancer. Hum Immunol; 2010 Sep;71(9):888-91
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CTLA-4 gene polymorphism +49 A/G contributes to genetic susceptibility to two infection-related cancers-hepatocellular carcinoma and cervical cancer.
  • In the present study, we expanded our study to two infection-related cancers, namely, hepatocellular carcinoma (HCC) and cervical cancer.
  • [MeSH-major] Antigens, CD / genetics. Carcinoma, Hepatocellular / genetics. Genetic Predisposition to Disease / genetics. Liver Neoplasms / genetics. Polymorphism, Single Nucleotide / genetics. Uterine Cervical Neoplasms / genetics
  • [MeSH-minor] Adult. Age Factors. Aged. Alcohol Drinking / adverse effects. Alcohol Drinking / epidemiology. CTLA-4 Antigen. Carcinoma, Squamous Cell / complications. China. Female. Gene Frequency / genetics. Genotype. Hepatitis B / complications. Hepatitis B / epidemiology. Hepatitis C / complications. Hepatitis C / epidemiology. Humans. Male. Menarche. Middle Aged. Parity. Parturition. Pregnancy. Premenopause. Risk Factors. Smoking / adverse effects. Smoking / epidemiology

  • Genetic Alliance. consumer health - Cervical cancer.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 American Society for Histocompatibility and Immunogenetics. Published by Elsevier Inc. All rights reserved.
  • (PMID = 20538028.001).
  • [ISSN] 1879-1166
  • [Journal-full-title] Human immunology
  • [ISO-abbreviation] Hum. Immunol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / CTLA-4 Antigen; 0 / CTLA4 protein, human
  •  go-up   go-down


44. Jeng JE, Chuang LY, Chuang WL, Chang JG, Tsai JF: Insulin-like growth factor II in hepatocellular carcinoma. Biomark Med; 2007 Aug;1(2):261-71

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Insulin-like growth factor II in hepatocellular carcinoma.
  • Hepatocellular carcinoma is one of the most common malignant human tumors.
  • Chronic hepatitis B and hepatitis C virus infection, alcohol drinking and cirrhosis of any etiology are the major risk factors for hepatocellular carcinoma.
  • Growth factors, their receptors and related proteins are involved in the process of malignant transformation.
  • Increased IGF-II bioavailability, protease activity of IGF-binding proteins and IGF-I receptor expression, decreased expression of IGF-II receptor and IGF-binding proteins are thought to contribute to hepatocellular carcinoma genesis.
  • In the second part it will emphasize circulating IGF-II levels in chronic liver disease and hepatocellular carcinoma, and diagnostic application of serum IGF-II level in both small and larger hepatocellular carcinoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20477401.001).
  • [ISSN] 1752-0371
  • [Journal-full-title] Biomarkers in medicine
  • [ISO-abbreviation] Biomark Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


45. Kanazir M, Boricic I, Delic D, Tepavcevic DK, Knezevic A, Jovanovic T, Pekmezovic T: Risk factors for hepatocellular carcinoma: a case-control study in Belgrade (Serbia). Tumori; 2010 Nov-Dec;96(6):911-7
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk factors for hepatocellular carcinoma: a case-control study in Belgrade (Serbia).
  • AIMS AND BACKGROUND: The objective of this case-control study was to test the existing hypotheses about factors related to the occurrence of hepatocellular carcinoma in the population of Belgrade (Serbia).
  • METHODS AND STUDY DESIGN: The investigation was conducted between 2004 and 2007 and consisted of 45 newly diagnosed, histologically confirmed hepatocellular carcinoma patients and 90 individually gender- and age-matched hospital controls.
  • RESULTS: A highly statistically significant association (P = 0.001) was demonstrated between hepatocellular carcinoma and HBsAg positivity and the presence of hepatitis C virus antibodies.
  • Diabetes mellitus was significantly (P = 0.018) associated with an increased risk of hepatocellular carcinoma.
  • A statistically significant inverse association was shown between low parity and the risk of hepatocellular carcinoma (P = 0.033).
  • A weekly intake of fish (P = 0.003) and yogurt (P = 0.003) and daily intake of boiled vegetables (P = 0.001) were reported more frequently by controls than hepatocellular carcinoma cases.
  • In the current study, a high intake of salty food also significantly increased the risk of hepatocellular carcinoma (P = 0.027).
  • Based on multivariate analysis, the presence of hepatitis C virus antibodies (OR = 24.6, P = 0.001) and duration of smoking > or =25 years (OR = 3.8, P = 0.020) were significantly related to hepatocellular carcinoma, whereas the daily consumption of boiled vegetables (OR = 0.1, P = 0.011) was inversely associated with the risk of hepatocellular carcinoma.
  • CONCLUSIONS: The findings obtained in the current study support the hypotheses that non-viral factors, such as lifestyle factors, reproductive factors, and a history of diabetes, might be involved in the etiology of hepatocellular carcinoma.
  • [MeSH-major] Carcinoma, Hepatocellular / epidemiology. Carcinoma, Hepatocellular / etiology. Liver Neoplasms / epidemiology. Liver Neoplasms / etiology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Alcohol Drinking / adverse effects. Case-Control Studies. Coffee / adverse effects. Comorbidity. Female. Food Habits. Humans. Male. Medical History Taking. Middle Aged. Odds Ratio. Risk Factors. Serbia / epidemiology. Smoking / adverse effects

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21388051.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Coffee
  •  go-up   go-down


46. Hussain SP, Schwank J, Staib F, Wang XW, Harris CC: TP53 mutations and hepatocellular carcinoma: insights into the etiology and pathogenesis of liver cancer. Oncogene; 2007 Apr 2;26(15):2166-76
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] TP53 mutations and hepatocellular carcinoma: insights into the etiology and pathogenesis of liver cancer.
  • Hepatocellular carcinoma (HCC) is one of the most common malignancies worldwide and the major risk factors include chronic infections with the hepatitis B (HBV) or C (HCV) virus, and exposure to dietary aflatoxin B(1) (AFB(1)) or alcohol consumption.
  • Chronic infection with HBV and HCV viruses, and oxyradical disorders including hemochromatosis, also generate reactive oxygen/nitrogen species that can both damage DNA and mutate cancer-related genes such as TP53.
  • [MeSH-major] Carcinoma, Hepatocellular / etiology. Genetic Predisposition to Disease. Liver Neoplasms / etiology. Tumor Suppressor Protein p53 / genetics

  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. AFLATOXIN B1 .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17401425.001).
  • [ISSN] 0950-9232
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Tumor Suppressor Protein p53; 9N2N2Y55MH / Aflatoxin B1
  • [Number-of-references] 128
  •  go-up   go-down


47. Raoul JL: Natural history of hepatocellular carcinoma and current treatment options. Semin Nucl Med; 2008 Mar;38(2):S13-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Natural history of hepatocellular carcinoma and current treatment options.
  • Hepatocellular carcinoma (HCC) is the most frequent primary liver cancer and the most severe complication of chronic liver disease.
  • The annual number of new cases worldwide is approximately 550,000, representing more than 5% of human cancers and is the third leading cause of cancer-related deaths.
  • In Europe, the United States, and Japan, the main risk factors are liver cirrhosis, hepatitis B and C virus, alcohol, and tobacco; in contrast, in Africa and Asia, these factors are hepatitis B and C virus, tobacco use, and aflatoxin exposure.
  • [MeSH-major] Carcinoma, Hepatocellular / etiology. Carcinoma, Hepatocellular / therapy. Liver Neoplasms / etiology. Liver Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18243838.001).
  • [ISSN] 0001-2998
  • [Journal-full-title] Seminars in nuclear medicine
  • [ISO-abbreviation] Semin Nucl Med
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Iodine Radioisotopes; 8001-40-9 / Iodized Oil
  • [Number-of-references] 29
  •  go-up   go-down


48. Derambure C, Coulouarn C, Caillot F, Daveau R, Hiron M, Scotte M, Francois A, Duclos C, Goria O, Gueudin M, Cavard C, Terris B, Daveau M, Salier JP: Genome-wide differences in hepatitis C- vs alcoholism-associated hepatocellular carcinoma. World J Gastroenterol; 2008 Mar 21;14(11):1749-58
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genome-wide differences in hepatitis C- vs alcoholism-associated hepatocellular carcinoma.
  • AIM: To look at a comprehensive picture of etiology-dependent gene abnormalities in hepatocellular carcinoma in Western Europe.
  • METHODS: With a liver-oriented microarray, transcript levels were compared in nodules and cirrhosis from a training set of patients with hepatocellular carcinoma (alcoholism, 12; hepatitis C, 10) and 5 controls.
  • CONCLUSION: Etiology-specific abnormalities (chromo-some preference; differences in transcriptomes and related functions) have been identified in hepatocellular carcinoma driven by alcoholism or hepatitis C.
  • [MeSH-major] Carcinoma, Hepatocellular / genetics. Gene Expression Regulation, Neoplastic. Hepatitis C / complications. Liver Cirrhosis / complications. Liver Cirrhosis, Alcoholic / complications. Liver Neoplasms / genetics

  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Cirrhosis.
  • MedlinePlus Health Information. consumer health - Hepatitis C.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Hepatol. 2005 Jun;42(6):860-9 [15885357.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Apr 1;329(1):370-80 [15721316.001]
  • [Cites] Hepatology. 2005 Sep;42(3):522-6 [16116624.001]
  • [Cites] Hepatology. 2005 Nov;42(5):1109-17 [16250053.001]
  • [Cites] Hepatology. 2006 Feb;43(2 Suppl 1):S63-74 [16447273.001]
  • [Cites] J Hepatol. 2006 Apr;44(4):798-805 [16488507.001]
  • [Cites] Oncogene. 2006 Jun 26;25(27):3778-86 [16799619.001]
  • [Cites] Liver Int. 2006 Oct;26(8):976-85 [16953838.001]
  • [Cites] Nat Genet. 2006 Dec;38(12):1386-96 [17099711.001]
  • [Cites] Cancer Res. 2001 Apr 1;61(7):3176-81 [11306505.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Apr 24;98(9):5116-21 [11309499.001]
  • [Cites] J Gastroenterol Hepatol. 2001 May;16(5):491-4 [11350542.001]
  • [Cites] Gastroenterology. 2001 Jun;120(7):1763-73 [11375957.001]
  • [Cites] Oncogene. 2001 Jul 27;20(33):4568-75 [11494152.001]
  • [Cites] Alcohol Clin Exp Res. 2001 Oct;25(10):1494-9 [11696670.001]
  • [Cites] Oncogene. 2002 Apr 25;21(18):2926-37 [11973655.001]
  • [Cites] Mol Biol Cell. 2002 Jun;13(6):1929-39 [12058060.001]
  • [Cites] Cancer Res. 2002 Jul 15;62(14):3939-44 [12124323.001]
  • [Cites] Lancet. 2003 Mar 15;361(9361):923-9 [12648972.001]
  • [Cites] Nat Med. 2003 Apr;9(4):416-23 [12640447.001]
  • [Cites] J Virol. 2003 Jun;77(11):6367-75 [12743294.001]
  • [Cites] Oncogene. 2003 May 15;22(19):3007-14 [12771952.001]
  • [Cites] Int J Cancer. 2003 Sep 1;106(3):334-41 [12845670.001]
  • [Cites] Exp Biol Med (Maywood). 2003 Sep;228(8):882-90 [12968059.001]
  • [Cites] Oncogene. 2004 Jan 8;23(1):298-302 [14647434.001]
  • [Cites] Hepatology. 2004 Feb;39(2):353-64 [14767988.001]
  • [Cites] Hepatology. 2004 Feb;39(2):518-27 [14768006.001]
  • [Cites] FEBS Lett. 2004 May 7;565(1-3):93-100 [15135059.001]
  • [Cites] J Hepatol. 2004 Aug;41(2):336-9 [15288485.001]
  • [Cites] Cancer Res. 2004 Sep 1;64(17):6058-64 [15342387.001]
  • [Cites] Hepatology. 2004 Sep;40(3):667-76 [15349906.001]
  • [Cites] J Clin Microbiol. 2004 Sep;42(9):3920-4 [15364969.001]
  • [Cites] Gastroenterology. 2004 Nov;127(5 Suppl 1):S87-96 [15508108.001]
  • [Cites] FEBS Lett. 2005 Feb 14;579(5):1089-100 [15710396.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jun 14;102(24):8621-6 [15939889.001]
  • (PMID = 18350606.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / RNA, Messenger
  • [Other-IDs] NLM/ PMC2695915
  •  go-up   go-down


49. Trevisani F, Frigerio M, Santi V, Grignaschi A, Bernardi M: Hepatocellular carcinoma in non-cirrhotic liver: a reappraisal. Dig Liver Dis; 2010 May;42(5):341-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatocellular carcinoma in non-cirrhotic liver: a reappraisal.
  • Although not frequently, hepatocellular carcinoma (HCC) can ensue in a non-cirrhotic liver.
  • (b) a lower prevalence of the three main risk factors (hepatitis B and C virus infections and alcohol abuse), with an increased prevalence of other etiologic factors, such as exposure to genotoxic substances and sex hormones, inherited diseases, genetic mutations;.
  • (c) a more advanced tumour stage at the time of diagnosis, as it is usually detected due to the occurrence of cancer-related symptoms, outside any scheduled surveillance program;.
  • [MeSH-major] Carcinoma, Hepatocellular / virology. Hepatitis, Viral, Human / complications. Liver Neoplasms / virology

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.
  • (PMID = 19828388.001).
  • [ISSN] 1878-3562
  • [Journal-full-title] Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  • [ISO-abbreviation] Dig Liver Dis
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Number-of-references] 105
  •  go-up   go-down


50. Fracanzani AL, Fargion S, Stazi MA, Valenti L, Amoroso P, Cariani E, Sangiovanni A, Tommasini M, Rossini A, Bertelli C, Fatta E, Patriarca V, Brescianini S, Stroffolini T: Association between heterozygosity for HFE gene mutations and hepatitis viruses in hepatocellular carcinoma. Blood Cells Mol Dis; 2005 Jul-Aug;35(1):27-32
Hazardous Substances Data Bank. IRON, ELEMENTAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association between heterozygosity for HFE gene mutations and hepatitis viruses in hepatocellular carcinoma.
  • Hepatitis B virus (HBV) and hepatitis C virus (HCV) infections are strong and independent risk factors for hepatocellular carcinoma (HCC) development.
  • In all subjects, hepatitis B surface antigen (HBsAg), anti-HCV and HFE gene mutations were assayed; alcohol intake was recorded by history.
  • The interaction between HFE genotypes and hepatitis viruses for HCC was estimated by multivariate analysis adjusting for the confounding effect of alcohol intake, area of residence and months of follow-up.
  • In conclusion, given the association between C282Y mutation and HBV infection in male patients with HCC, a careful evaluation and follow-up should be considered in the C282Y-positive subjects with hepatitis B virus related liver disease.
  • [MeSH-major] Carcinoma, Hepatocellular / genetics. Carcinoma, Hepatocellular / virology. Hepatitis Viruses / isolation & purification. Histocompatibility Antigens Class I / genetics. Membrane Proteins / genetics. Mutation

  • Genetic Alliance. consumer health - Hepatitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15894495.001).
  • [ISSN] 1079-9796
  • [Journal-full-title] Blood cells, molecules & diseases
  • [ISO-abbreviation] Blood Cells Mol. Dis.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Viral; 0 / HFE protein, human; 0 / Hepatitis B Surface Antigens; 0 / Histocompatibility Antigens Class I; 0 / Membrane Proteins; E1UOL152H7 / Iron
  •  go-up   go-down


51. Ohishi W, Fujiwara S, Cologne JB, Suzuki G, Akahoshi M, Nishi N, Takahashi I, Chayama K: Risk factors for hepatocellular carcinoma in a Japanese population: a nested case-control study. Cancer Epidemiol Biomarkers Prev; 2008 Apr;17(4):846-54
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk factors for hepatocellular carcinoma in a Japanese population: a nested case-control study.
  • BACKGROUND: Epidemiologic studies have shown effects of lifestyle-related factors on risk for hepatocellular carcinoma.
  • METHODS: We conducted a nested case-control study using sera stored before hepatocellular carcinoma diagnosis in the longitudinal cohort of atomic bomb survivors.
  • The study included 224 hepatocellular carcinoma cases and 644 controls that were matched to the cases on gender, age, city, time of serum storage, and method of serum storage, and countermatched on radiation dose.
  • RESULTS: Univariate analysis showed that HBV and HCV infections, alcohol consumption, smoking habit, body mass index (BMI), and diabetes mellitus were associated with increased hepatocellular carcinoma risk, whereas coffee drinking was associated with decreased hepatocellular carcinoma risk.
  • Multivariate relative risks of hepatocellular carcinoma (95% confidence interval) were 45.8 (15.2-138), 101 (38.7-263), 70.7 (8.3-601), 4.36 (1.48-13.0), and 4.57 (1.85-11.3), for HBV infection alone, HCV infection alone, both HBV and HCV infections, alcohol consumption of > or =40 g of ethanol per day, and BMI of >25.0 kg/m(2) 10 years before diagnosis, respectively.
  • Among HCV-infected individuals, the relative risk of hepatocellular carcinoma for a 1 kg/m(2) increase in BMI was 1.39 (P = 0.003).
  • CONCLUSIONS: To limit the risk for hepatocellular carcinoma, control of excess weight may be crucial for individuals with chronic liver disease, especially those with chronic hepatitis C.
  • [MeSH-major] Carcinoma, Hepatocellular / etiology. Hepacivirus / isolation & purification. Hepatitis B virus / isolation & purification. Liver Neoplasms / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18398026.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


52. Baillargeon J, Snyder N, Soloway RD, Paar D, Baillargeon G, Spaulding AC, Pollock BH, Arcari CM, Williams BA, Raimer BG: Hepatocellular carcinoma prevalence and mortality in a male state prison population. Public Health Rep; 2009 Jan-Feb;124(1):120-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatocellular carcinoma prevalence and mortality in a male state prison population.
  • OBJECTIVES: The incidence of hepatocellular carcinoma (HCC) in the United States has increased dramatically over the last two decades, largely because of an increase in the number of people with advanced hepatitis C virus (HCV) infection. U.S. prisoners are at high risk for HCC, given their elevated rates of HCV infection, comorbid hepatitis B virus (HBV) infection, and alcoholic liver disease.
  • These findings likely reflect the high concentration of HCC-related risk factors, particularly HCV, among prisoners.
  • [MeSH-major] Carcinoma, Hepatocellular / mortality. Liver Neoplasms / mortality. Prisoners

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Public Health. 2003 Jan;117(1):43-8 [12802904.001]
  • [Cites] Hepatology. 2002 Nov;36(5):1206-13 [12395331.001]
  • [Cites] Am J Public Health. 2004 Jul;94(7):1218-23 [15226146.001]
  • [Cites] Gastroenterology. 2004 Nov;127(5 Suppl 1):S27-34 [15508094.001]
  • [Cites] Gastroenterology. 1989 Dec;97(6):1559-61 [2511056.001]
  • [Cites] Br J Haematol. 1994 Oct;88(2):397-9 [7803289.001]
  • [Cites] J Hepatol. 1997 Jan;26(1):1-5 [9147999.001]
  • [Cites] Diabetes Care. 1998 Apr;21(4):518-24 [9571335.001]
  • [Cites] Am J Drug Alcohol Abuse. 1998 Nov;24(4):573-87 [9849769.001]
  • [Cites] N Engl J Med. 1999 Mar 11;340(10):745-50 [10072408.001]
  • [Cites] N Engl J Med. 1999 Aug 19;341(8):556-62 [10451460.001]
  • [Cites] Hepatology. 1999 Oct;30(4):1054-8 [10498659.001]
  • [Cites] AIDS. 2005 Oct;19 Suppl 3:S41-6 [16251827.001]
  • [Cites] Addiction. 2006 Feb;101(2):181-91 [16445547.001]
  • [Cites] Ann Intern Med. 2006 May 16;144(10):705-14 [16702586.001]
  • [Cites] Diabetes Care. 2006 Jun;29(6):1263-8 [16732006.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Jun;15(6):1198-203 [16775181.001]
  • [Cites] Oncogene. 2006 Jun 26;25(27):3771-7 [16799618.001]
  • [Cites] J Hepatol. 2007 Oct;47(4):447-50 [17692426.001]
  • [Cites] Ann Epidemiol. 2007 Oct;17(10):808-13 [17689260.001]
  • [Cites] Hepatology. 2000 Mar;31(3):777-82 [10706572.001]
  • [Cites] Arch Intern Med. 2000 Nov 27;160(21):3227-30 [11088082.001]
  • [Cites] Clin Infect Dis. 2001 Feb 1;32(3):492-7 [11170959.001]
  • [Cites] Clin Infect Dis. 2002 Aug 1;35(3):305-12 [12115097.001]
  • [Cites] Ann Intern Med. 2003 Nov 18;139(10):817-23 [14623619.001]
  • (PMID = 19413034.001).
  • [ISSN] 0033-3549
  • [Journal-full-title] Public health reports (Washington, D.C. : 1974)
  • [ISO-abbreviation] Public Health Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2602937
  •  go-up   go-down


53. Gelatti U, Covolo L, Franceschini M, Pirali F, Tagger A, Ribero ML, Trevisi P, Martelli C, Nardi G, Donato F, Brescia HCC Study Group: Coffee consumption reduces the risk of hepatocellular carcinoma independently of its aetiology: a case-control study. J Hepatol; 2005 Apr;42(4):528-34
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Coffee consumption reduces the risk of hepatocellular carcinoma independently of its aetiology: a case-control study.
  • BACKGROUND/AIMS: The role of coffee in the development of hepatocellular carcinoma (HCC) is debated.
  • We recruited 250 HCC cases and 500 controls hospitalized for any reasons other than neoplasms, and liver and alcohol-related diseases.
  • The ORs for HCC decreased for drinking >2, compared to 0-2 cups/day of coffee, for an alcohol intake >80 g/day (OR from 5.7 to 3.3), for presence of hepatitis B virus infection (OR from 16.4 to 7.3) or hepatitis C virus infection (OR from 38.2 to 9.0).
  • [MeSH-major] Carcinoma, Hepatocellular / epidemiology. Coffee. Liver Neoplasms / epidemiology
  • [MeSH-minor] Aged. Alcohol Drinking / epidemiology. Case-Control Studies. Female. Hepatitis B, Chronic / epidemiology. Hepatitis C, Chronic / epidemiology. Humans. Male. Middle Aged. Risk Factors. Risk Reduction Behavior

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Hepatol. 2005 Apr;42(4):444-6 [15763323.001]
  • (PMID = 15868652.001).
  • [ISSN] 0168-8278
  • [Journal-full-title] Journal of hepatology
  • [ISO-abbreviation] J. Hepatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Coffee
  •  go-up   go-down


54. Chung C, Al Ali J, Owen DA, Weiss AA, Yoshida EM, Tai IT: A rare case of isolated duodenal metastases from hepatocellular carcinoma associated with p53 and ki-67 expression: a case report. Cases J; 2009;2:9344
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A rare case of isolated duodenal metastases from hepatocellular carcinoma associated with p53 and ki-67 expression: a case report.
  • Hepatocellular carcinoma (HCC) is the most common primary tumor of the liver worldwide.
  • The incidence of HCC is increasing in North America secondary to rises in chronic liver disease from alcohol abuse and viral hepatitis.
  • We examined the molecular features related to this extremely rare case of isolated duodenal metastasis of HCC and noted p53 and Ki-67 positive staining.
  • Here, we review the possible molecular and immunohistochemical studies that may aid definitive diagnosis and the evidence for the management of metastatic hepatocellular carcinoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mod Pathol. 2005 Nov;18(11):1498-503 [16007066.001]
  • [Cites] J Gastroenterol Hepatol. 2000 May;15(5):536-41 [10847441.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] Endoscopy. 1987 Jan;19(1):37-8 [3030716.001]
  • [Cites] Eur J Surg Oncol. 1987 Aug;13(4):367-9 [3622790.001]
  • [Cites] Endoscopy. 1990 May;22(3):118-23 [2162757.001]
  • [Cites] Am J Clin Pathol. 2004 Nov;122(5):721-7 [15491968.001]
  • [Cites] Am J Clin Pathol. 2004 Sep;122(3):377-82 [15362367.001]
  • [Cites] Lancet. 2003 Dec 6;362(9399):1907-17 [14667750.001]
  • [Cites] Hepatogastroenterology. 2003 Jul-Aug;50(52):1034-6 [12845974.001]
  • [Cites] Mod Pathol. 2003 Feb;16(2):137-44 [12591966.001]
  • [Cites] Am J Gastroenterol. 2001 Aug;96(8):2392-400 [11513180.001]
  • [Cites] Surg Today. 2001;31(2):180-3 [11291718.001]
  • [Cites] J Hepatol. 2001 Jan;34(1):172 [11211897.001]
  • [Cites] Saudi Med J. 2005 Mar;26(3):478-80 [15806225.001]
  • (PMID = 20062599.001).
  • [ISSN] 1757-1626
  • [Journal-full-title] Cases journal
  • [ISO-abbreviation] Cases J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2803999
  •  go-up   go-down


55. El-Serag HB, Hampel H, Javadi F: The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence. Clin Gastroenterol Hepatol; 2006 Mar;4(3):369-80
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence.
  • BACKGROUND & AIMS: We conducted a systematic review and a meta-analysis to estimate the magnitude and determinants of association between diabetes and hepatocellular carcinoma (HCC).
  • The significant association between HCC and diabetes was independent of alcohol use or viral hepatitis in the 10 studies that examined these factors.
  • However, more research is required to examine issues related to the duration and treatment of diabetes, and confounding by diet and obesity.
  • [MeSH-major] Carcinoma, Hepatocellular / etiology. Diabetes Mellitus, Type 2 / complications. Liver Neoplasms / etiology

  • Genetic Alliance. consumer health - Diabetes.
  • MedlinePlus Health Information. consumer health - Diabetes Type 2.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16527702.001).
  • [ISSN] 1542-3565
  • [Journal-full-title] Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
  • [ISO-abbreviation] Clin. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 41
  •  go-up   go-down


56. Takamatsu S, Noguchi N, Kudoh A, Nakamura N, Kawamura T, Teramoto K, Igari T, Arii S: Influence of risk factors for metabolic syndrome and non-alcoholic fatty liver disease on the progression and prognosis of hepatocellular carcinoma. Hepatogastroenterology; 2008 Mar-Apr;55(82-83):609-14
MedlinePlus Health Information. consumer health - Metabolic Syndrome.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Influence of risk factors for metabolic syndrome and non-alcoholic fatty liver disease on the progression and prognosis of hepatocellular carcinoma.
  • BACKGROUND/AIMS: We investigated a relationship between the risk factors for metabolic syndrome, such as obesity, diabetes mellitus, hypertension, and hyperlipidemia, and the pathogenesis and outcome of hepatocellular carcinoma (HCC).
  • The preoperative laboratory data, risk factors for metabolic syndrome, history of alcohol abuse, and outcome after surgery were investigated.
  • RESULTS: The incidence of diabetes mellitus, hyperlipidemia, and alcohol abuse, and the serum level of triglyceride were significantly higher in group NBNC than in groups B or C.
  • CONCLUSIONS: It is suggested that the pathogenesis of non-B non-C HCC may be more closely associated with the risk factors for metabolic syndrome than that of hepatitis virus related HCC.
  • [MeSH-major] Carcinoma, Hepatocellular / etiology. Fatty Liver / complications. Liver Neoplasms / etiology. Metabolic Syndrome X / complications


57. Ikeda K, Marusawa H, Osaki Y, Nakamura T, Kitajima N, Yamashita Y, Kudo M, Sato T, Chiba T: Antibody to hepatitis B core antigen and risk for hepatitis C-related hepatocellular carcinoma: a prospective study. Ann Intern Med; 2007 May 1;146(9):649-56
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Antibody to hepatitis B core antigen and risk for hepatitis C-related hepatocellular carcinoma: a prospective study.
  • BACKGROUND: Previous exposure to hepatitis B virus (HBV) and occult HBV infection may have an important role in the development of hepatocellular carcinoma (HCC) in patients with chronic liver disease related to hepatitis C virus (HCV).
  • OBJECTIVE: To prospectively study the association between antibody to hepatitis B core antigen (anti-HBc) and clinical outcomes in patients with HCV-related chronic liver disease.
  • Hepatocellular carcinoma occurred in 237 of 846 patients (28.0%) during follow-up.
  • Among patients with cirrhosis, HCC was diagnosed in 85 of 141 patients (60.3%) with anti-HBc and 58 of 129 patients (45.0%) without HBV-related serologic markers.
  • LIMITATIONS: The study included only 1 assessment of smoking and alcohol consumption at study entry and did not precisely determine the duration of smoking or alcohol use.
  • CONCLUSIONS: Anti-HBc-positive results on serologic testing are a marker of high risk for HCC among patients with HCV-related cirrhosis.
  • [MeSH-major] Carcinoma, Hepatocellular / virology. Hepatitis B Antibodies / blood. Hepatitis B Core Antigens / immunology. Hepatitis C, Chronic / immunology. Liver Neoplasms / virology

  • Genetic Alliance. consumer health - Hepatitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Intern Med. 2008 Jan 15;148(2):166-7; author reply 167 [18195343.001]
  • [SummaryForPatientsIn] Ann Intern Med. 2007 May 1;146(9):I59 [17470828.001]
  • (PMID = 17470833.001).
  • [ISSN] 1539-3704
  • [Journal-full-title] Annals of internal medicine
  • [ISO-abbreviation] Ann. Intern. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / Hepatitis B Antibodies; 0 / Hepatitis B Core Antigens; 0 / Interferon-alpha; 77238-31-4 / Interferon-beta
  •  go-up   go-down


58. Yokoi Y, Suzuki S, Baba S, Inaba K, Konno H, Nakamura S: Clinicopathological features of hepatocellular carcinomas (HCCs) arising in patients without chronic viral infection or alcohol abuse: a retrospective study of patients undergoing hepatic resection. J Gastroenterol; 2005 Mar;40(3):274-82
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathological features of hepatocellular carcinomas (HCCs) arising in patients without chronic viral infection or alcohol abuse: a retrospective study of patients undergoing hepatic resection.
  • BACKGROUND: This study was carried out to clarify the etiology and clinicopathological features of hepatocellular carcinomas (HCCs) arising in patients without chronic viral infection or alcohol abuse.
  • METHODS: HCC patients who underwent resection were divided into three groups: a non-B non-C (NBNC) group (n = 13), who were seronegative for hepatitis B surface antigen (HBs Ag) and anti-hepatitis C antibody (HCV Ab), excluding a history of alcohol abuse; a B group (n = 25), who were seropositive for HBs Ag only; and a C group (n = 116), who were seropositive for HCV Ab only.
  • We analyzed the features of tumor- and host-related factors and the outcome of the NBNC group.
  • There were no significant differences in tumor-related factors, except for higher serum levels of alpha-fetoprotein in the NBNC group.
  • [MeSH-major] Carcinoma, Hepatocellular / etiology. Hepatectomy. Liver / pathology. Liver Neoplasms / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15830287.001).
  • [ISSN] 0944-1174
  • [Journal-full-title] Journal of gastroenterology
  • [ISO-abbreviation] J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / DNA, Viral; 0 / Hepatitis B Antigens; 0 / Hepatitis C Antibodies; 0 / alpha-Fetoproteins
  •  go-up   go-down


59. Delhem N, Carpentier A, Moralès O, Miroux C, Groux H, Auriault C, Pancré V: [Regulatory T-cells and hepatocellular carcinoma: implication of the regulatory T lymphocytes in the control of the immune response]. Bull Cancer; 2008 Dec;95(12):1219-25
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Regulatory T-cells and hepatocellular carcinoma: implication of the regulatory T lymphocytes in the control of the immune response].
  • Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide and also the third most common cause of cancer-related death.
  • HCC arises most frequently in males with cirrhosis, which is most often a consequence of chronic hepatitis infection (HBV and HCV) or alcohol abuse.
  • [MeSH-major] Carcinoma, Hepatocellular / immunology. Hepatitis B, Chronic / immunology. Hepatitis C, Chronic / immunology. Liver Neoplasms / immunology. T-Lymphocytes, Regulatory / immunology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19091657.001).
  • [ISSN] 1769-6917
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antigens, CD4; 0 / Interleukin-2 Receptor alpha Subunit
  • [Number-of-references] 45
  •  go-up   go-down


60. Ladero JM, Martínez C, García-Martín E, Ropero P, Briceño O, Villegas A, Díaz-Rubio M, Agúndez JA: Glutathione S-transferase M1 and T1 genetic polymorphisms are not related to the risk of hepatocellular carcinoma: a study in the Spanish population. Eur J Cancer; 2006 Jan;42(1):73-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Glutathione S-transferase M1 and T1 genetic polymorphisms are not related to the risk of hepatocellular carcinoma: a study in the Spanish population.
  • Glutathione S-transferases constitute a superfamily of enzymes that catalyse the inactivating conjugation of endogenous and environmental substrates involved in the pathogenesis of hepatocellular carcinoma (HCC) and glutathione.
  • Gender, age at diagnosis, tobacco use, chronic infection with hepatitis B or C virus and alcohol abuse did not influence these results.
  • In conclusion, polymorphisms in GSTM1 and GSTT1 genes are not related to the incidence of HCC in a high-risk Spanish population.
  • [MeSH-major] Carcinoma, Hepatocellular / genetics. Glutathione Transferase / genetics. Liver Neoplasms / genetics. Polymorphism, Genetic / genetics

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16314088.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] EC 2.5.1.- / glutathione S-transferase T1; EC 2.5.1.18 / Glutathione Transferase; EC 2.5.1.18 / glutathione S-transferase M1
  •  go-up   go-down


61. Marelli L, Stigliano R, Triantos C, Senzolo M, Cholongitas E, Davies N, Tibballs J, Meyer T, Patch DW, Burroughs AK: Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol; 2007 Jan-Feb;30(1):6-25
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies.
  • BACKGROUND: Chemoembolization (TACE) improves survival in cirrhotic patients with hepatocellular carcinoma (HCC).
  • Embolizing agents used were: gelatin sponge particles (71%), polyvinyl alcohol (PVA) particles (8%), degradable starch microspheres (DSM) (4%), and embospheres (4%).
  • Treatment-related mortality was 2.4% (0-9.5%), mainly due to acute liver failure.
  • [MeSH-major] Carcinoma, Hepatocellular / therapy. Chemoembolization, Therapeutic / methods. Liver Neoplasms / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17103105.001).
  • [ISSN] 0174-1551
  • [Journal-full-title] Cardiovascular and interventional radiology
  • [ISO-abbreviation] Cardiovasc Intervent Radiol
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis; Review
  • [Publication-country] United States
  • [Number-of-references] 134
  •  go-up   go-down


62. Hassan MM, Kaseb A, Li D, Patt YZ, Vauthey JN, Thomas MB, Curley SA, Spitz MR, Sherman SI, Abdalla EK, Davila M, Lozano RD, Hassan DM, Chan W, Brown TD, Abbruzzese JL: Association between hypothyroidism and hepatocellular carcinoma: a case-control study in the United States. Hepatology; 2009 May;49(5):1563-70
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association between hypothyroidism and hepatocellular carcinoma: a case-control study in the United States.
  • Hypothyroidism has been associated with nonalcoholic steatohepatitis; however, the association between thyroid diseases and hepatocellular carcinoma (HCC) in men and women has not been well established.
  • A long-term history of hypothyroidism (>10 years) was associated with a statistically significant high risk of HCC in women; after adjusting for demographic factors, diabetes, hepatitis, alcohol consumption, cigarette smoking, and family history of cancer, the odds ratio (OR) was 2.9 (95% confidence interval [CI], 1.3-6.3).
  • A history of hyperthyroidism was not significantly related to HCC (OR = 1.7; CI = 0.6-5.1).

  • MedlinePlus Health Information. consumer health - Hypothyroidism.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gastroenterology. 2002 Jul;123(1):134-40 [12105842.001]
  • [Cites] J Clin Gastroenterol. 2002 Sep;35(3):266-9 [12192205.001]
  • [Cites] J Clin Gastroenterol. 2003 Oct;37(4):340-3 [14506393.001]
  • [Cites] Thyroid. 2003 Aug;13(8):755-60 [14558918.001]
  • [Cites] Am J Med. 2004 Jul 1;117(1):10-3 [15210382.001]
  • [Cites] Minerva Med. 1999 Apr;90(4):111-21 [10518956.001]
  • [Cites] Am J Epidemiol. 1980 Oct;112(4):467-70 [7424895.001]
  • [Cites] CMAJ. 1988 Jun 1;138(11):1017-25 [3370569.001]
  • [Cites] Am J Prev Med. 1988 Jul-Aug;4(4):188-93 [3166823.001]
  • [Cites] Am J Epidemiol. 1992 May 1;135(9):1019-28 [1595688.001]
  • [Cites] Am J Epidemiol. 1992 May 1;135(9):1029-41 [1595689.001]
  • [Cites] Am J Epidemiol. 1992 May 1;135(9):1042-50 [1595690.001]
  • [Cites] Hepatology. 1992 Oct;16(4):949-55 [1328012.001]
  • [Cites] J Hepatol. 1993 Apr;18(1):136-8 [7688009.001]
  • [Cites] Arthritis Rheum. 1999 Oct;42(10):2204-12 [10524695.001]
  • [Cites] Gastroenterology. 2004 Nov;127(5):1372-80 [15521006.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] Clin Endocrinol (Oxf). 2005 Apr;62(4):480-6 [15807880.001]
  • [Cites] J Korean Med Sci. 2005 Jun;20(3):502-5 [15953878.001]
  • [Cites] Thyroid. 2005 Aug;15(8):899-903 [16131332.001]
  • [Cites] Clin Gastroenterol Hepatol. 2007 Jan;5(1):118-23 [17008133.001]
  • [Cites] Thyroid. 2007 Dec;17(12):1211-23 [18177256.001]
  • [Cites] Ann Hepatol. 2008 Jan-Mar;7(1):72-7 [18376370.001]
  • [Cites] Int J Cancer. 2008 Oct 15;123(8):1883-91 [18688864.001]
  • [Cites] Pediatr Diabetes. 2008 Jul 28;9(4 Pt 1):272-6 [18466214.001]
  • [Cites] J Hepatol. 2009 Feb;50(2):334-41 [19070394.001]
  • [Cites] Gastroenterology. 2004 Nov;127(5 Suppl 1):S27-34 [15508094.001]
  • [Cites] Endocrine. 2000 Jun;12(3):265-71 [10963047.001]
  • [Cites] Int J Obes Relat Metab Disord. 2000 Jun;24 Suppl 2:S56-8 [10997610.001]
  • [Cites] Int J Obes Relat Metab Disord. 2000 Jun;24 Suppl 2:S64-70 [10997612.001]
  • [Cites] Int J Obes Relat Metab Disord. 2000 Jun;24 Suppl 2:S109-12 [10997623.001]
  • [Cites] Am J Epidemiol. 1976 May;103(5):506-11 [1274952.001]
  • [Cites] Eur J Endocrinol. 1995 May;132(5):587-93 [7749499.001]
  • [Cites] Diabet Med. 1995 Jul;12(7):622-7 [7554786.001]
  • [Cites] Horm Res. 1996;45(6):273-8 [8793521.001]
  • [Cites] Nurs Clin North Am. 1996 Dec;31(4):827-44 [8969342.001]
  • [Cites] Eur J Clin Invest. 1997 Jun;27(6):475-83 [9229227.001]
  • [Cites] JAMA. 1999 May 5;281(17):1588 [10235149.001]
  • [Cites] Int J Obes Relat Metab Disord. 2000 Jun;24 Suppl 2:S116-9 [10997625.001]
  • [Cites] Cancer Res. 2000 Sep 15;60(18):5106-10 [11016636.001]
  • [Cites] Gastroenterology. 2001 Apr;120(5):1183-92 [11266382.001]
  • [CommentIn] Hepatology. 2009 Sep;50(3):993-4; author reply 994 [19575455.001]
  • (PMID = 19399911.001).
  • [ISSN] 1527-3350
  • [Journal-full-title] Hepatology (Baltimore, Md.)
  • [ISO-abbreviation] Hepatology
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / K07 CA106458-04; United States / NCI NIH HHS / CA / K07 CA106458; United States / NCI NIH HHS / CA / CA106458-04; United States / NIEHS NIH HHS / ES / R03 ES11481; United States / NCI NIH HHS / CA / CA106458-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS115593; NLM/ PMC3715879
  •  go-up   go-down


63. N'Kontchou G, Paries J, Htar MT, Ganne-Carrie N, Costentin L, Grando-Lemaire V, Trinchet JC, Beaugrand M: Risk factors for hepatocellular carcinoma in patients with alcoholic or viral C cirrhosis. Clin Gastroenterol Hepatol; 2006 Aug;4(8):1062-8
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk factors for hepatocellular carcinoma in patients with alcoholic or viral C cirrhosis.
  • BACKGROUND & AIMS: Influence of being overweight and diabetes mellitus on the occurrence of hepatocellular carcinoma (HCC) in patients with cirrhosis has not been evaluated prospectively.
  • The aim of this study was to show the predictive value of these factors in a cohort of 771 patients with well-compensated alcohol- or hepatitis C (HCV)-related cirrhosis who were screened prospectively for HCC.
  • Cirrhosis was caused by alcohol (n = 478), HCV (n = 220), or the association of both factors (n = 73).
  • CONCLUSIONS: Overweight and diabetes mellitus are associated with an increased risk of HCC occurrence in patients with HCV- or alcohol-related cirrhosis.
  • [MeSH-major] Carcinoma, Hepatocellular / epidemiology. Liver Cirrhosis / epidemiology. Liver Cirrhosis / virology. Liver Cirrhosis, Alcoholic / epidemiology. Liver Neoplasms / epidemiology

  • MedlinePlus Health Information. consumer health - Cirrhosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16844421.001).
  • [ISSN] 1542-3565
  • [Journal-full-title] Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
  • [ISO-abbreviation] Clin. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


64. Lodato F, Mazzella G, Festi D, Azzaroli F, Colecchia A, Roda E: Hepatocellular carcinoma prevention: a worldwide emergence between the opulence of developed countries and the economic constraints of developing nations. World J Gastroenterol; 2006 Dec 7;12(45):7239-49
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatocellular carcinoma prevention: a worldwide emergence between the opulence of developed countries and the economic constraints of developing nations.
  • Hepatocellular carcinoma (HCC) is the fifth most common neoplasm, the major cause of death in patients with liver cirrhosis, and the third most common cause of cancer-related death in the world.
  • The treatment of HCC is difficult because most patients are diagnosed when the tumour is in an advanced stage and is not amenable to potential curative therapy, thus prevention is the key to reducing HCC and its related morbidity and mortality.
  • Substantial progresses in the prevention of virusl-related hepatitis (screening of blood units, use of disposable sanitary tools, HBV vaccination) have been achieved in developed countries, but in the same areas, alcohol- and dysmetabolism-related HCCs are emerging problems which require specific interventions in terms of public health measures.
  • [MeSH-major] Carcinoma, Hepatocellular / prevention & control. Developed Countries / economics. Developing Countries / economics. Liver Neoplasms / prevention & control

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gut. 2000 Jul;47(1):131-6 [10861275.001]
  • [Cites] Hepatology. 2000 Aug;32(2):228-32 [10915728.001]
  • [Cites] Semin Cancer Biol. 2000 Jun;10(3):211-31 [10936070.001]
  • [Cites] Hepatology. 2000 Oct;32(4 Pt 1):842-6 [11003632.001]
  • [Cites] JAMA. 2000 Dec 20;284(23):3040-2 [11122592.001]
  • [Cites] Clin Liver Dis. 2001 Feb;5(1):87-107, vi [11218921.001]
  • [Cites] Hepatology. 2001 Mar;33(3):647-51 [11230745.001]
  • [Cites] J Hepatol. 2001 Feb;34(2):306-13 [11281561.001]
  • [Cites] Gut. 2001 Jun;48(6):843-8 [11358906.001]
  • [Cites] J Hepatol. 2001 Apr;34(4):593-602 [11394661.001]
  • [Cites] J Hepatol. 2001 Jul;35(1):134-46 [11495032.001]
  • [Cites] J Hepatol. 2001 Aug;35(2):284-9 [11580153.001]
  • [Cites] Gastroenterology. 1997 Feb;112(2):463-72 [9024300.001]
  • [Cites] Hepatology. 1997 Mar;25(3):754-8 [9049231.001]
  • [Cites] Cancer. 1997 Apr 15;79(8):1494-500 [9118029.001]
  • [Cites] Am J Epidemiol. 1997 Jun 1;145(11):1039-47 [9169913.001]
  • [Cites] N Engl J Med. 1997 Jun 26;336(26):1855-9 [9197213.001]
  • [Cites] J Hepatol. 1997 Jul;27(1):30-5 [9252070.001]
  • [Cites] Hepatology. 1997 Sep;26(3 Suppl 1):34S-38S [9305661.001]
  • [Cites] Hepatology. 1997 Nov;26(5):1338-42 [9362381.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Apr 2;99(7):4650-5 [11904369.001]
  • [Cites] Carcinogenesis. 2002 May;23(5):885-92 [12016164.001]
  • [Cites] Hepatology. 2002 Jun;35(6):1522-7 [12029639.001]
  • [Cites] J Hepatol. 2002 Jul;37(1):154-60 [12076877.001]
  • [Cites] Gastroenterology. 2002 Jul;123(1):134-40 [12105842.001]
  • [Cites] J Med Virol. 2002 Jul;67(3):444-6 [12116042.001]
  • [Cites] N Engl J Med. 2002 Jul 18;347(3):168-74 [12124405.001]
  • [Cites] Lancet Infect Dis. 2002 Jul;2(7):395-403 [12127351.001]
  • [Cites] N Engl J Med. 2002 Sep 26;347(13):975-82 [12324553.001]
  • [Cites] Hepatology. 2002 Nov;36(5):1206-13 [12395331.001]
  • [Cites] Hepatology. 2002 Nov;36(5 Suppl 1):S121-7 [12407585.001]
  • [Cites] Biochem Pharmacol. 2002 Nov 15;64(10):1425-30 [12417255.001]
  • [Cites] Am J Gastroenterol. 2002 Nov;97(11):2886-95 [12425564.001]
  • [Cites] Br J Cancer. 2002 Oct 21;87(9):956-9 [12434283.001]
  • [Cites] Cancer. 2002 Dec 15;95(12):2539-45 [12467068.001]
  • [Cites] J Gastroenterol Hepatol. 2002 Dec;17 Suppl:S441-8 [12534775.001]
  • [Cites] Ann Intern Med. 2003 Feb 18;138(4):299-306 [12585827.001]
  • [Cites] Hepatology. 2003 Mar;37(3):520-7 [12601348.001]
  • [Cites] J Antimicrob Chemother. 2003 Apr;51(4):761-85 [12654750.001]
  • [Cites] Am J Epidemiol. 2003 Apr 15;157(8):674-82 [12697571.001]
  • [Cites] Curr Cancer Drug Targets. 2004 May;4(3):285-98 [15134535.001]
  • [Cites] QJM. 2004 Jun;97(6):315-24 [15152104.001]
  • [Cites] Ann Med. 2004;36(3):215-24 [15181977.001]
  • [Cites] JAMA. 2004 Jul 21;292(3):358-61 [15265851.001]
  • [Cites] Gastroenterology. 2004 Sep;127(3):756-63 [15362032.001]
  • [Cites] Hepatology. 2004 Oct;40(4):883-91 [15382125.001]
  • [Cites] World J Gastroenterol. 2004 Nov 1;10(21):3099-102 [15457551.001]
  • [Cites] N Engl J Med. 2004 Oct 7;351(15):1521-31 [15470215.001]
  • [Cites] Gastroenterology. 2004 Nov;127(5 Suppl 1):S294-302 [15508097.001]
  • [Cites] Gastroenterology. 2004 Nov;127(5 Suppl 1):S310-8 [15508099.001]
  • [Cites] Gastroenterology. 2004 Nov;127(5 Suppl 1):S35-50 [15508101.001]
  • [Cites] Bull World Health Organ. 1984;62(2):163-82 [6610488.001]
  • [Cites] Dig Dis Sci. 1985 Jul;30(7):642-9 [4006646.001]
  • [Cites] J Natl Cancer Inst. 1985 Jul;75(1):81-4 [2989605.001]
  • [Cites] N Engl J Med. 1985 Nov 14;313(20):1256-62 [4058506.001]
  • [Cites] Gastroenterology. 1986 Feb;90(2):263-7 [2416625.001]
  • [Cites] Cancer Res. 1987 Sep 15;47(18):4967-72 [3040235.001]
  • [Cites] Cancer. 1988 May 15;61(10):1942-56 [2834034.001]
  • [Cites] Hepatology. 1988 Nov-Dec;8(6):1642-6 [3192178.001]
  • [Cites] Liver. 1989 Aug;9(4):235-41 [2770436.001]
  • [Cites] Cancer Res. 1990 Jan 1;50(1):2-9 [2403415.001]
  • [Cites] Cell. 1989 Dec 22;59(6):1145-56 [2598264.001]
  • [Cites] Gut. 1991 Mar;32(3):294-8 [2013423.001]
  • [Cites] Dig Dis Sci. 1991 Jul;36(7):962-72 [1649041.001]
  • [Cites] Cancer Res. 1991 Dec 1;51(23 Pt 1):6215-8 [1933881.001]
  • [Cites] Cancer Chemother Pharmacol. 1992;31 Suppl:S137-42 [1333900.001]
  • [Cites] Ann Intern Med. 1993 Feb 1;118(3):191-4 [8417636.001]
  • [Cites] Gastroenterology. 1993 Jan;104(1):228-34 [8419246.001]
  • [Cites] Lancet. 2001 Sep 22;358(9286):958-65 [11583749.001]
  • [Cites] Int J Cancer. 2001 Oct 15;94(2):153-6 [11668491.001]
  • [Cites] Int J Cancer. 2001 Oct 15;94(2):290-6 [11668511.001]
  • [Cites] Ann Intern Med. 2001 Nov 6;135(9):796-800 [11694104.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Dec 4;98(25):14601-6 [11724948.001]
  • [Cites] J Hepatol. 2002 Feb;36(2):263-70 [11830339.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2002 Apr;11(4):369-76 [11927497.001]
  • [Cites] Hepatology. 1999 Jun;29(6):1870-5 [10347132.001]
  • [Cites] Hepatology. 1999 Jul;30(1):257-64 [10385664.001]
  • [Cites] Ann Intern Med. 1999 Aug 3;131(3):174-81 [10428733.001]
  • [Cites] Hepatology. 1999 Aug;30(2):573-5 [10421671.001]
  • [Cites] Am J Gastroenterol. 1999 Aug;94(8):2246-50 [10445557.001]
  • [Cites] Lancet. 1999 Mar 6;353(9155):797-801 [10459961.001]
  • [Cites] FASEB J. 1999 Oct;13(13):1796-9 [10506582.001]
  • [Cites] Eur J Gastroenterol Hepatol. 1999 Aug;11(8):915-9 [10514128.001]
  • [Cites] Semin Liver Dis. 1999;19(3):271-85 [10518307.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Jan;14(1):164-9 [15668491.001]
  • [Cites] Radiology. 2005 Mar;234(3):961-7 [15665226.001]
  • [Cites] Clin Liver Dis. 2005 Feb;9(1):151-69 [15763234.001]
  • [Cites] J Hepatol. 2005 Apr;42(4):444-6 [15763323.001]
  • [Cites] Intervirology. 2005;48(1):39-45 [15785088.001]
  • [Cites] Obes Surg. 2005 Mar;15(3):442-6 [15826485.001]
  • [Cites] J Hepatol. 2005 Apr;42(4):528-34 [15868652.001]
  • [Cites] Semin Liver Dis. 2005;25(2):155-61 [15918144.001]
  • [Cites] Liver Int. 2005 Aug;25(4):696-703 [15998418.001]
  • [Cites] Alcohol. 2005 Apr;35(3):195-203 [16054981.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2000 Feb;9(2):213-6 [10698484.001]
  • [Cites] Mutat Res. 2000 Apr;462(2-3):381-93 [10767647.001]
  • [Cites] N Engl J Med. 1996 Feb 29;334(9):555-60 [8569822.001]
  • [Cites] N Engl J Med. 1996 May 30;334(22):1422-7 [8618580.001]
  • [Cites] N Engl J Med. 1996 Jun 13;334(24):1561-7 [8628336.001]
  • [Cites] Hepatology. 1996 Apr;23(4):695-9 [8666319.001]
  • [Cites] Am J Gastroenterol. 1996 Jun;91(6):1195-203 [8651170.001]
  • [Cites] N Engl J Med. 1996 Jun 27;334(26):1685-90 [8637512.001]
  • [Cites] J Hepatol. 1996 Feb;24(2):141-7 [8907566.001]
  • [Cites] Hepatology. 1997 Jan;25(1):87-92 [8985270.001]
  • [Cites] Int J Parasitol. 2003 May;33(5-6):517-23 [12782052.001]
  • [Cites] Gut. 2003 Jul;52(7):1030-4 [12801962.001]
  • [Cites] Cochrane Database Syst Rev. 2003;(2):CD003181 [12804455.001]
  • [Cites] Cancer Invest. 2003 Jun;21(3):394-9 [12901286.001]
  • [Cites] Am J Gastroenterol. 2003 Nov;98(11):2535-42 [14638360.001]
  • [Cites] Lancet. 2003 Dec 6;362(9399):1907-17 [14667750.001]
  • [Cites] Gastroenterology. 2004 Jan;126(1):102-10 [14699492.001]
  • [Cites] Gastroenterology. 2003 Dec;125(6):1733-41 [14724826.001]
  • [Cites] Lancet. 1998 Jan 17;351(9097):214-5 [9449893.001]
  • [Cites] Int J Cancer. 1998 Jan 30;75(3):347-54 [9455792.001]
  • [Cites] Cancer. 1998 Mar 1;82(5):827-35 [9486570.001]
  • [Cites] Hepatology. 1998 May;27(5):1435-40 [9581703.001]
  • [Cites] Am J Gastroenterol. 1998 Jun;93(6):896-900 [9647014.001]
  • [Cites] Ann Intern Med. 1998 Jul 15;129(2):94-9 [9669992.001]
  • [Cites] J Hepatol. 1998 Jun;28(6):930-8 [9672166.001]
  • [Cites] Hepatology. 1998 Aug;28(2):562-7 [9696025.001]
  • [Cites] Mol Cell Biol. 1998 Sep;18(9):5208-18 [9710605.001]
  • [Cites] Cancer. 1998 Sep 1;83(5):901-9 [9731893.001]
  • [Cites] Hepatology. 1998 Dec;28(6):1687-95 [9828236.001]
  • [Cites] J Natl Cancer Inst. 1999 Feb 17;91(4):347-54 [10050868.001]
  • [Cites] Hepatology. 1999 Mar;29(3):971-5 [10051505.001]
  • [Cites] N Engl J Med. 1999 Apr 1;340(13):1046-7 [10189289.001]
  • [Cites] Hepatology. 1999 Apr;29(4):1124-30 [10094956.001]
  • [Cites] Cancer. 1999 May 15;85(10):2132-7 [10326690.001]
  • [Cites] Lancet. 1998 May 23;351(9115):1535-9 [10326535.001]
  • [Cites] Alcohol. 2005 Apr;35(3):243-9 [16054986.001]
  • [Cites] J Hepatol. 2005 Oct;43(4):623-9 [16098627.001]
  • [Cites] Hepatogastroenterology. 2005 Sep-Oct;52(65):1491-6 [16201104.001]
  • [Cites] Dig Liver Dis. 2006 Jan;38(1):64-5 [16266838.001]
  • [Cites] Am J Gastroenterol. 2006;101 Suppl 1:S1-6 [16448446.001]
  • [Cites] J Clin Virol. 2005 Dec;34 Suppl 1:S1-3 [16461208.001]
  • [Cites] Dig Dis Sci. 2006 Mar;51(3):603-9 [16614974.001]
  • [Cites] Ann Intern Med. 2006 May 16;144(10):705-14 [16702586.001]
  • [Cites] J Med Screen. 2003;10(4):204-9 [14738659.001]
  • [Cites] Gut. 2004 Mar;53(3):425-30 [14960528.001]
  • [Cites] Int J Oncol. 2004 Apr;24(4):797-805 [15010815.001]
  • [Cites] N Engl J Med. 1993 Jun 24;328(25):1797-801 [7684822.001]
  • [Cites] Cancer. 1994 Oct 15;74(8):2234-8 [7922974.001]
  • [Cites] Hepatology. 1994 Dec;20(6):1426-31 [7982640.001]
  • [Cites] Hepatology. 1995 Mar;21(3):650-5 [7875662.001]
  • [Cites] Alcohol. 1995 Mar-Apr;12(2):87-96 [7772271.001]
  • [Cites] Lancet. 1995 Oct 21;346(8982):1051-5 [7564784.001]
  • (PMID = 17143937.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antiviral Agents
  • [Number-of-references] 154
  • [Other-IDs] NLM/ PMC4087479
  •  go-up   go-down


65. Leone N, Rizzetto M: Natural history of hepatitis C virus infection: from chronic hepatitis to cirrhosis, to hepatocellular carcinoma. Minerva Gastroenterol Dietol; 2005 Mar;51(1):31-46
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Natural history of hepatitis C virus infection: from chronic hepatitis to cirrhosis, to hepatocellular carcinoma.
  • Acquired infection after age 40, male sex, excessive alcohol-consumption, hepatitis B virus (HBV) or HIV co-infection, steatosis, and immunosuppressed state have been identified as co-factors associated with progression of fibrosis and development of cirrhosis.
  • In patients with cirrhosis, the incidence of hepatocellular carcinoma is 2-5% per year.
  • At present, HCV-related end-stage cirrhosis is the first cause of liver transplantation.
  • [MeSH-major] Carcinoma, Hepatocellular / etiology. Hepatitis C / complications. Hepatitis C, Chronic / complications. Liver Cirrhosis / etiology. Liver Neoplasms / etiology
  • [MeSH-minor] AIDS-Related Opportunistic Infections. Adult. Clinical Enzyme Tests. Disease Progression. Female. Follow-Up Studies. Genotype. Hepacivirus / genetics. Humans. Immunocompromised Host. Liver Transplantation. Male. RNA, Viral / analysis. Time Factors. Viral Load

  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Cirrhosis.
  • MedlinePlus Health Information. consumer health - Hepatitis C.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15756144.001).
  • [ISSN] 1121-421X
  • [Journal-full-title] Minerva gastroenterologica e dietologica
  • [ISO-abbreviation] Minerva Gastroenterol Dietol
  • [Language] eng; ita
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / RNA, Viral
  •  go-up   go-down


66. Lu SC, Ramani K, Ou X, Lin M, Yu V, Ko K, Park R, Bottiglieri T, Tsukamoto H, Kanel G, French SW, Mato JM, Moats R, Grant E: S-adenosylmethionine in the chemoprevention and treatment of hepatocellular carcinoma in a rat model. Hepatology; 2009 Aug;50(2):462-71
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] S-adenosylmethionine in the chemoprevention and treatment of hepatocellular carcinoma in a rat model.
  • Hepatocellular carcinoma (HCC) remains a common cancer worldwide that lacks effective chemoprevention or treatment.
  • SAMe's chemopreventive effect may be related to its proapoptotic action and its ability to inhibit angiogenesis.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Pathol Lab Med. 2000 Jun;124(6):848-52 [10835519.001]
  • [Cites] Gastroenterology. 2009 Mar;136(3):1025-36 [18983843.001]
  • [Cites] Int J Cancer. 2001 Oct 15;94(2):153-6 [11668491.001]
  • [Cites] Hepatology. 2002 Feb;35(2):274-80 [11826399.001]
  • [Cites] Oncology. 2002;62 Suppl 1:24-8 [11868781.001]
  • [Cites] FASEB J. 2002 Aug;16(10):1292-4 [12060674.001]
  • [Cites] Alcohol Clin Exp Res. 2004 Jan;28(1):173-81 [14745316.001]
  • [Cites] FASEB J. 2004 May;18(7):914-6 [15033934.001]
  • [Cites] Hepatology. 2004 Jul;40(1):221-31 [15239106.001]
  • [Cites] Am J Physiol. 1984 Sep;247(3 Pt 2):R595-9 [6433728.001]
  • [Cites] Cancer Res. 1989 May 1;49(9):2506-9 [2539905.001]
  • [Cites] Carcinogenesis. 1989 Jul;10(7):1183-92 [2472229.001]
  • [Cites] Scand J Gastroenterol. 1989 May;24(4):407-15 [2781235.001]
  • [Cites] Anticancer Res. 1991 Jul-Aug;11(4):1617-24 [1684097.001]
  • [Cites] Cancer Res. 1992 Sep 15;52(18):4979-86 [1516054.001]
  • [Cites] Carcinogenesis. 1995 Feb;16(2):427-30 [7859377.001]
  • [Cites] Cell. 1997 Jan 24;88(2):277-85 [9008168.001]
  • [Cites] Hepatology. 1997 Dec;26(6):1484-91 [9397988.001]
  • [Cites] J Hepatol. 1999 Jun;30(6):1081-9 [10406187.001]
  • [Cites] Intervirology. 2005;48(1):39-45 [15785088.001]
  • [Cites] J Viral Hepat. 2005 Sep;12(5):543-50 [16108772.001]
  • [Cites] Gastroenterology. 2006 Jul;131(1):223-32 [16831604.001]
  • [Cites] Hepatology. 2007 May;45(5):1306-12 [17464973.001]
  • [Cites] Gastroenterology. 2007 Jul;133(1):207-18 [17631143.001]
  • [Cites] Hepatology. 2007 Sep;46(3):749-58 [17659576.001]
  • [Cites] Hepatology. 2008 Feb;47(2):521-31 [18041713.001]
  • [Cites] Hepatology. 2008 Apr;47(4):1288-97 [18167064.001]
  • [Cites] Hepatology. 2008 Apr;47(4):1191-9 [18318442.001]
  • [Cites] Hepatology. 2008 May;47(5):1655-66 [18393372.001]
  • [Cites] N Engl J Med. 2008 Jul 24;359(4):378-90 [18650514.001]
  • [Cites] Lab Invest. 2008 Oct;88(10):1121-9 [18695670.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 May 8;98(10):5560-5 [11320206.001]
  • (PMID = 19444874.001).
  • [ISSN] 1527-3350
  • [Journal-full-title] Hepatology (Baltimore, Md.)
  • [ISO-abbreviation] Hepatology
  • [Language] ENG
  • [Grant] United States / NIAAA NIH HHS / AA / T32 AA007578; None / None / / R01 DK051719-12; United States / NIAAA NIH HHS / AA / P50AA11999; United States / NCCIH NIH HHS / AT / R01 AT001576; United States / NIDDK NIH HHS / DK / R01 DK051719; United States / NIDDK NIH HHS / DK / R01 DK051719-12; United States / NCCIH NIH HHS / AT / AT1576; United States / NCCIH NIH HHS / AT / R21 AT002311; United States / NCCIH NIH HHS / AT / AT002311; United States / NIAAA NIH HHS / AA / T32AA07578; United States / NIDDK NIH HHS / DK / DK51719; United States / NIDDK NIH HHS / DK / P30DK48522; United States / NIDDK NIH HHS / DK / P30 DK048522; United States / NIAAA NIH HHS / AA / P50 AA011999
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 7LP2MPO46S / S-Adenosylmethionine
  • [Other-IDs] NLM/ NIHMS117036; NLM/ PMC2754739
  •  go-up   go-down


67. Aguilera V, Berenguer M, Rubín A, San-Juan F, Rayón JM, Prieto M, Mir J: Cirrhosis of mixed etiology (hepatitis C virus and alcohol): Posttransplantation outcome-Comparison with hepatitis C virus-related cirrhosis and alcoholic-related cirrhosis. Liver Transpl; 2009 Jan;15(1):79-87
MedlinePlus Health Information. consumer health - Liver Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cirrhosis of mixed etiology (hepatitis C virus and alcohol): Posttransplantation outcome-Comparison with hepatitis C virus-related cirrhosis and alcoholic-related cirrhosis.
  • Hepatitis C virus (HCV)-related liver disease is enhanced by alcohol consumption.
  • Of HCV-related liver transplantation (LT) recipients, 25% have a history of alcohol intake.
  • The purpose of this research was to determine whether LT outcome differs between patients with cirrhosis of mixed etiology compared to HCV or alcohol alone.
  • Of 494 LT (1997-2001), recipient/donor features, post-LT histological, metabolic complications [hypertension, diabetes-diabetes mellitus (DM)], and de novo tumors were compared in 3 groups [HCV-related cirrhosis = 170 (HCV group), alcohol-related cirrhosis (alcohol group) = 107, and cirrhosis of mixed etiology (mixed group) = 60].
  • Severe recurrent HCV disease was defined as: 1-year fibrosis >1, cholestatic hepatitis, recurrent cirrhosis, or HCV-related liver retransplantation (reLT) within 5 years.
  • Patients in the mixed group were younger (mean age: HCV group = 59 years; mixed group = 49 years; alcohol group = 53 years; P < 0.05) and mainly men (% men: HCV group = 51%; mixed group = 97%; alcohol group = 87%).
  • Hepatocellular carcinoma (HCC) was more frequent in HCV patients (HCV group = 44%; mixed group = 35%; alcohol group = 18%; P = 0.05).
  • Five-year survival was lowest in the HCV group (HCV group = 49% versus mixed group = 73% versus alcohol group = 76%; and P < 0.01 for the HCV group versus the alcohol group or the HCV group versus the mixed group; P = 0.74 for the alcohol group versus the mixed group).
  • Metabolic complications and de novo tumors were more frequent in the alcohol groups.
  • Post-LT survival was lower in the isolated HCV group compared to the alcohol or mixed groups despite a similar recurrence of HCV disease.
  • The incidence of metabolic complications and de novo tumors was greater in the alcohol groups.

  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Cirrhosis.
  • MedlinePlus Health Information. consumer health - Hepatitis C.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2008 AASLD.
  • (PMID = 19109849.001).
  • [ISSN] 1527-6473
  • [Journal-full-title] Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society
  • [ISO-abbreviation] Liver Transpl.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunosuppressive Agents
  •  go-up   go-down


68. Wu CH, Tian GS, Xu XY, Yu YY, Huang T: [An analysis of clinical characteristics and risk factors of cirrhosis-related hepatocellular carcinomas in patients with hepatitis C virus infection]. Zhonghua Gan Zang Bing Za Zhi; 2008 Mar;16(3):210-4
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [An analysis of clinical characteristics and risk factors of cirrhosis-related hepatocellular carcinomas in patients with hepatitis C virus infection].
  • OBJECTIVE: To study the epidemiological and clinical characteristics and risk factors of cirrhosis-related hepatocellular carcinomas (HCC) in patients with hepatitis C virus (HCV) infection.
  • Of the 35 HCC patients, 4 had a family history of hepatitis C, 12 had a familial history of HCC, and 7 had a history of alcohol ingestion.
  • Child-Pugh score and the severity of the hepatic steatosis are related to the risk factors.
  • History of alcohol ingestion and family history of hepatitis C are also related to liver cancer.
  • [MeSH-major] Carcinoma, Hepatocellular / etiology. Hepatitis C, Chronic / complications. Liver Cirrhosis / complications. Liver Neoplasms / etiology

  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Cirrhosis.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18364082.001).
  • [ISSN] 1007-3418
  • [Journal-full-title] Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology
  • [ISO-abbreviation] Zhonghua Gan Zang Bing Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


69. McKillop IH, Schrum LW: Role of alcohol in liver carcinogenesis. Semin Liver Dis; 2009 May;29(2):222-32
Hazardous Substances Data Bank. ACETALDEHYDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of alcohol in liver carcinogenesis.
  • Hepatocellular carcinoma (HCC) is one of the most common malignant tumors in the world and contributes significantly to cancer-related morbidity and mortality.
  • Chronic alcohol consumption has long been associated with progressive liver disease toward the development of hepatic cirrhosis and the subsequent increased risk for developing HCC.
  • In assessing the role of alcohol during hepatic disease, and as a carcinogen, many of the deleterious effects of alcohol can be attributed to alcohol metabolism in hepatocytes.
  • In addition to the direct effects of alcohol/alcohol metabolism on hepatocyte transformation, increasing evidence indicates that other intrahepatic and systemic effects of alcohol are likely to play an equally significant role in the process of hepatic tumorigenesis.
  • [MeSH-major] Alcohol Drinking / adverse effects. Carcinoma, Hepatocellular / etiology. Ethanol / toxicity. Liver / drug effects. Liver Diseases, Alcoholic / etiology. Liver Neoplasms / etiology

  • MedlinePlus Health Information. consumer health - Alcohol.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. ETHANOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19387921.001).
  • [ISSN] 1098-8971
  • [Journal-full-title] Seminars in liver disease
  • [ISO-abbreviation] Semin. Liver Dis.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 3K9958V90M / Ethanol; GO1N1ZPR3B / Acetaldehyde
  • [Number-of-references] 146
  •  go-up   go-down


70. Berretta M, Zanet E, Di Benedetto F, Simonelli C, Bearz A, Morra A, Bonanno S, Berretta S, Tirelli U: Unusual presentation of metastatic hepatocellular carcinoma in an HIV/HCV coinfected patient: case report and review of the literature. Tumori; 2008 Jul-Aug;94(4):589-91
HIV InSite. treatment guidelines - Coinfection with Hepatitis Viruses and HIV .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unusual presentation of metastatic hepatocellular carcinoma in an HIV/HCV coinfected patient: case report and review of the literature.
  • Hepatocellular carcinoma (HCC) is an increasing cause of mortality in human immunodeficiency virus (HIV) seropositive patients.
  • Viral hepatitis and alcohol abuse are the main risk factors for HCC in developed countries.
  • [MeSH-major] AIDS-Related Opportunistic Infections / complications. Carcinoma, Hepatocellular / diagnosis. Hepatitis C / complications. Liver Neoplasms / diagnosis


71. Petta S, Craxì A: Hepatocellular carcinoma and non-alcoholic fatty liver disease: from a clinical to a molecular association. Curr Pharm Des; 2010;16(6):741-52
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatocellular carcinoma and non-alcoholic fatty liver disease: from a clinical to a molecular association.
  • Hepatocellular carcinoma (HCC) is the most frequent primary neoplasm of the liver, and is the fourth most common malignancy worldwide.
  • It is also the third leading cause of cancer-related deaths.
  • Most cases of HCC develop on a pre-existing chronic liver disease, usually due to hepatitis C virus (HCV), hepatitis B virus (HBV), or alcohol.
  • [MeSH-major] Carcinoma, Hepatocellular / metabolism. Fatty Liver / metabolism. Liver Diseases, Alcoholic. Liver Neoplasms / metabolism

  • Genetic Alliance. consumer health - Liver Disease.
  • Genetic Alliance. consumer health - Non-alcoholic steatohepatitis (NASH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20388084.001).
  • [ISSN] 1873-4286
  • [Journal-full-title] Current pharmaceutical design
  • [ISO-abbreviation] Curr. Pharm. Des.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Number-of-references] 142
  •  go-up   go-down


72. McDonald SA, Hutchinson SJ, Bird SM, Robertson C, Mills PR, Dillon JF, Goldberg DJ: A record-linkage study of the development of hepatocellular carcinoma in persons with hepatitis C infection in Scotland. Br J Cancer; 2008 Sep 02;99(5):805-10
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A record-linkage study of the development of hepatocellular carcinoma in persons with hepatitis C infection in Scotland.
  • We investigated trends in first-time hospital admissions and deaths attributable to hepatocellular carcinoma (HCC) in a large population-based cohort of 22 073 individuals diagnosed with hepatitis C viral (HCV) infection through laboratory testing in Scotland in 1991-2006.
  • Hepatocellular carcinoma incidence increased between 1996 and 2006 (average annual change of 6.1, 95% confidence interval (CI): 0.9-11.6%, P=0.021).
  • The adjusted relative risk of HCC was greater for males (hazard ratio=2.7, 95% CI: 1.7-4.2), for those aged 60 years or older (hazard ratio=2.7, 95% CI: 1.9-4.1) compared with 50-59 years, and for those with a previous alcohol-related hospital admission (hazard ratio=2.5, 95% CI: 1.7-3.7).
  • [MeSH-major] Carcinoma, Hepatocellular / pathology. Hepatitis C / pathology. Liver Neoplasms / pathology. Medical Record Linkage

  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Hepatitis C.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet. 1995 Oct 14;346(8981):987-90 [7475591.001]
  • [Cites] Health Bull (Edinb). 1993 Mar;51(2):72-9 [8514493.001]
  • [Cites] Alcohol Clin Exp Res. 1996 Jun;20(4):758-62 [8800396.001]
  • [Cites] Hepatology. 1998 Jun;27(6):1730-5 [9620350.001]
  • [Cites] Hepatology. 1998 Dec;28(6):1687-95 [9828236.001]
  • [Cites] N Engl J Med. 1999 Mar 11;340(10):745-50 [10072408.001]
  • [Cites] Lancet. 1999 Apr 10;353(9160):1253-7 [10217098.001]
  • [Cites] Hepatology. 1999 May;29(5):1596-601 [10216148.001]
  • [Cites] Hepatology. 2005 Sep;42(3):711-23 [16116637.001]
  • [Cites] Liver Int. 2006 Feb;26(1):62-72 [16420511.001]
  • [Cites] Scott Med J. 2006 May;51(2):8-15 [16722130.001]
  • [Cites] J Hepatol. 2006 Aug;45(2):197-203 [16684579.001]
  • [Cites] J Viral Hepat. 2007 Feb;14(2):107-15 [17244250.001]
  • [Cites] J Viral Hepat. 2007 Aug;14(8):570-6 [17650291.001]
  • [Cites] Aust N Z J Public Health. 2007 Oct;31(5):475-82 [17931297.001]
  • [Cites] J Viral Hepat. 2007 Dec;14(12):870-4 [18070290.001]
  • [Cites] Stat Methods Med Res. 2009 Jun;18(3):271-83 [19036907.001]
  • [Cites] J Hepatol. 2004 Feb;40(2):319-26 [14739105.001]
  • [Cites] Med J Aust. 2000 Oct 16;173(8):403-5 [11090031.001]
  • [Cites] Hepatology. 2001 Oct;34(4 Pt 1):714-8 [11584367.001]
  • [Cites] Hepatology. 2001 Oct;34(4 Pt 1):809-16 [11584380.001]
  • [Cites] Hepatology. 2002 Nov;36(5 Suppl 1):S35-46 [12407575.001]
  • [Cites] Hepatology. 2003 Mar;37(3):520-7 [12601348.001]
  • [Cites] J Viral Hepat. 2003 Jul;10(4):285-93 [12823595.001]
  • [Cites] Hepatology. 2004 Mar;39(3):826-34 [14999703.001]
  • [Cites] Commun Dis Public Health. 2003 Dec;6(4):305-10 [15067856.001]
  • [Cites] Gut. 2004 May;53(5):744-9 [15082595.001]
  • [Cites] J Hepatol. 2004 May;40(5):823-30 [15094231.001]
  • [Cites] N Engl J Med. 1991 Sep 5;325(10):675-80 [1651452.001]
  • [Cites] Int J Cancer. 1992 Jul 30;51(6):898-902 [1639537.001]
  • [Cites] Alcohol Clin Exp Res. 1996 Feb;20(1 Suppl):91A-94A [8659700.001]
  • (PMID = 18728670.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / MC/ U105260794; United Kingdom / Medical Research Council / / U 1052 00 002 00001.01
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2528155
  •  go-up   go-down


73. Nahon P, Sutton A, Rufat P, Faisant C, Simon C, Barget N, Trinchet JC, Beaugrand M, Gattegno L, Charnaux N: Lack of association of some chemokine system polymorphisms with the risks of death and hepatocellular carcinoma occurrence in patients with alcoholic cirrhosis: a prospective study. Eur J Gastroenterol Hepatol; 2007 May;19(5):425-31
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lack of association of some chemokine system polymorphisms with the risks of death and hepatocellular carcinoma occurrence in patients with alcoholic cirrhosis: a prospective study.
  • BACKGROUND: Polymorphisms in genes encoding for the chemokines stromal cell-derived factor-1 (SDF-1)/CXCL12, monocyte chemotactic protein-1 (MCP-1)/CCL2, or for the chemokine receptors, CC chemokine receptor 5 (CCR5) or CC chemokine receptor 2 (CCR2) have been associated with the progression of hepatitis C virus-related liver injury and with various cancer development.
  • The occurrence of death (75/222; 33.7%) or hepatocellular carcinoma (67/222; 30.1%) during follow-up was similar among carriers and noncarriers of each polymorphism.
  • Baseline RANTES, SDF-1alpha and MCP-1 sera levels were associated neither with the risk of death nor with the risk of hepatocellular carcinoma.
  • CONCLUSIONS: The present study suggests the lack of association of SDF-1 3'A, MCP-1(-2518), CCR5-Delta32 and CCR2-64I polymorphisms with death and hepatocellular carcinoma occurrence in cirrhotic alcoholic patients.
  • [MeSH-major] Carcinoma, Hepatocellular / genetics. Chemokines / genetics. Liver Cirrhosis, Alcoholic / genetics. Liver Neoplasms / genetics. Polymorphism, Genetic
  • [MeSH-minor] Adult. Aged. Alcohol Drinking. Chemokine CCL2 / blood. Chemokine CCL2 / genetics. Chemokine CCL5 / blood. Chemokine CXCL12. Chemokines, CXC / blood. Chemokines, CXC / genetics. Epidemiologic Methods. Female. Genetic Predisposition to Disease. Genotype. Humans. Male. Middle Aged. Prognosis. Receptors, CCR2. Receptors, CCR5 / genetics. Receptors, Chemokine / genetics. Temperance

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17413295.001).
  • [ISSN] 0954-691X
  • [Journal-full-title] European journal of gastroenterology & hepatology
  • [ISO-abbreviation] Eur J Gastroenterol Hepatol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / CCL2 protein, human; 0 / CCR2 protein, human; 0 / CXCL12 protein, human; 0 / Chemokine CCL2; 0 / Chemokine CCL5; 0 / Chemokine CXCL12; 0 / Chemokines; 0 / Chemokines, CXC; 0 / Receptors, CCR2; 0 / Receptors, CCR5; 0 / Receptors, Chemokine
  •  go-up   go-down


74. Parikh S, Hyman D: Hepatocellular cancer: a guide for the internist. Am J Med; 2007 Mar;120(3):194-202
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatocellular cancer: a guide for the internist.
  • Hepatocellular cancer is the third leading cause of cancer-related deaths worldwide.
  • Hepatitis B virus, hepatitis C virus, and chronic heavy alcohol use leading to cirrhosis of the liver remain the most important causes.
  • The diagnosis of hepatocellular cancer rests on a combination of radiologic, serologic, and histopathologic criteria.
  • Resection of the tumor and other percutaneous therapies are more commonly used in practice, because most hepatocellular cancers are detected at an advanced stage.
  • Patients who are at high risk for the development of hepatocellular cancer should be screened with an ultrasound of the liver every 6 months.
  • The aim of this review is to familiarize internists in screening, diagnosis, and referral of patients with hepatocellular cancer in an appropriate and timely fashion.
  • [MeSH-major] Carcinoma, Hepatocellular / diagnosis. Carcinoma, Hepatocellular / epidemiology. Liver Neoplasms / diagnosis. Liver Neoplasms / epidemiology. Practice Guidelines as Topic

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17349437.001).
  • [ISSN] 1555-7162
  • [Journal-full-title] The American journal of medicine
  • [ISO-abbreviation] Am. J. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 73
  •  go-up   go-down


75. Suruki RY, Mueller N, Hayashi K, Harn D, DeGruttola V, Raker CA, Tsubouchi H, Stuver SO: Host immune status and incidence of hepatocellular carcinoma among subjects infected with hepatitis C virus: a nested case-control study in Japan. Cancer Epidemiol Biomarkers Prev; 2006 Dec;15(12):2521-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Host immune status and incidence of hepatocellular carcinoma among subjects infected with hepatitis C virus: a nested case-control study in Japan.
  • A nested case-control study was conducted to examine the association between host immune status, as characterized by serum immune marker levels, and the development of hepatocellular carcinoma (HCC) up to 8 years later in persons with chronic hepatitis C virus (HCV) infection.
  • Adjustment for alcohol consumption and HCV serotype did not materially alter these associations.
  • Results from this prospective, community-based study suggest that a dysregulation in both type 1-related and type 2-related host immunity contributes to the development of HCV-associated HCC.
  • [MeSH-major] Carcinoma, Hepatocellular / immunology. Hepacivirus / isolation & purification. Hepatitis C, Chronic / immunology. Liver Neoplasms / immunology

  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17164379.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA-87982; United States / NCI NIH HHS / CA / T32-CA09001-28
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers
  •  go-up   go-down


76. Nagaya T, Tanaka N, Komatsu M, Ichijo T, Sano K, Horiuchi A, Joshita S, Umemura T, Matsumoto A, Yoshizawa K, Aoyama T, Kiyosawa K, Tanaka E: Development from simple steatosis to liver cirrhosis and hepatocellular carcinoma: a 27-year follow-up case. Clin J Gastroenterol; 2008 Oct;1(3):116-121

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Development from simple steatosis to liver cirrhosis and hepatocellular carcinoma: a 27-year follow-up case.
  • It is well recognized that NASH may develop into cirrhosis and hepatocellular carcinoma (HCC), both with unfavorable prognoses.
  • He had no history of alcohol intake and was negative for hepatitis virus markers and autoantibodies.
  • The patient's serum aminotransferase levels did not normalize despite repeated dietary instruction, and in 2001, liver histology demonstrated cirrhosis with mild steatosis and hepatocyte ballooning, leading to the diagnosis of NASH-related cirrhosis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Gastroenterol. 1999 Sep;94(9):2467-74 [10484010.001]
  • [Cites] Hepatology. 2004 Nov;40(5):1222-5 [15382153.001]
  • [Cites] J Gastroenterol Hepatol. 2006 Sep;21(9):1459-65 [16911693.001]
  • [Cites] Liver Int. 2006 Oct;26(8):956-63 [16953836.001]
  • [Cites] Am J Gastroenterol. 2003 Sep;98(9):2042-7 [14499785.001]
  • [Cites] J Hepatol. 2005 Jan;42(1):132-8 [15629518.001]
  • [Cites] Hepatology. 2005 Jun;41(6):1313-21 [15915461.001]
  • [Cites] Gastroenterology. 2007 May;132(6):2169-80 [17498510.001]
  • [Cites] Liver Int. 2006 Feb;26(1):32-8 [16420508.001]
  • [Cites] Hepatology. 2006 Oct;44(4):865-73 [17006923.001]
  • [Cites] Gastroenterology. 1999 Jun;116(6):1413-9 [10348825.001]
  • [Cites] Int J Cancer. 2008 Jan 1;122(1):124-31 [17764115.001]
  • [Cites] J Hepatol. 2002 Jul;37(1):56-62 [12076862.001]
  • [Cites] Hepatology. 2006 Feb;43(2 Suppl 1):S99-S112 [16447287.001]
  • [Cites] J Clin Invest. 2008 Feb;118(2):683-94 [18188449.001]
  • [Cites] Gastroenterology. 1998 Apr;114(4):842-5 [9547102.001]
  • [Cites] J Gastroenterol. 2006 Aug;41(8):725-32 [16988759.001]
  • [Cites] Hepatology. 2004 Oct;40(4):820-6 [15382171.001]
  • [Cites] J Clin Gastroenterol. 2008 Apr;42(4):413-8 [18277895.001]
  • [Cites] Gut. 2002 Jul;51(1):100-4 [12077100.001]
  • [Cites] Gastroenterology. 2005 Jun;128(7):1898-906 [15940625.001]
  • [Cites] Hepatology. 2007 Jun;45(6):1375-81 [17518368.001]
  • (PMID = 26193649.001).
  • [ISSN] 1865-7257
  • [Journal-full-title] Clinical journal of gastroenterology
  • [ISO-abbreviation] Clin J Gastroenterol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Keywords] NOTNLM ; Hepatocellular carcinoma / Hyaluronic acid / Liver cirrhosis / Simple steatosis
  •  go-up   go-down


77. Romeo R, Del Ninno E, Rumi M, Russo A, Sangiovanni A, de Franchis R, Ronchi G, Colombo M: A 28-year study of the course of hepatitis Delta infection: a risk factor for cirrhosis and hepatocellular carcinoma. Gastroenterology; 2009 May;136(5):1629-38
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A 28-year study of the course of hepatitis Delta infection: a risk factor for cirrhosis and hepatocellular carcinoma.
  • BACKGROUND & AIMS: Chronic infection with hepatitis Delta virus (HDV) is a risk factor for cirrhosis and hepatocellular carcinoma (HCC); predictors of disease outcome are, however, poorly defined.
  • Female sex, alcohol abuse, and HDV replication were associated with liver decompensation; HBV replication and interferon were associated with HCC development.
  • CONCLUSIONS: Persistent HDV replication leads to cirrhosis and HCC at annual rates of 4% and 2.8%, respectively, and is the only predictor of liver-related mortality.
  • [MeSH-major] Carcinoma, Hepatocellular / virology. Hepatitis D / complications. Liver Cirrhosis / virology. Liver Neoplasms / virology

  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Cirrhosis.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19208358.001).
  • [ISSN] 1528-0012
  • [Journal-full-title] Gastroenterology
  • [ISO-abbreviation] Gastroenterology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


78. Hsu LM, Huang YS, Yang SY, Chang FY, Lee SD: Polymorphism of T-cell receptor gamma short tandem repeats as a susceptibility risk factor of hepatocellular carcinoma. Anticancer Res; 2006 Sep-Oct;26(5B):3787-91
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Polymorphism of T-cell receptor gamma short tandem repeats as a susceptibility risk factor of hepatocellular carcinoma.
  • The aim of this study was to test the relationship of TCR-gamma STR genetic polymorphisms and hepatocellular carcinoma (HCC).
  • MATERIALS AND METHODS: A total of 225 chronic hepatitis B- or C-related HCC and liver cirrhosis patients were enrolled in this study.
  • RESULTS: Compared to controls, the HCC patients were older in age (64.9 +/- 10.3 vs. 53.5 +/- 10.1 years, p < 0.001) and had a higher percentage of family history of HCC (13.3% vs. 7.6%, p = 0.045) and habitual alcohol use (23.1% vs. 15.6%, p= 0.042).
  • After adjustment for age, family history of HCC and habitual alcohol use, the TCR-gamma genotype 16 remained a significant risk factor for HCC (OR: 2.18, 95% CI: 1.02-4.65, p= 0.045).
  • [MeSH-major] Carcinoma, Hepatocellular / genetics. Liver Neoplasms / genetics. Polymorphism, Genetic. Receptors, Antigen, T-Cell, gamma-delta / genetics. Tandem Repeat Sequences

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17094402.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / DNA Primers; 0 / Receptors, Antigen, T-Cell, gamma-delta
  •  go-up   go-down


79. Seitz HK, Stickel F: Risk factors and mechanisms of hepatocarcinogenesis with special emphasis on alcohol and oxidative stress. Biol Chem; 2006 Apr;387(4):349-60
Hazardous Substances Data Bank. IRON, ELEMENTAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk factors and mechanisms of hepatocarcinogenesis with special emphasis on alcohol and oxidative stress.
  • Hepatocellular cancer is the fifth most frequent cancer in men and the eighth in women worldwide.
  • Established risk factors are chronic hepatitis B and C infection, chronic heavy alcohol consumption, obesity and type 2 diabetes, tobacco use, use of oral contraceptives, and aflatoxin-contaminated food.
  • Almost 90% of all hepatocellular carcinomas develop in cirrhotic livers.
  • In Western countries, attributable risks are highest for cirrhosis due to chronic alcohol abuse and viral hepatitis B and C infection.
  • Among those with alcoholic cirrhosis, the annual incidence of hepatocellular cancer is 1-2%.
  • An important mechanism implicated in alcohol-related hepatocarcinogenesis is oxidative stress from alcohol metabolism, inflammation, and increased iron storage.
  • Furthermore, alcohol impairs the antioxidant defense system, resulting in mitochondrial damage and apoptosis.
  • Chronic alcohol exposure elicits hepatocyte hyperregeneration due to the activation of survival factors and interference with retinoid metabolism.
  • Finally, chronic alcohol abuse interferes with methyl group transfer and may thereby alter gene expression.
  • [MeSH-major] Alcohol Drinking. Carcinoma, Hepatocellular / etiology. Liver Neoplasms / etiology. Oxidative Stress

  • MedlinePlus Health Information. consumer health - Alcohol.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. ETHANOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16606331.001).
  • [ISSN] 1431-6730
  • [Journal-full-title] Biological chemistry
  • [ISO-abbreviation] Biol. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Retinoids; 3K9958V90M / Ethanol; E1UOL152H7 / Iron; EC 1.14.13.- / Cytochrome P-450 CYP2E1
  • [Number-of-references] 140
  •  go-up   go-down


80. Hassan MM, Spitz MR, Thomas MB, El-Deeb AS, Glover KY, Nguyen NT, Chan W, Kaseb A, Curley SA, Vauthey JN, Ellis LM, Abdalla E, Lozano RD, Patt YZ, Brown TD, Abbruzzese JL, Li D: Effect of different types of smoking and synergism with hepatitis C virus on risk of hepatocellular carcinoma in American men and women: case-control study. Int J Cancer; 2008 Oct 15;123(8):1883-91
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of different types of smoking and synergism with hepatitis C virus on risk of hepatocellular carcinoma in American men and women: case-control study.
  • The International Agency for Research on Cancer has declared smoking to be a risk factor for hepatocellular carcinoma (HCC).
  • Use of smokeless tobacco (chewing tobacco and snuff), cigars, pipes and passive smoking exposure were not related to HCC among noncigarette smokers.
  • Heavy alcohol consumption was associated with HCC in women: AOR, 7.7 (95% CI, 2.3-25.1).
  • Cigarette smoking interacted synergistically with chronic infection of hepatitis C virus in men: AOR, 136.3 (95% CI, 43.2-429.6) and with heavy alcohol consumption in women: AOR, 13.7 (95% CI, 3.2-57.9).
  • We conclude that sex differences were observed in HCC relationship with cigarette smoking and alcohol consumption.

  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Secondhand Smoke.
  • MedlinePlus Health Information. consumer health - Smoking.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Causes Control. 1997 May;8(3):346-55 [9498898.001]
  • [Cites] Am J Epidemiol. 1998 Feb 1;147(3):315-23 [9482507.001]
  • [Cites] Chem Res Toxicol. 1998 Jun;11(6):559-603 [9625726.001]
  • [Cites] Stat Methods Med Res. 1998 Jun;7(2):119-36 [9654638.001]
  • [Cites] J Natl Cancer Inst. 1999 Apr 21;91(8):697-701 [10218507.001]
  • [Cites] Int J Cancer. 1999 May 31;81(5):695-9 [10328218.001]
  • [Cites] J Natl Cancer Inst. 2004 Dec 15;96(24):1851-6 [15601641.001]
  • [Cites] J Hepatol. 2005 Feb;42(2):218-24 [15664247.001]
  • [Cites] Cancer Detect Prev. 2005;29(1):15-24 [15734213.001]
  • [Cites] Addiction. 2005 Oct;100(10):1526-36 [16185214.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Apr;15(4):683-9 [16614109.001]
  • [Cites] Neurosci Biobehav Rev. 2007;31(2):246-53 [16908064.001]
  • [Cites] Cancer Causes Control. 2007 Apr;18(3):315-21 [17294291.001]
  • [Cites] Am J Epidemiol. 2000 Jan 15;151(2):131-9 [10645815.001]
  • [Cites] Alcohol Alcohol. 1999 Nov-Dec;34(6):894-902 [10659726.001]
  • [Cites] Lung Cancer. 2000 Jan;27(1):3-18 [10672779.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 16;92(4):333-7 [10675383.001]
  • [Cites] Int J Cancer. 2000 Feb 15;85(4):498-502 [10699921.001]
  • [Cites] JAMA. 2000 Aug 9;284(6):735-40 [10927783.001]
  • [Cites] Br J Cancer. 2001 Mar 2;84(5):709-13 [11237396.001]
  • [Cites] Alcohol Clin Exp Res. 2001 Apr;25(4):502-7 [11329488.001]
  • [Cites] Br J Cancer. 2001 Jul 6;85(1):46-54 [11437401.001]
  • [Cites] Cancer Causes Control. 2001 Nov;12(9):797-802 [11714107.001]
  • [Cites] Am J Epidemiol. 2002 Feb 15;155(4):323-31 [11836196.001]
  • [Cites] Eur J Clin Nutr. 2002 Aug;56 Suppl 3:S50-3 [12142963.001]
  • [Cites] Hepatology. 2002 Nov;36(5):1206-13 [12395331.001]
  • [Cites] Am J Epidemiol. 2003 Apr 15;157(8):674-82 [12697571.001]
  • [Cites] Cancer Causes Control. 2003 Apr;14(3):241-50 [12814203.001]
  • [Cites] Cancer. 2004 Sep 1;101(5):1009-17 [15329910.001]
  • [Cites] Gastroenterology. 2004 Nov;127(5 Suppl 1):S27-34 [15508094.001]
  • [Cites] Gastroenterology. 2004 Nov;127(5 Suppl 1):S87-96 [15508108.001]
  • [Cites] Am J Epidemiol. 1976 May;103(5):506-11 [1274952.001]
  • [Cites] Br Med J. 1976 Dec 25;2(6051):1525-36 [1009386.001]
  • [Cites] J Natl Cancer Inst. 1984 Aug;73(2):377-81 [6087005.001]
  • [Cites] J Epidemiol Community Health. 1987 Jun;41(2):166-72 [3655638.001]
  • [Cites] N Engl J Med. 1988 Dec 1;319(22):1452-60 [3054556.001]
  • [Cites] N Engl J Med. 1990 Jan 11;322(2):95-9 [2248624.001]
  • [Cites] Int J Cancer. 1990 Feb 15;45(2):231-6 [2154409.001]
  • [Cites] Hepatology. 1991 Mar;13(3):398-406 [1847891.001]
  • [Cites] Cancer Causes Control. 1990 Nov;1(3):217-21 [2102294.001]
  • [Cites] J Natl Cancer Inst. 1991 Dec 18;83(24):1820-6 [1660542.001]
  • [Cites] Am J Epidemiol. 1992 May 1;135(9):1019-28 [1595688.001]
  • [Cites] Am J Epidemiol. 1992 May 1;135(9):1029-41 [1595689.001]
  • [Cites] Am J Epidemiol. 1992 May 1;135(9):1042-50 [1595690.001]
  • [Cites] Int J Cancer. 1992 Jun 19;51(4):509-14 [1318264.001]
  • [Cites] J Oral Pathol Med. 1992 Jul;21(6):261-4 [1501158.001]
  • [Cites] Int J Cancer. 1995 Jan 17;60(2):190-3 [7829214.001]
  • [Cites] Epidemiology. 1995 Jan;6(1):36-41 [7888442.001]
  • [Cites] Cancer Causes Control. 1995 Mar;6(2):91-8 [7749057.001]
  • [Cites] JAMA. 1996 Apr 24;275(16):1233-40 [8601954.001]
  • [Cites] BMJ. 1997 Oct 18;315(7114):980-8 [9365295.001]
  • (PMID = 18688864.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / K07 CA106458-04; United States / NCI NIH HHS / CA / K07 CA106458; United States / NCI NIH HHS / CA / CA106458-04; United States / NIEHS NIH HHS / ES / R03 ES11481; United States / NCI NIH HHS / CA / CA106458-01; United States / NIEHS NIH HHS / ES / R03 ES011481
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Tobacco Smoke Pollution
  • [Other-IDs] NLM/ NIHMS93249; NLM/ PMC2673571
  •  go-up   go-down


81. Grossi S, Sumberaz A, Gosmar M, Mattioli F, Testino G, Martelli A: DNA damage in peripheral blood lymphocytes of patients with cirrhosis related to alcohol abuse or to hepatitis B and C viruses. Eur J Gastroenterol Hepatol; 2008 Jan;20(1):22-5
MedlinePlus Health Information. consumer health - Hepatitis C.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] DNA damage in peripheral blood lymphocytes of patients with cirrhosis related to alcohol abuse or to hepatitis B and C viruses.
  • BACKGROUND: Both alcohol abuse and hepatitis B or C virus infections are implicated in the development of hepatocellular carcinoma, but it is still controversial whether the pathogenetic mechanism is epigenetic or genotoxic.
  • AIM: Considering that alcohol promotes the generation of reactive oxygen species and both viruses infect peripheral lymphocytes, in this study we investigated the occurrence of DNA fragmentation in peripheral blood lymphocytes from patients with alcoholic cirrhosis and from patients with cirrhosis related to B and C viruses, and analyzed the correlation between the degree of DNA fragmentation and the Child-Pugh score used to assess the degree of hepatic insufficiency.
  • CONCLUSION: The occurrence of DNA fragmentation in peripheral blood lymphocytes reflects a direct genotoxic effect of either alcohol or HBV and HCV and suggests that the same genotoxic effect may operate in the liver and contribute to hepatocarcinogenesis.
  • [MeSH-minor] Carcinoma, Hepatocellular / genetics. Comet Assay / methods. Female. Humans. Liver Neoplasms / genetics. Male. Middle Aged. Oxidative Stress / immunology

  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Hepatitis B.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18090985.001).
  • [ISSN] 0954-691X
  • [Journal-full-title] European journal of gastroenterology & hepatology
  • [ISO-abbreviation] Eur J Gastroenterol Hepatol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


82. Shrestha SM: Liver cirrhosis and hepatocellular carcinoma in hepatic vena cava disease, a liver disease caused by obstruction of inferior vena cava. Hepatol Int; 2009 Jun;3(2):392-402

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liver cirrhosis and hepatocellular carcinoma in hepatic vena cava disease, a liver disease caused by obstruction of inferior vena cava.
  • It is a chronic disease characterized by the development of liver cirrhosis (LC) and hepatocellular carcinoma (HCC).
  • Other risk factors for LC/HCC such as alcohol use and HBV and hepatitis C virus (HCV) infections were assayed.
  • LC/HCC occurred more frequently among those who had severe or frequent acute exacerbations (P = 0.017), but it was not related to alcohol use or HBV and HCV infections.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1991 Sep 5;325(10):729-31 [1651454.001]
  • [Cites] J Gastroenterol Hepatol. 2007 Nov;22(11):1921-8 [17914971.001]
  • [Cites] J Commun Dis. 1990 Mar;22(1):27-32 [2230016.001]
  • [Cites] Hepatology. 1989 Jan;9(1):121-5 [2461892.001]
  • [Cites] Indian J Med Res. 1972 Mar;60(3):385-402 [4659918.001]
  • [Cites] Am J Med. 1971 Jul;51(1):11-20 [5570315.001]
  • [Cites] Angiology. 1968 Sep;19(8):479-98 [5677579.001]
  • [Cites] Am J Med. 1967 May;42(5):838-43 [6024240.001]
  • [Cites] Gastroenterology. 1982 Feb;82(2):171-8 [6274728.001]
  • [Cites] Hepatology. 1995 May;21(5):1232-7 [7737628.001]
  • [Cites] J Hepatol. 1995 Jan;22(1):1-9 [7751574.001]
  • [Cites] J Trop Med Hyg. 1995 Feb;98(1):64-8 [7861482.001]
  • [Cites] Am J Gastroenterol. 1994 Feb;89(2):249-53 [8304312.001]
  • [Cites] Carcinogenesis. 1993 Jun;14(6):1233-5 [8508511.001]
  • [Cites] J Gastroenterol Hepatol. 1996 Feb;11(2):170-9 [8672764.001]
  • [Cites] J Med Virol. 1997 Mar;51(3):167-74 [9139079.001]
  • [Cites] Hepatology. 1998 Nov;28(5):1191-8 [9794901.001]
  • [Cites] J Hepatol. 1999 Mar;30(3):433-9 [10190726.001]
  • [Cites] Semin Liver Dis. 2002 Feb;22(1):15-26 [11928076.001]
  • [Cites] Medicine (Baltimore). 1959 Dec;38:369-402 [14430507.001]
  • [Cites] Hepatol Res. 2007 Mar;37(3):196-204 [17362302.001]
  • [Cites] Gastroenterology. 1992 Jun;102(6):2081-90 [1587428.001]
  • [Cites] Hepatology. 1990 Oct;12(4 Pt 1):671-5 [2170265.001]
  • [Cites] Medicine (Baltimore). 1985 Mar;64(2):134-43 [3871892.001]
  • [Cites] Surgery. 1972 Oct;72(4):551-9 [5057647.001]
  • [Cites] Gastroenterology. 1968 Jun;54(6):1070-84 [5656326.001]
  • [Cites] Radiology. 1984 Sep;152(3):775-9 [6087405.001]
  • [Cites] Tohoku J Exp Med. 1982 Sep;138(1):119-20 [6293115.001]
  • [Cites] Am J Gastroenterol. 1995 Feb;90(2):303-6 [7847306.001]
  • [Cites] J Med Virol. 1994 Jun;43(2):182-6 [8083667.001]
  • [Cites] Medicine (Baltimore). 1994 Jan;73(1):21-36 [8309360.001]
  • [Cites] Trop Gastroenterol. 1996 Jul-Sep;17(3):165-71 [8987408.001]
  • [Cites] Hepatology. 1998 Feb;27(2):488-96 [9462648.001]
  • [Cites] J Gastroenterol Hepatol. 2000 Feb;15(2):202-10 [10735545.001]
  • [Cites] J Med Virol. 2002 Jul;67(3):394-400 [12116033.001]
  • [Cites] Arch Dis Child. 1956 Jun;31(157):225-8 [13328163.001]
  • [Cites] J Gastroenterol Hepatol. 1991 Jul-Aug;6(4):368-73 [1912446.001]
  • (PMID = 19669366.001).
  • [ISSN] 1936-0533
  • [Journal-full-title] Hepatology international
  • [ISO-abbreviation] Hepatol Int
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2716770
  •  go-up   go-down


83. Zhang R, Zhang F, Wang C, Wang S, Shiao YH, Guo Z: Identification of sequence polymorphism in the D-Loop region of mitochondrial DNA as a risk factor for hepatocellular carcinoma with distinct etiology. J Exp Clin Cancer Res; 2010 Sep 18;29:130
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of sequence polymorphism in the D-Loop region of mitochondrial DNA as a risk factor for hepatocellular carcinoma with distinct etiology.
  • BACKGROUND: Hepatocellular carcinoma (HCC) is frequently preceded by hepatitis virus infection or alcohol abuse.
  • METHODS: Mitochondrial DNA (mtDNA) of peripheral blood, tumor, and/or adjacent non-tumor tissue from 49 hepatitis B virus-related and 11 alcohol-related HCC patients, and from 38 controls without HCC were examined for single nucleotide polymorphisms (SNPs) and mutations in the D-Loop region.
  • Individual SNPs, namely the 16266C/T, 16293A/G, 16299A/G, 16303G/A, 242C/T, 368A/G, and 462C/T minor alleles, were associated with increased risk for alcohol- HCC, and the 523A/del was associated with increased risks of both HCC types.
  • The mitochondrial haplotypes under the M haplogroup with a defining 489C polymorphism were detected in 27 (55.1%) of HBV-HCC and 8 (72.7%) of alcohol- HCC patients, and in 15 (39.5%) of controls.
  • In contrast, the haplotypes of 489C with 152T, 249A, 309C, 523Del, or 525Del associated significantly with increase of alcohol-HCC risk.
  • Mutations in the D-Loop region were detected in 5 adjacent non-tumor tissues and increased in cancer stage (21 of 49 HBV-HCC and 4 of 11 alcohol- HCC, p < 0.002).
  • CONCLUSIONS: In sum, mitochondrial haplotypes may differentially predispose patients to HBV-HCC and alcohol-HCC.

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Annu Rev Biochem. 1997;66:409-35 [9242913.001]
  • [Cites] Curr Opin Neurobiol. 1996 Oct;6(5):661-6 [8937831.001]
  • [Cites] Trends Genet. 1997 Nov;13(11):450-5 [9385842.001]
  • [Cites] J Biol Chem. 1998 Nov 13;273(46):30614-21 [9804833.001]
  • [Cites] Biochim Biophys Acta. 1999 Feb 9;1410(2):103-23 [10076021.001]
  • [Cites] Am J Clin Pathol. 2006 Oct;126(4):593-601 [16938655.001]
  • [Cites] Exp Cell Res. 2007 Jan 1;313(1):77-87 [17045586.001]
  • [Cites] Cancer Res. 2007 May 15;67(10):4687-94 [17510395.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Jul;16(7):1455-9 [17627010.001]
  • [Cites] World J Gastroenterol. 2008 Jul 21;14(27):4300-8 [18666317.001]
  • [Cites] BMC Cancer. 2008;8:285 [18834532.001]
  • [Cites] Ann N Y Acad Sci. 2008 Oct;1141:304-17 [18991965.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Dec;17(12):3558-66 [19064571.001]
  • [Cites] J Gastroenterol. 2009;44 Suppl 19:96-101 [19148801.001]
  • [Cites] Chin Med J (Engl). 2009 Jan 5;122(1):3-4 [19187608.001]
  • [Cites] Mol Cancer Res. 2005 Jan;3(1):14-20 [15671245.001]
  • [Cites] Science. 2000 Mar 17;287(5460):2017-9 [10720328.001]
  • [Cites] Cancer Res. 2001 Mar 1;61(5):1843-5 [11280735.001]
  • [Cites] Am J Med Genet. 2001 Spring;106(1):18-26 [11579421.001]
  • [Cites] Am J Med Genet. 2001 Spring;106(1):71-93 [11579427.001]
  • [Cites] Cancer Res. 2001 Oct 1;61(19):7015-9 [11585726.001]
  • [Cites] Clin Cancer Res. 2002 Feb;8(2):481-7 [11839667.001]
  • [Cites] J Med Virol. 2002 Jul;67(3):447-50 [12116043.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Feb 18;100(4):1838-43 [12578990.001]
  • [Cites] Mutat Res. 2004 Mar 22;547(1-2):71-8 [15013701.001]
  • [Cites] Arch Biochem Biophys. 1994 Mar;309(2):377-86 [8135551.001]
  • [Cites] Mol Cell Biol. 1995 Jan;15(1):580-9 [7528331.001]
  • [Cites] Free Radic Biol Med. 1996;21(5):641-9 [8891667.001]
  • [Cites] J Hepatol. 1997 Jul;27(1):96-102 [9252080.001]
  • (PMID = 20849651.001).
  • [ISSN] 1756-9966
  • [Journal-full-title] Journal of experimental & clinical cancer research : CR
  • [ISO-abbreviation] J. Exp. Clin. Cancer Res.
  • [Language] ENG
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Mitochondrial
  • [Other-IDs] NLM/ PMC2949825
  •  go-up   go-down


84. Marcellin P, Pequignot F, Delarocque-Astagneau E, Zarski JP, Ganne N, Hillon P, Antona D, Bovet M, Mechain M, Asselah T, Desenclos JC, Jougla E: Mortality related to chronic hepatitis B and chronic hepatitis C in France: evidence for the role of HIV coinfection and alcohol consumption. J Hepatol; 2008 Feb;48(2):200-7
HIV InSite. treatment guidelines - Coinfection with Hepatitis Viruses and HIV .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mortality related to chronic hepatitis B and chronic hepatitis C in France: evidence for the role of HIV coinfection and alcohol consumption.
  • BACKGROUND/AIMS: Mortality related to HCV and HBV infections was estimated in France.
  • Physicians who reported the deaths were sent a questionnaire to identify how many deaths were related to HBV/HCV infection.
  • In the HCV infection group, 95 percent had cirrhosis; 33 percent had hepatocellular carcinoma (HCC).
  • Deaths related to HBV or HCV infection occurred at an earlier age in patients with a history of excessive alcohol consumption.
  • CONCLUSIONS: In France, 4000-5000 deaths related to HCV and HBV infection occurred in 2001.
  • Alcohol consumption and HIV infection were important co-factors.
  • [MeSH-major] Alcohol Drinking. HIV Infections / mortality. Hepatitis B, Chronic / mortality. Hepatitis C, Chronic / mortality


85. Gitto S, Micco L, Conti F, Andreone P, Bernardi M: Alcohol and viral hepatitis: a mini-review. Dig Liver Dis; 2009 Jan;41(1):67-70
Hazardous Substances Data Bank. ETHANOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alcohol and viral hepatitis: a mini-review.
  • Due to their high prevalence in the general population, alcohol use and abuse can be associated with hepatitis B and C virus infections and it has been demonstrated that alcohol plays a role as a co-morbid factor in the development of liver disease.
  • There is evidence that alcohol abuse accelerates the progression of liver fibrosis and affects the survival of patients with chronic hepatitis C.
  • The mechanism by which alcohol worsens hepatitis C virus-related liver disease has not been fully clarified, but enhanced viral replication, increased oxidative stress, cytotoxicity and impairment of immune response could play a relevant role.
  • Alcohol abuse also seems to reduce both sensitivity to interferon and adherence to treatment.
  • However, more studies are warranted to improve our knowledge about the interaction between alcohol intake and hepatitis B virus infection.
  • In conclusion alcohol abuse is associated with an accelerated progression of liver injury, leading to an earlier development of cirrhosis, higher incidence of hepatocellular carcinoma, and higher mortality.
  • [MeSH-minor] Antiviral Agents / therapeutic use. Carcinoma, Hepatocellular / epidemiology. Comorbidity. Disease Progression. Ethanol / pharmacology. Ethanol / poisoning. Humans. Interferons / therapeutic use. Liver Cirrhosis / chemically induced. Liver Cirrhosis / physiopathology. Liver Cirrhosis / virology. Oxidative Stress / drug effects. Treatment Outcome

  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Alcoholism and Alcohol Abuse.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18602355.001).
  • [ISSN] 1878-3562
  • [Journal-full-title] Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  • [ISO-abbreviation] Dig Liver Dis
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antiviral Agents; 3K9958V90M / Ethanol; 9008-11-1 / Interferons
  • [Number-of-references] 45
  •  go-up   go-down


86. Merion RM: Current status and future of liver transplantation. Semin Liver Dis; 2010 Nov;30(4):411-21
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Indications for liver transplant have evolved to include previously contraindicated conditions such as hepatocellular carcinoma and alcohol-related liver disease.
  • [MeSH-minor] Body Dysmorphic Disorders. Carcinoma, Hepatocellular / surgery. End Stage Liver Disease / surgery. Hepatitis C, Chronic / surgery. Humans. Liver Neoplasms / surgery. Living Donors. Patient Selection. Severity of Illness Index. Tissue and Organ Procurement. Treatment Outcome. Waiting Lists

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Liver Diseases.
  • MedlinePlus Health Information. consumer health - Liver Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © Thieme Medical Publishers.
  • (PMID = 20960380.001).
  • [ISSN] 1098-8971
  • [Journal-full-title] Seminars in liver disease
  • [ISO-abbreviation] Semin. Liver Dis.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  •  go-up   go-down


87. Gelatti U, Covolo L, Talamini R, Tagger A, Barbone F, Martelli C, Cremaschini F, Franceschi S, Ribero ML, Garte S, Nardi G, Donadon V, Donato F: N-Acetyltransferase-2, glutathione S-transferase M1 and T1 genetic polymorphisms, cigarette smoking and hepatocellular carcinoma: a case-control study. Int J Cancer; 2005 Jun 10;115(2):301-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] N-Acetyltransferase-2, glutathione S-transferase M1 and T1 genetic polymorphisms, cigarette smoking and hepatocellular carcinoma: a case-control study.
  • Our aim was to evaluate the role of N-acetyltransferase (NAT2) and glutathione S-transferase M1 and T1 (GSTM1 and GSTT1) polymorphisms in hepatocellular carcinoma (HCC) according to cigarette smoking, taking into account hepatitis B (HBV) and C (HCV) viral infection as well as alcohol consumption.
  • Cases (n = 200) were patients hospitalized for HCC, and controls (n = 400) were patients admitted for reasons other than liver disease, neoplasms and tobacco- and alcohol-related diseases.
  • [MeSH-major] Arylamine N-Acetyltransferase / genetics. Carcinoma, Hepatocellular / genetics. Glutathione Transferase / genetics. Liver Neoplasms / genetics. Polymorphism, Genetic. Smoking / adverse effects

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Smoking.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 Wiley-Liss, Inc
  • (PMID = 15688397.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.3.1.5 / Arylamine N-Acetyltransferase; EC 2.3.1.5 / NAT2 protein, human; EC 2.5.1.- / glutathione S-transferase T1; EC 2.5.1.18 / Glutathione Transferase; EC 2.5.1.18 / glutathione S-transferase M1
  •  go-up   go-down


88. Homann N, Stickel F, König IR, Jacobs A, Junghanns K, Benesova M, Schuppan D, Himsel S, Zuber-Jerger I, Hellerbrand C, Ludwig D, Caselmann WH, Seitz HK: Alcohol dehydrogenase 1C*1 allele is a genetic marker for alcohol-associated cancer in heavy drinkers. Int J Cancer; 2006 Apr 15;118(8):1998-2002
MedlinePlus Health Information. consumer health - Alcohol.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alcohol dehydrogenase 1C*1 allele is a genetic marker for alcohol-associated cancer in heavy drinkers.
  • Chronic alcohol consumption is associated with an increased risk for upper aerodigestive tract cancer and hepatocellular carcinoma.
  • Increased acetaldehyde production via alcohol dehydrogenase (ADH) has been implicated in the pathogenesis.
  • So far, the association between the ADH1C*1 allele and alcohol-related cancers among heavy drinkers is controversial.
  • ADH1C genotypes were determined by polymerase chain reaction and restriction fragment length polymorphism in a total of 818 patients with alcohol-associated esophageal (n=123), head and neck (n=84) and hepatocellular cancer (n=86) as well as in patients with alcoholic pancreatitis (n=117), alcoholic liver cirrhosis (n=217), combined liver cirrhosis and pancreatitis (n=17) and in alcoholics without gastrointestinal organ damage (n=174).
  • The ADH1C*1 allele and genotype ADH1C*1/1 were significantly more frequent in patients with alcohol-related cancers than that in individuals with nonmalignant alcohol-related organ damage.
  • Using multivariate analysis, ADH1C*1 allele frequency and rate of homozygosity were significantly associated with an increased risk for alcohol-related cancers (p<0.001 in all instances).
  • The odds ratio for genotype ADH1C*1/1 regarding the development of esophageal, hepatocellular and head and neck cancer were 2.93 (CI, 1.84-4.67), 3.56 (CI, 1.33-9.53) and 2.2 (CI, 1.11-4.36), respectively.
  • The data identify genotype ADH1C*1/1 as an independent risk factor for the development of alcohol-associated tumors among heavy drinkers, indicating a genetic predisposition of individuals carrying this genotype.
  • [MeSH-major] Alcohol Dehydrogenase / genetics. Alcohol Dehydrogenase / metabolism. Alcohol Drinking / adverse effects. Alcohol Drinking / genetics. Genetic Markers. Genetic Predisposition to Disease

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2005 Wiley-Liss, Inc.
  • (PMID = 16287084.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Genetic Markers; EC 1.1.1.1 / Alcohol Dehydrogenase
  •  go-up   go-down


89. Kim SO, Choi YH: The ethyl alcohol extract of Hizikia fusiforme inhibits matrix metalloproteinase activity and regulates tight junction related protein expression in Hep3B human hepatocarcinoma cells. J Med Food; 2010 Feb;13(1):31-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The ethyl alcohol extract of Hizikia fusiforme inhibits matrix metalloproteinase activity and regulates tight junction related protein expression in Hep3B human hepatocarcinoma cells.
  • We tested the correlation between the tightness of tight junctions (TJs) and the anti-invasive activity of the ethyl alcohol extract of Hizikia fusiforme (EHF) in Hep3B human hepatocarcinoma cells.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / therapeutic use. Carcinoma, Hepatocellular / drug therapy. Liver Neoplasms / drug therapy. Matrix Metalloproteinases / metabolism. Phaeophyta. Plant Extracts / therapeutic use. Tight Junctions / drug effects

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20136433.001).
  • [ISSN] 1557-7600
  • [Journal-full-title] Journal of medicinal food
  • [ISO-abbreviation] J Med Food
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Cadherins; 0 / Claudins; 0 / Plant Extracts; 0 / RNA, Messenger; 0 / Thrombospondin 1; EC 2.7.10.1 / Receptor, IGF Type 1; EC 3.4.24.- / Matrix Metalloproteinases
  •  go-up   go-down


90. Ndububa DA, Ojo OS, Adetiloye VA, Aladegbaiye AO, Adebayo RA, Adekanle O: The contribution of alcohol to chronic liver disease in patients from South-west Nigeria. Niger J Clin Pract; 2010 Dec;13(4):360-4
MedlinePlus Health Information. consumer health - Alcohol.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The contribution of alcohol to chronic liver disease in patients from South-west Nigeria.
  • OBJECTIVE: This study aimed at determining the level and type of alcohol consumed by patients diagnosed with chronic liver disease (CLD) and, hence, the extent to which alcohol may have contributed to the development of the condition.
  • Alcohol consumption was considered significant if a patient took >50 g/day for > 10 years.
  • Fifty-one (35.2%) patients, all males, drank significant alcohol while consumption was not significant in 43 (29.6%) patients.
  • Alcohol was not consumed at all by 51 (35.2%) patients made up of 18 males (35.3%) and 33 females (64.7%).
  • Beer was the commonest form of alcohol consumed (70.2%) followed by palm wine (50%) and locally-brewed gin (20.2%).
  • The diagnoses made were liver cirrhosis [LC] (60, 41.38%), chronic hepatitis [CH] (54, 37.20%), hepatocellular carcinoma [HCC] (23, 15.86%), alcoholic liver disease [ALD] (6, 4.14%) and non-alcoholic fatty liver disease [NAFLD] (2, 1.38%).
  • The liver disease spectrum did not differ between the patients who drank significant alcohol and those who did not.
  • However, the proportion of LC/HCC cases increased relative to CH with increasing age and consumption of alcohol.
  • CONCLUSIONS: The proportion of CLD directly attributable to alcohol (i.e.
  • However, the burden of LC and HCC is directly related to age and the amount of alcohol consumed and the determinants of alcohol abuse are gender and affluence.
  • [MeSH-major] Alcohol Drinking / adverse effects. Liver Diseases, Alcoholic / diagnosis. Liver Diseases, Alcoholic / epidemiology

  • Genetic Alliance. consumer health - Liver Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21220846.001).
  • [ISSN] 1119-3077
  • [Journal-full-title] Nigerian journal of clinical practice
  • [ISO-abbreviation] Niger J Clin Pract
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  •  go-up   go-down


91. Manekeller S, Sauerbruch T, Fischer HP, Propping P, Hirner A: [Heterozygous alpha-1-antitrypsin deficiency (PiMZ): risk factor in the development of primary liver carcinoma in non-cirrhotic liver?]. Z Gastroenterol; 2010 Oct;48(10):1211-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Heterozygous alpha-1-antitrypsin deficiency (PiMZ): risk factor in the development of primary liver carcinoma in non-cirrhotic liver?].
  • Here we report on a patient with a primary hepatocellular carcinoma in a non-cirrhotic liver, in whom heterozygosity for an AAT-deficiency allele was found (PiMZ).
  • Based on this observation and the current literature, the possible mechanisms for an eventual contribution of a heterozygosity of a heterozygous AAT-deficiency for a hepatocellular carcinoma are discussed.
  • Alpha-1-antitrypsin (AAT)-deficiency (Laurell-Eriksson syndrome) is a genetic disorder, in which individuals who are homozygous for a deficiency allele are at an increased lifetime risk for pulmonary emphysema, liver cirrhosis, and primary hepatocellular carcinoma.
  • Since not all patients with precipitates of AAT-aggregates are develop a hepatocellular carcinoma related comorbidities such as chronic hepatitis B, C, chronic alcohol abuse, or so far unknown genetic and environmental factors may be crucial.
  • [MeSH-major] Carcinoma, Hepatocellular / genetics. Genetic Predisposition to Disease / genetics. Liver Neoplasms / genetics. Loss of Heterozygosity / genetics. Polymorphism, Single Nucleotide / genetics. alpha 1-Antitrypsin / genetics

  • Genetic Alliance. consumer health - Alpha 1-Antitrypsin Deficiency.
  • Genetic Alliance. consumer health - Antitrypsin Deficiency.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © Georg Thieme Verlag KG Stuttgart · New York.
  • (PMID = 20886426.001).
  • [ISSN] 1439-7803
  • [Journal-full-title] Zeitschrift für Gastroenterologie
  • [ISO-abbreviation] Z Gastroenterol
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / SERPINA1 protein, human; 0 / alpha 1-Antitrypsin
  •  go-up   go-down


92. Otani K, Korenaga M, Beard MR, Li K, Qian T, Showalter LA, Singh AK, Wang T, Weinman SA: Hepatitis C virus core protein, cytochrome P450 2E1, and alcohol produce combined mitochondrial injury and cytotoxicity in hepatoma cells. Gastroenterology; 2005 Jan;128(1):96-107
Hazardous Substances Data Bank. ETHANOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatitis C virus core protein, cytochrome P450 2E1, and alcohol produce combined mitochondrial injury and cytotoxicity in hepatoma cells.
  • BACKGROUND & AIMS: Alcohol consumption exacerbates liver injury in chronic hepatitis C, and enhanced mitochondrial oxidative stress is one possible mechanism.
  • The aim of this study was to determine whether hepatitis C virus core protein and alcohol-inducible cytochrome P450 2E1 contribute to reactive oxygen species production and cytotoxicity in human hepatoma cells.
  • Alcohol further depletes mitochondrial reduced glutathione, which exacerbates depolarization and cell death.
  • Sensitization of mitochondria to oxidative insults is thus a potential mechanism for alcohol-related exacerbation of liver injury in chronic hepatitis C.
  • [MeSH-minor] Carcinoma, Hepatocellular. Cell Death / physiology. Cell Line, Tumor. Chronic Disease. Glutathione. Humans. Liver Neoplasms. Models, Biological. Oxidative Stress / physiology. Reactive Oxygen Species / metabolism. Tumor Necrosis Factor-alpha

  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Hepatitis C.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Gastroenterology. 2005 Jan;128(1):232-4 [15633141.001]
  • (PMID = 15633127.001).
  • [ISSN] 0016-5085
  • [Journal-full-title] Gastroenterology
  • [ISO-abbreviation] Gastroenterology
  • [Language] eng
  • [Grant] United States / NIAAA NIH HHS / AA / AA 12863
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Alcohols; 0 / Reactive Oxygen Species; 0 / Tumor Necrosis Factor-alpha; 0 / Viral Core Proteins; 0 / nucleocapsid protein, Hepatitis C virus; 3K9958V90M / Ethanol; EC 1.14.13.- / Cytochrome P-450 CYP2E1; GAN16C9B8O / Glutathione
  •  go-up   go-down


93. Toshikuni N, Izumi A, Nishino K, Inada N, Sakanoue R, Yamato R, Suehiro M, Kawanaka M, Yamada G: Comparison of outcomes between patients with alcoholic cirrhosis and those with hepatitis C virus-related cirrhosis. J Gastroenterol Hepatol; 2009 Jul;24(7):1276-83
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of outcomes between patients with alcoholic cirrhosis and those with hepatitis C virus-related cirrhosis.
  • The cumulative rates of hepatocellular carcinoma (HCC) development were significantly lower in the alcoholic patients than in the HCV-infected patients (6.8% vs 50.3% at 10 years, P = 0.0003), while the cumulative rates of hepatic decompensation (37.4% vs 51.7% at 10 years) and survival (53.8% vs 47.4% at 10 years) did not significantly differ between the two groups (Kaplan-Meir analysis).
  • Multivariate analyses using the Cox proportional hazard model revealed that the risk of HCC was lower in alcoholic cirrhosis than in HCV-related cirrhosis (hazard ratio (HR), 0.46), while the risk of hepatic decompensation and mortality was the same.
  • CONCLUSIONS: Survival of patients with alcoholic cirrhosis was similar to that of patients with HCV-related cirrhosis.
  • The risk of HCC development was lower in alcoholic cirrhosis than in HCV-related cirrhosis.
  • Abstinence from alcohol was important for improving the survival of patients with alcoholic cirrhosis.
  • [MeSH-major] Carcinoma, Hepatocellular / etiology. Hepatitis C / complications. Liver Cirrhosis / virology. Liver Cirrhosis, Alcoholic / complications. Liver Failure / etiology. Liver Neoplasms / etiology

  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Cirrhosis.
  • MedlinePlus Health Information. consumer health - Hepatitis C.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19486451.001).
  • [ISSN] 1440-1746
  • [Journal-full-title] Journal of gastroenterology and hepatology
  • [ISO-abbreviation] J. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


94. Rosenthal E, Salmon-Céron D, Lewden C, Bouteloup V, Pialoux G, Bonnet F, Karmochkine M, May T, François M, Burty C, Jougla E, Costagliola D, Morlat P, Chêne G, Cacoub P, Mortavic/Mortalité 2005 Study Group: Liver-related deaths in HIV-infected patients between 1995 and 2005 in the French GERMIVIC Joint Study Group Network (Mortavic 2005 study in collaboration with the Mortalité 2005 survey, ANRS EN19). HIV Med; 2009 May;10(5):282-9
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liver-related deaths in HIV-infected patients between 1995 and 2005 in the French GERMIVIC Joint Study Group Network (Mortavic 2005 study in collaboration with the Mortalité 2005 survey, ANRS EN19).
  • Results Among 287 reported deaths in 2005, 100 (35%) were related to AIDS, and 48 (17%) to ESLD.
  • Three out of four patients who died from ESLD-related causes had chronic hepatitis C.
  • Excessive alcohol consumption was reported in approximately half of the patients (48%).
  • The proportion of deaths caused by hepatocellular carcinoma increased from 5% in 1995 to 25% in 2005 (P=0.0337).
  • CONCLUSIONS: Over the 10 years from 1995 to 2005, the proportion of deaths caused by hepatitis C virus-related ESLD has increased in HIV-infected patients.
  • ESLD is currently a leading cause of death in this population, with hepatocellular carcinoma representing a quarter of liver-related deaths.
  • Recommendations for the detection of hepatocellular carcinoma should be strictly applied in these patients.
  • [MeSH-major] Carcinoma, Hepatocellular / mortality. HIV Infections / mortality. Hepatitis C, Chronic / mortality. Liver Neoplasms / mortality
  • [MeSH-minor] Acquired Immunodeficiency Syndrome / complications. Acquired Immunodeficiency Syndrome / mortality. Adult. Aged. Alcohol Drinking / mortality. Antiretroviral Therapy, Highly Active. CD4 Lymphocyte Count. Cause of Death / trends. Cross-Sectional Studies. Female. France / epidemiology. Humans. Liver Cirrhosis, Alcoholic / complications. Liver Cirrhosis, Alcoholic / mortality. Male. Middle Aged. Prospective Studies. alpha-Fetoproteins / analysis

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19226410.001).
  • [ISSN] 1468-1293
  • [Journal-full-title] HIV medicine
  • [ISO-abbreviation] HIV Med.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 0 / alpha-Fetoproteins
  • [Investigator] Pautard-Huchemblé B; Schmit JL; Bonnefoy M; Bru JP; Gaillat J; Lerousseau L; Dubois D; Azzedine A; De La Blanchardière A; Lepeu G; Faller JP; Balvay P; Barale F; Estavoyer JM; Vuitton D; Bentata M; Cohen P; Guillevin L; Jarrousse B; Padrazzi B; Beylot J; Bernard N; Constans J; Loury I; Moreau F; Morlat P; Ragnaud JM; Viaud JF; Lacoste D; Baglin A; Dorra M; Dupont C; Hanslik T; Rouveix E; Granier P; Cénac A; Bazin C; Hazera P; Verdon R; Schmidt J; Rogeaux O; Menalba C; Boué F; Fior R; Galanaud P; Pik JJ; Beytout J; Laurichesse H; Ruivard M; Laplatte G; Audoy B; Plaisance N; Bouterra C; Laylotte G; Delarocque E; Vinceneux P; Lesprit P; Schaeffer A; Grappin M; Greuzard MC; Loudes-Chauvin MC; Portier H; Vinceneux M; Guillaumie J; Dournovo P; De Truchis P; Perronne C; Bouchard O; Micoud M; Morand P; Boucher J; Chambourlier P; Renou C; Arvin-Berod C; Poubeau P; Perre P; Hachulla E; Devulder B; Hatron PY; Loustaud-Ratti V; Berthou JD; Baborier D; Constant E; Dufay E; Peyramond D; Trémolières F; Bourgeade A; Durand JM; Gastaut JA; Gallais H; Moreau J; Perret JL; Poizot-Martin I; Soubeyrand J; Meissonnier P; Hayek R; Constant C; Raabe JJ; Wang A; Astruc J; Blanc F; Perney P; Vandôme A; Bautoille D; Guerbois C; Loyau C; Raffi F; Villers D; Burty C; Canton P; de Korwin JD; Thibaut G; Wahl D; Dellamonica P; Cassuto JP; Ceppi C; Fuzibet JG; Poirée M; Pradier C; Rosenthal E; Raffanel C; Amoura Z; Aumaitre H; Bani-Sadr F; Bergmann JF; Bissuel F; Boissonnas A; Bouvet E; Bricaire F; Cabane J; Cabié A; Cacoub P; Caquet R; Carbon C; Caulin C; Chemlal K; Coulaud JP; de Beaumont T; Devars du Mayne F; Dupont C; Durand B; Farge D; Galanaud P; Gaudebout C; Gilquin J; Goujard C; Hausfater P; Katlama C; Karmochkine M; Krainik F; Le Bras P; Le Moing V; Leport C; Modaï J; Molina JM; Pialoux G; Piette JC; Poinsignon Y; Quertainmont Y; Raguin G; Rozenbaum W; Sicard D; Simon J; Vachon F; Valleron AJ; Vildé JL; Arsac P; Calamy G; Mille C; Mercie P; Pellegrin JL; Becq-Giraudon B B; Breux JP; Le Moal G; Michelet C; Cartier F; Beguinot I; Rémy G; Gueit I; Borsa-Lebas F; Humbert G; Wemeau J; Hascouet C; Le Cam B; Khuong MA; Mechali D; Roblin X; Defontaine C; Lucht F; Fégueux S; Veyssier-Belot C; Ouzan D; Kitschke B; Clément-Bertoldo C; Gonzales G; Poubeau P; Fischer P; Lang JM; Rey D; Ruellan A; Schlienger JL; Zucman D; Blétry O; Romand P; Alric L; Cuzin L; Duffaut M; Ajana F; Mouton Y; Yazdanpanah Y; Borderon JC; Choutet P; Guimard Y; Patey O
  •  go-up   go-down


95. Sehonou J, Kodjoh N, Sake K, Mouala C: [Liver cirrhosis in Cotonou, Republic of Benin: clinical aspects and factors related to death]. Med Trop (Mars); 2010 Aug;70(4):375-8
MedlinePlus Health Information. consumer health - Cirrhosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Liver cirrhosis in Cotonou, Republic of Benin: clinical aspects and factors related to death].
  • The purpose of this retrospective study was to evaluate clinical and epidemiological features as well as factors related to death in cirrhosis patients admitted to the National University Hospital in Cotonou, Benin.
  • Hepatitis B and alcohol consumption were the main etiological factors: 53.3% and 23.2% respectively.
  • The revealing manifestations were ascitis (75%), jaundice (71.7%), and hepatocellular carcinoma (42.3%).
  • Higher risk for in-hospital death (42.3%) was correlated with male gender, salaried employment, and presentation with jaundice, ascitis, or hepatocellular carcinoma.
  • The risk of death during hospitalization was higher for patients who were of male gender, working as salaried employees and admitted for the first time with jaundice, ascitis, or hepatocellular carcinoma.
  • CONCLUSION: A program for mass vaccination of children against hepatitis B virus is needed to prevent cirrhosis and hepatocellular carcinoma.
  • A campaign against alcohol abuse could reduce cirrhosis due to alcohol consumption.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22368937.001).
  • [ISSN] 0025-682X
  • [Journal-full-title] Médecine tropicale : revue du Corps de santé colonial
  • [ISO-abbreviation] Med Trop (Mars)
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


96. Rosenthal E, Pialoux G, Bernard N, Pradier C, Rey D, Bentata M, Michelet C, Pol S, Perronne C, Cacoub P, GERMIVIC Joint Study Group: Liver-related mortality in human-immunodeficiency-virus-infected patients between 1995 and 2003 in the French GERMIVIC Joint Study Group Network (MORTAVIC 2003 Study). J Viral Hepat; 2007 Mar;14(3):183-8
MedlinePlus Health Information. consumer health - Liver Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liver-related mortality in human-immunodeficiency-virus-infected patients between 1995 and 2003 in the French GERMIVIC Joint Study Group Network (MORTAVIC 2003 Study).
  • Among 215 deaths observed during 2003, 101 (46.9%) were related to AIDS, 27 (12.6%) to ESLD and 87 (40.5%) to other causes.
  • Mortality because of ESLD represented 23.7% of non-AIDS-related deaths.
  • Patients dying from ESLD had chronic hepatitis because of hepatitis C virus (HCV) in 92.6% of cases and moderate (30-60 g) or high (>60 g) alcohol consumption (43.5% and 26.0%, respectively).
  • The prevalence of hepatocellular carcinoma as a cause of death remained high in 2003 but stable when compared with 2001 (25%vs 14.8%).
  • [MeSH-minor] Adult. Aged. Carcinoma, Hepatocellular / mortality. Female. France. Hepatitis C, Chronic / mortality. Humans. Liver Diseases, Alcoholic / mortality. Liver Neoplasms / mortality. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17305884.001).
  • [ISSN] 1352-0504
  • [Journal-full-title] Journal of viral hepatitis
  • [ISO-abbreviation] J. Viral Hepat.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


97. Das K, Das K, Datta S, Pal S, Hembram JR, Dhali GK, Santra A, Chowdhury A: Course of disease and survival after onset of decompensation in hepatitis B virus-related cirrhosis. Liver Int; 2010 Aug;30(7):1033-42
MedlinePlus Health Information. consumer health - Hepatitis B.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Course of disease and survival after onset of decompensation in hepatitis B virus-related cirrhosis.
  • BACKGROUND: Data regarding the outcome of hepatitis B virus (HBV)-related cirrhosis after the onset of decompensation is scanty.
  • METHOD: From January 1998 to December 2008, a retrospective-prospective inception cohort study involving HBV-related decompensated cirrhotics was performed.
  • Patients with co-infection with hepatitis C virus and/or human immunodeficiency virus, alcohol consumption to any degree and diabetes diagnosed before the detection of liver disease were excluded.
  • [MeSH-minor] Adolescent. Adult. Aged. Antiviral Agents / therapeutic use. Ascites / mortality. Ascites / virology. Carcinoma, Hepatocellular / mortality. Carcinoma, Hepatocellular / virology. Chi-Square Distribution. Disease Progression. Esophageal and Gastric Varices / mortality. Esophageal and Gastric Varices / virology. Female. Gastrointestinal Hemorrhage / mortality. Gastrointestinal Hemorrhage / virology. Hepatorenal Syndrome / mortality. Hepatorenal Syndrome / virology. Humans. India. Jaundice / mortality. Jaundice / virology. Liver Neoplasms / mortality. Liver Neoplasms / virology. Male. Middle Aged. Proportional Hazards Models. Prospective Studies. Retrospective Studies. Risk Assessment. Risk Factors. Survival Analysis. Systemic Inflammatory Response Syndrome / mortality. Systemic Inflammatory Response Syndrome / virology. Time Factors. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Cirrhosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20492502.001).
  • [ISSN] 1478-3231
  • [Journal-full-title] Liver international : official journal of the International Association for the Study of the Liver
  • [ISO-abbreviation] Liver Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antiviral Agents
  •  go-up   go-down


98. Yamaguchi M, Daimon Y: Overexpression of regucalcin suppresses cell proliferation in cloned rat hepatoma H4-II-E cells: involvement of intracellular signaling factors and cell cycle-related genes. J Cell Biochem; 2005 Aug 15;95(6):1169-77
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Overexpression of regucalcin suppresses cell proliferation in cloned rat hepatoma H4-II-E cells: involvement of intracellular signaling factors and cell cycle-related genes.
  • This study demonstrates that overexpression of regucalcin has a suppressive effect on cell proliferation that is partly mediated through various intracellular signaling-related factors, and that the effect may be partly involved in the change in p21 or IGF-I mRNA expression.
  • [MeSH-major] Calcium-Binding Proteins / genetics. Calcium-Binding Proteins / metabolism. Carcinoma, Hepatocellular / metabolism. Carcinoma, Hepatocellular / pathology. Cell Cycle / genetics. Cell Cycle Proteins / metabolism. Intracellular Signaling Peptides and Proteins / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15962315.001).
  • [ISSN] 0730-2312
  • [Journal-full-title] Journal of cellular biochemistry
  • [ISO-abbreviation] J. Cell. Biochem.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Calcium-Binding Proteins; 0 / Cell Cycle Proteins; 0 / Intracellular Signaling Peptides and Proteins; 0 / Rgn protein, rat; 67763-96-6 / Insulin-Like Growth Factor I; EC 2.8.2.- / Sulfotransferases; EC 2.8.2.2 / alcohol sulfotransferase
  •  go-up   go-down


99. Solà R, Alvarez MA, Ballesté B, Montoliu S, Rivera M, Miquel M, Cirera I, Morillas RM, Coll S, Planas R: Probability of liver cancer and survival in HCV-related or alcoholic-decompensated cirrhosis. A study of 377 patients. Liver Int; 2006 Feb;26(1):62-72
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Probability of liver cancer and survival in HCV-related or alcoholic-decompensated cirrhosis. A study of 377 patients.
  • BACKGROUND: Although chronic alcohol intake and chronic hepatitis C may progress to cirrhosis and hepatocellular carcinoma (HCC), few data are available about survival and probability of developing HCC in decompensated cirrhosis of both aetiologies.
  • METHODS: This study identified factors related with probability of developing HCC and survival in a cohort of 377 consecutive patients with decompensated HCV-related cirrhosis (200 cases) or alcoholic cirrhosis (177 cases) without known HCC, hospitalized for their first hepatic decompensation, as well as to evaluate differences between both aetiologies.
  • RESULTS: During follow-up, 42 patients (11.1%) developed HCC (16.5% vs 5.1%) in groups HCV and alcohol, respectively; p = 0.0008), and 131 patients (34.7%) died (42% vs 26.6% in groups HCV and alcohol, respectively; p = 0.002).
  • Age and HCV-cirrhosis were independently related to HCC development, while baseline age and Child-Turcotte-Pugh score were independently correlated with survival.
  • CONCLUSION: Survival in decompensated HCV-related or alcoholic cirrhosis is influenced by age and baseline Child-Turcotte-Pugh score, without differences in cirrhosis aetiology.
  • The risk of developing HCC is greater in HCV-related cirrhosis than in alcoholic cirrhosis.

  • Genetic Alliance. consumer health - Liver cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16420511.001).
  • [ISSN] 1478-3223
  • [Journal-full-title] Liver international : official journal of the International Association for the Study of the Liver
  • [ISO-abbreviation] Liver Int.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


100. Gramenzi A, Conti F, Felline F, Cursaro C, Riili A, Salerno M, Gitto S, Micco L, Scuteri A, Andreone P, Bernardi M: Hepatitis C Virus-related chronic liver disease in elderly patients: an Italian cross-sectional study. J Viral Hepat; 2010 May;17(5):360-6
Genetic Alliance. consumer health - Liver Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatitis C Virus-related chronic liver disease in elderly patients: an Italian cross-sectional study.
  • Comparison of younger and older groups showed that 51% patients > or =65 years had advanced liver disease (liver cirrhosis or hepatocellular carcinoma) compared with 26% younger patients (P < 0.0001).
  • By multivariate analysis, age > or = 65 years, alcohol consumption and diabetes were independently associated with advanced liver disease.
  • [MeSH-minor] Adult. Aged. Antiviral Agents / therapeutic use. Carcinoma, Hepatocellular / epidemiology. Cross-Sectional Studies. Female. Hepatitis C Antibodies / blood. Humans. Italy / epidemiology. Liver Cirrhosis / epidemiology. Liver Neoplasms / epidemiology. Male. Middle Aged. Prevalence. RNA, Viral / blood. Risk Factors. Young Adult

  • Genetic Alliance. consumer health - Hepatitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19758274.001).
  • [ISSN] 1365-2893
  • [Journal-full-title] Journal of viral hepatitis
  • [ISO-abbreviation] J. Viral Hepat.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / Hepatitis C Antibodies; 0 / RNA, Viral
  •  go-up   go-down






Advertisement